Heteroaromatic ring compound as well as pharmaceutical composition and application thereof
By developing a heteroaromatic ring compound with novel structure, the problem of insufficient activator of p53 Y220C in the prior art was solved, the proliferation inhibition of p53 Y220C mutant cancer cells was achieved, and the tumor suppression function of p53 was restored, and the tumor suppression function of p53 was provided. Effective treatment options for anti-cancer cell resistance.
Patent Information
- Application Number
- CN202410656873.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2023-12-06
- Filing Date
- 2024-05-24
- Publication Date
- 2024-11-26
AI Technical Summary
The lack of effective p53 Y220C activator in the prior art is unable to effectively treat related cancers, especially the problem of drug resistance of cancer cells caused by p53 Y220C mutations.
A heteroaromatic ring compound with a novel structure was developed, which can reactivate the mutated p53 protein through a specific chemical structure design to restore its tumor suppressor function, and is manifested in BxPC-3 human pancreatic cancer cells and HuH-7 human liver cancer cells. Good proliferation inhibitory activity.
This compound can effectively inhibit the proliferation of cancer cells with p53 Y220C mutation and restore the tumor suppression function of p53, providing a potential therapeutic option to overcome the drug resistance of cancer cells to treatment.
Smart Images

Figure CN119019362A_ABST
Abstract
Description
Technical Field
[0001] The invention relates to a heteroaromatic ring compound, a pharmaceutical composition thereof and application thereof. Background Art
[0002] The p53 protein is a tetrameric transcription factor that prevents genomic mutations by regulating the expression of a subset of target genes. Each p53 monomer is composed of 393 amino acids and is divided into five key regulatory domains: the transactivation domain (TAD), the proline-rich region (PR), the DNA binding domain (DBD), the oligomerization domain (OD), and the C-terminus. The p53 gene is a very important tumor suppressor gene in the human body. Its existence ensures the normal growth and division of cells and is the guardian of the human genome.
[0003] As a very important tumor suppressor protein in the human body, P53 protein plays an important role in blocking the proliferation cycle of cancer cells and promoting apoptosis of cancer cells. Mutations in p53 protein affect its ability to bind to DNA and lose its ability to inhibit tumor growth, giving cancer cells a growth advantage and resistance to treatment. There are many types of p53 mutants. To date, more than 25,000 unique p53 mutations have been found, among which p53 Y220C mutation is a major mutation of P53 protein, accounting for 2% of the total mutations. The p53 Y220C mutation is a substitution of cysteine at position 220 for tyrosine. The mutant reduces the stability of p53, making the P53 protein with Y220C mutation unable to bind to relevant DNA and lose its function of inhibiting cancer cells. More than 50% of tumor patients have changes in the p53 gene. Moreover, p53 mutations are associated with nearly half of cancers, including lung cancer, gastric cancer, liver cancer, bladder cancer, esophageal cancer, breast cancer, cervical cancer, and other cancers. p53 Y220C mutations are present in breast cancer, lung cancer, colorectal cancer, gastric cancer, head and neck cancer, and other cancer types. There are about 100,000 new cancer patients with this mutation worldwide each year. Patients with pP53 protein mutations are more likely to develop resistance to targeted drugs or chemotherapy.
[0004] Currently, no drugs that reactivate p53 Y220C have been approved for marketing, so it is very necessary to develop efficient, stable and safe small molecule p53 Y220C activators for the treatment of related diseases, such as cancer. Summary of the invention
[0005] The technical problem to be solved by the present invention is to overcome the defect of insufficient types of p53 Y220C activators in the prior art, and to provide a novel heteroaromatic ring compound, a pharmaceutical composition thereof and its application. The compound of the present invention can reactivate mutated p53 to restore the p53 tumor suppressor function. The compound of the present invention exhibits good proliferation inhibition activity on BxPC-3 human pancreatic cancer cells and / or HuH-7 human liver cancer cells with p53 Y220C mutation.
[0006] The invention solves the above technical problems through the following technical solutions.
[0007] The present invention provides a compound as shown in formula (I) or a pharmaceutically acceptable salt thereof,
[0008]
[0009] in,
[0010] X1 is CH or N;
[0011] X2 is CH or N;
[0012] X3 is CH or N;
[0013] X4 is CH or N;
[0014] Each R 1 are independently deuterium, hydroxyl, cyano, halogen, nitro, -N(R 8 )2. -SR 8 、-COR 8 、-COOR 8 、-OCOR 8 、-CON(R 8 )2.-NR 8 COR 8 、-NR 8 COOR 8 、-NR 8 CON(R 8 2. -SOR 8 ,-SON(R 8 )2.-NR 8 SOR 8 、-NR 8 SON(R 8 2. -SO2R 8 、-SO2N(R 8 )2.-NR 8 S02R 8 、-NR 8 SO2N(R 8 )2.-PO(R 8 2. C 1-6Alkyl, with one or more R 1a Substituted C 1-6 Alkyl, -OC 1-6 Alkyl, with one or more R 1b Replaced-OC 1-6 Alkyl, C 2-6 Alkenyl, one or more R 1c Substituted C 2-6 Alkenyl, C 2-6 Alkynyl, with one or more R 1d Substituted C 2-6 Alkynyl, C 3-7 Cyclic hydrocarbon group, one or more R 1e Substituted C 3-7 Cyclic hydrocarbon group, 3-12 membered heterocyclic hydrocarbon group, one or more R 1f Substituted 3-12 membered heterocyclic hydrocarbon group, C 6-10 Aryl, one or more R 1g Substituted C 6-10 Aryl, 5-10 membered heteroaryl or one or more R 1h substituted 5-10 membered heteroaryl;
[0015] Each R 1a , R 1b , R 1c , R 1d , R 1e , R 1f , R 1g and R 1h are independently deuterium, hydroxyl, cyano, halogen, -N(R 8 2. C 1-6 Alkyl, one or more -CON(R 13 )2 substituted C 1-6 Alkyl, -OC 1-6 Alkyl or C 3-7 Cycloalkyl;
[0016] m is 0, 1, 2, 3 or 4;
[0017] Each R 8 are independently hydrogen, C 1-6 Alkyl, C 3-7 Cyclic hydrocarbon group, 3-12 membered heterocyclic hydrocarbon group or one or more R 8-1 Substituted 3-12 membered heterocyclic hydrocarbon group;
[0018] Each R 8-1 are independently deuterium, hydroxyl, cyano, halogen, -NH2 or C 1-6 alkyl;
[0019] Each R 13 are independently hydrogen, C1-6 Alkyl, C 3-7 Cycloalkyl or 3-12 membered heterocycloalkyl;
[0020] R 2 For hydrogen, -COR 8 、-COOR 8 、-CON(R 8 2. -SOR 8 ,-SON(R 8 2. -SO2R 8 、-SO2N(R 8 2. C 1-6 Alkyl, with one or more R 2a Substituted C 1-6 Alkyl, C 2-6 Alkenyl, one or more R 2b Substituted C 2-6 Alkenyl, C 2-6 Alkynyl, with one or more R 2c Substituted C 2-6 Alkynyl, C 3-7 Cyclic hydrocarbon group, one or more R 2d Substituted C 3-7 Cyclic hydrocarbon group, 3-12 membered heterocyclic hydrocarbon group, one or more R 2e Substituted 3-12 membered heterocyclic hydrocarbon group, C 6-10 Aryl, one or more R 2f Substituted C 6-10 Aryl, 5-10 membered heteroaryl or one or more R 2g substituted 5-10 membered heteroaryl;
[0021] Each R 2a , R 2b , R 2c , R 2d , R 2e , R 2f and R 2g are each independently deuterium, hydroxyl, cyano, halogen, -N(R 8 2. C 1-6 Alkyl, -OC 1-6 Alkyl or C 3-7 Cycloalkyl;
[0022] R 3 is hydrogen, deuterium, hydroxyl, cyano, halogen, nitro, -N(R 8 )2. -SR 8 、-COR 8 、-COOR 8 、-OCOR 8 、-CON(R 8 )2.-NR8 COR 8 、-NR 8 COOR 8 、-NR 8 CON(R 8 )2. -SOR 8 ,-SON(R 8 )2.-NR 8 SOR 8 、-NR 8 SON(R 8 2. -SO2R 8 、-SO2N(R 8 )2.-NR 8 S02R 8 、-NR 8 SO2N(R 8 )2.-PO(R 8 2. C 1-6 Alkyl, with one or more R 3a Substituted C 1-6 Alkyl, -OC 1-6 Alkyl, with one or more R 3b Replaced-OC 1-6 Alkyl, C 2-6 Alkenyl, one or more R 3c Substituted C 2-6 Alkenyl, C 2-6 Alkynyl, with one or more R 3d Substituted C 2-6 Alkynyl, C 3-7 Cyclic hydrocarbon group, one or more R 3e Substituted C 3-7 Cyclic hydrocarbon group, 3-12 membered heterocyclic hydrocarbon group, one or more R 3f Substituted 3-12 membered heterocyclic hydrocarbon group, C 6-10 Aryl, one or more R 3g Substituted C 6-10 Aryl, 5-10 membered heteroaryl or one or more R 3h substituted 5-10 membered heteroaryl;
[0023] Each R 3a , R 3b , R 3c , R 3d , R 3e , R 3f , R 3g and R 3h are independently deuterium, hydroxyl, cyano, halogen, -N(R 8 2. C 1-6 Alkyl, -OC 1-6 Alkyl or C3-7 Cycloalkyl;
[0024] R 4 and R 5 are independently hydrogen, deuterium, hydroxyl, cyano, halogen, -N(R 8 2. C 1-6 Alkyl, with one or more R 4a Substituted C 1-6 Alkyl, -OC 1-6 Alkyl, with one or more R 4b Replaced-OC 1-6 Alkyl, C 2-6 Alkenyl, one or more R 4c Substituted C 2-6 Alkenyl, C 2-6 Alkynyl, with one or more R 4d Substituted C 2-6 Alkynyl, C 3-7 Cyclic hydrocarbon group, one or more R 4e Substituted C 3-7 Cyclic hydrocarbon group, 3-12 membered heterocyclic hydrocarbon group, one or more R 4f Substituted 3-12 membered heterocyclic hydrocarbon group, C 6-10 Aryl, one or more R 4g Substituted C 6-10 Aryl, 5-10 membered heteroaryl or one or more R 4h substituted 5-10 membered heteroaryl, or R 4 and R 5 Combine to form an oxo group, or R 4 and R 5 Together with the carbon atom to which they are attached, they form C 3-7 Cyclic hydrocarbon group, one or more R 4i Substituted C 3-7 Cyclic hydrocarbon group, 3-12 membered heterocyclic hydrocarbon group or one or more R 4j Substituted 3-12 membered heterocyclic hydrocarbon group;
[0025] Each R 4a , R 4b , R 4c , R 4d , R 4e , R 4f , R 4g , R 4h , R 4i and R 4j are each independently deuterium, hydroxyl, cyano, halogen, -N(R 8 2. C 1-6 Alkyl, -OC 1-6 Alkyl or C 3-7 Cycloalkyl;
[0026] R 6 For hydrogen, -COR 8 、-COOR 8 、-CON(R 8 )2. -SOR 8 ,-SON(R 8 2. -SO2R 8 、-SO2N(R 8 2. C 1-6 Alkyl, with one or more R 6a Substituted C 1-6 Alkyl, C 2-6 Alkenyl, one or more R 6b Substituted C 2-6 Alkenyl, C 2-6 Alkynyl, with one or more R 6c Substituted C 2-6 Alkynyl, C 3-7 Cyclic hydrocarbon group, one or more R 6d Substituted C 3-7 Cyclic hydrocarbon group, 3-12 membered heterocyclic hydrocarbon group, one or more R 6e Substituted 3-12 membered heterocyclic hydrocarbon group, C 6-10 Aryl, one or more R 6f Substituted C 6-10 Aryl, 5-10 membered heteroaryl or one or more R 6g substituted 5-10 membered heteroaryl;
[0027] Each R 6a , R 6b , R 6c , R 6d , R 6e , R 6f and R 6g are independently deuterium, hydroxyl, cyano, halogen, -N(R 8 2. C 1-6 Alkyl, -OC 1-6 Alkyl or C 3-7 Cycloalkyl;
[0028] R 7 For one or more R 7a Substituted C 3-7 Cyclic hydrocarbon group, one or more R 7b substituted 3-12 membered heterocyclic hydrocarbon group, 7c Substituted C 6-10 Aryl or one or more R 7d substituted 5-10 membered heteroaryl;
[0029] Each R7a , R 7b , R 7c and R 7d are each independently deuterium, hydroxyl, cyano, halogen, nitro, -N(R 9 )2. -SR 9 、-COR 10 、-COOR 10 、-OCOR 10 、-CON(R 9 )2.-NR 9 COR 10 、-NR 9 COOR 9 、-NR 9 CON(R 9 )2.-SON(R 9 )2. -SOR 10 、-NR 9 SOR 10 、-NR 9 SON(R 9 )2、-SO2N(R 9 2. -SO2R 10 、-NR 9 S02R 10 、-NR 9 SO2N(R 9 )2, -S(=O)(=NR 9 )R 10 ,-P(=O)(R 11 2. C 1-6 Alkyl, with one or more R 7-a Substituted C 1-6 Alkyl, -OC 1-6 Alkyl, with one or more R 7-b Replaced-OC 1-6 Alkyl, C 2-6 Alkenyl, one or more R 7-c Substituted C 2-6 Alkenyl, C 2-6 Alkynyl, with one or more R 7-d Substituted C 2-6 Alkynyl, C 3-7 Cyclic hydrocarbon group, one or more R 7-e Substituted C 3-7 Cyclic hydrocarbon group, 3-12 membered heterocyclic hydrocarbon group, one or more R 7-f Substituted 3-12 membered heterocyclic hydrocarbon group, C 6-10 Aryl, one or more R 7-g Substituted C 6-10 Aryl, 5-10 membered heteroaryl, substituted by one or more R7-h Substituted 5-10 membered heteroaryl, -OC 3-7 Cyclic hydrocarbon group, one or more R 7-i Replaced-OC 3-7 Cycloalkyl, -O-(3-12 membered heterocycloalkyl), 7-j substituted-O-(3-12 membered heterocyclic hydrocarbon group); and R 7a , R 7b , R 7c and R 7d Each has at least one -SON(R 9 2. -SOR 10 、-SO2N(R 9 2. -SO2R 10 、-S(=O)(=NR 9 )R 10 or -P(=O)(R 11 )2;
[0030] Each R 7-a , R 7-b , R 7-c , R 7-d , R 7-e , R 7-f , R 7-g , R 7-h and R 7-i and R 7-j are each independently deuterium, hydroxyl, cyano, halogen, -N(R 12 2. C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, -OC 1-6 Alkyl, -SC 1-6 Alkyl, C 3-7 Cycloalkyl, 3-12 membered heterocyclic alkyl, C 6-10 Aryl, 5-10 membered heteroaryl, -COR 10 、-COOR 10 、-OCOR 10 、-CON(R 9 )2.-NR 9 COR 10 、-NR 9 COOR 9 、-NR 9 CON(R 9 )2.-SON(R 9 2. -SOR 10 、-NR 9 SOR 10 、-NR 9 SON(R 9)2、-SO2N(R 9 2. -SO2R 10 、-NR 9 S02R 10 、-NR 9 SO2N(R 9 )2, -S(=O)(=NR 9 )R 10 or -P(=O)(R 11 ) 2, said C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, -OC 1-6 Alkyl, -SC 1-6 Alkyl, C 3-7 Cycloalkyl, 3-12 membered heterocyclic alkyl, C 6-10 The aryl and 5-10 membered heteroaryl groups are each independently optionally substituted with one or more R 7-a-1 replace;
[0031] Each R 7-a-1 are each independently deuterium, hydroxyl, cyano, halogen, -NH2 or C 1-6 alkyl;
[0032] Each R 9 are independently hydrogen, cyano, -CO(C 1-6 Alkyl), C 1-6 Alkyl, with one or more R 9a Substituted C 1-6 Alkyl, C 3-7 Cyclic hydrocarbon group, one or more R 9b Substituted C 3-7 Cyclic hydrocarbon group, 3-12 membered heterocyclic hydrocarbon group or one or more R 9c Substituted 3-12 membered heterocyclic hydrocarbon group;
[0033] Each R 9a , R 9b and R 9c are each independently deuterium, hydroxyl, cyano, halogen, -N(R 12 2. C 1-6 Alkyl, -OC 1-6 Alkyl or C3-7 cycloalkyl;
[0034] Each R 10 are independently hydrogen, hydroxyl, C 1-6 Alkyl, with one or more R 10a Substituted C 1-6 Alkyl, C 3-7 Cyclic hydrocarbon group, one or more R 10b Substituted C 3-7Cyclic hydrocarbon group, 3-12 membered heterocyclic hydrocarbon group or one or more R 10c Substituted 3-12 membered heterocyclic hydrocarbon group;
[0035] Each R 10a , R 10b and R 10c are each independently deuterium, hydroxyl, cyano, halogen, -N(R 12 2. C 1-6 Alkyl, -OC 1-6 Alkyl or C 3-7 Cycloalkyl;
[0036] Each R 11 are independently hydrogen, hydroxyl, C 1-6 Alkyl, with one or more R 11a Substituted C 1-6 Alkyl, C 3-7 Cyclic hydrocarbon group, one or more R 11b Substituted C 3-7 Cyclic hydrocarbon group, 3-12 membered heterocyclic hydrocarbon group or one or more R 11c substituted 3-12 membered heterocyclic hydrocarbon group, or two R 11 Connected to them Together form a 4-8 membered heterocyclic hydrocarbon group or one or more R l1d Substituted 4-8 membered heterocyclic hydrocarbon group;
[0037] Each R 11a , R 11b , R 11c and R 11d are each independently deuterium, hydroxyl, cyano, halogen, -N(R 12 2. C 1-6 Alkyl, -OC 1-6 Alkyl or C 3-7 Cycloalkyl;
[0038] Each R 12 are independently hydrogen or C 1-6 alkyl;
[0039] In each "3-12 membered heterocyclic hydrocarbon group", the heteroatom species are each independently selected from one, two or more of N, O and S, and the number of heteroatoms is each independently 1, 2 or 3;
[0040] “Two R’s 11 Connected with them Together form a 4-8 membered heterocyclic hydrocarbon group or one or more R l1dIn each of the "4-8 membered heterocyclic hydrocarbon groups" in the "substituted 4-8 membered heterocyclic hydrocarbon group", the number of heteroatoms or heteroatom groups is independently 1, 2 or 3. When the number of "hetero" is 1, it is a heteroatom group P(O). When the number of "hetero" is 2 or 3, 1 of them is a heteroatom group P(O), and the rest are heteroatoms, and the heteroatoms are independently selected from one or two of N, O and S.
[0041] In each "5-10 membered heteroaryl", the heteroatom species are independently selected from one, two or more of N, O and S, and the number of heteroatoms is independently 1, 2 or 3;
[0042] When m is 1, R 1 Not halogen.
[0043] In a certain embodiment, in the compound represented by formula (I) or a pharmaceutically acceptable salt thereof, certain groups have the following definitions, and the definitions of the groups not mentioned are as described in any embodiment of the present invention (this paragraph is hereinafter referred to as "in a certain embodiment").
[0044] In one embodiment, the compound represented by formula (I) or a pharmaceutically acceptable salt thereof,
[0045]
[0046] in,
[0047] X1 is CH or N;
[0048] X2 is CH or N;
[0049] X3 is CH or N;
[0050] X4 is CH or N;
[0051] Each R 1 are independently deuterium, hydroxyl, cyano, halogen, nitro, -N(R 8 )2. -SR 8 、-COR 8 、-COOR 8 、-OCOR 8 、-CON(R 8 )2.-NR 8 COR 8 、-NR 8 COOR 8 、-NR 8 CON(R 8 2. -SOR 8 ,-SON(R 8 )2.-NR 8 SOR 8 、-NR8 SON(R 8 2. -SO2R 8 、-SO2N(R 8 )2.-NR 8 S02R 8 、-NR 8 SO2N(R 8 )2.-PO(R 8 2. C 1-6 Alkyl, with one or more R 1a Substituted C 1-6 Alkyl, -OC 1-6 Alkyl, with one or more R 1b Replaced-OC 1-6 Alkyl, C 2-6 Alkenyl, one or more R 1c Substituted C 2-6 Alkenyl, C 2-6 Alkynyl, with one or more R 1d Substituted C 2-6 Alkynyl, C 3-7 Cyclic hydrocarbon group, one or more R 1e Substituted C 3-7 Cyclic hydrocarbon group, 3-12 membered heterocyclic hydrocarbon group, one or more R 1f Substituted 3-12 membered heterocyclic hydrocarbon group, C 6-10 Aryl, one or more R 1g Substituted C 6-10 Aryl, 5-10 membered heteroaryl or one or more R 1h substituted 5-10 membered heteroaryl;
[0052] Each R 1a , R 1b , R 1c , R 1d , R 1e , R 1f , R 1g and R 1h are each independently deuterium, hydroxyl, cyano, halogen, -N(R 8 2. C 1-6 Alkyl, -OC 1-6 Alkyl or C 3-7 Cycloalkyl;
[0053] m is 0, 1, 2, 3 or 4;
[0054] Each R 8 are independently hydrogen, C 1-6 Alkyl, C 3-7 Cycloalkyl or 3-12 membered heterocycloalkyl;
[0055] R2 For hydrogen, -COR 8 、-COOR 8 、-CON(R 8 2. -SOR 8 ,-SON(R 8 2. -SO2R 8 、-SO2N(R 8 2. C 1-6 Alkyl, with one or more R 2a Substituted C 1-6 Alkyl, C 2-6 Alkenyl, one or more R 2b Substituted C 2-6 Alkenyl, C 2-6 Alkynyl, with one or more R 2c Substituted C 2-6 Alkynyl, C 3-7 Cyclic hydrocarbon group, one or more R 2d Substituted C 3-7 Cyclic hydrocarbon group, 3-12 membered heterocyclic hydrocarbon group, one or more R 2e Substituted 3-12 membered heterocyclic hydrocarbon group, C 6-10 Aryl, one or more R 2f Substituted C 6-10 Aryl, 5-10 membered heteroaryl or one or more R 2g substituted 5-10 membered heteroaryl;
[0056] Each R 2a , R 2b , R 2c , R 2d , R 2e , R 2f and R 2g are each independently deuterium, hydroxyl, cyano, halogen, -N(R 8 2. C 1-6 Alkyl, -OC 1-6 Alkyl or C 3-7 Cycloalkyl;
[0057] R 3 is hydrogen, deuterium, hydroxyl, cyano, halogen, nitro, -N(R 8 )2. -SR 8 、-COR 8 、-COOR 8 、-OCOR 8 、-CON(R 8 )2.-NR 8 COR 8 、-NR 8 COOR 8 、-NR8 CON(R 8 )2. -SOR 8 ,-SON(R 8 )2.-NR 8 SOR 8 、-NR 8 SON(R 8 2. -SO2R 8 、-SO2N(R 8 )2.-NR 8 S02R 8 、-NR 8 SO2N(R 8 )2.-PO(R 8 2. C 1-6 Alkyl, with one or more R 3a Substituted C 1-6 Alkyl, -OC 1-6 Alkyl, with one or more R 3b Replaced-OC 1-6 Alkyl, C 2-6 Alkenyl, one or more R 3c Substituted C 2-6 Alkenyl, C 2-6 Alkynyl, with one or more R 3d Substituted C 2-6 Alkynyl, C 3-7 Cyclic hydrocarbon group, one or more R 3e Substituted C 3-7 Cyclic hydrocarbon group, 3-12 membered heterocyclic hydrocarbon group, one or more R 3f Substituted 3-12 membered heterocyclic hydrocarbon group, C 6-10 Aryl, one or more R 3g Substituted C 6-10 Aryl, 5-10 membered heteroaryl or one or more R 3h substituted 5-10 membered heteroaryl;
[0058] Each R 3a , R 3b , R 3c , R 3d , R 3e , R 3f , R 3g and R 3h are independently deuterium, hydroxyl, cyano, halogen, -N(R 8 2. C 1-6 Alkyl, -OC 1-6 Alkyl or C 3-7 Cycloalkyl;
[0059] R 4 and R5 are independently hydrogen, deuterium, hydroxyl, cyano, halogen, -N(R 8 2. C 1-6 Alkyl, with one or more R 4a Substituted C 1-6 Alkyl, -OC 1-6 Alkyl, with one or more R 4b Replaced-OC 1-6 Alkyl, C 2-6 Alkenyl, one or more R 4c Substituted C 2-6 Alkenyl, C 2-6 Alkynyl, with one or more R 4d Substituted C 2-6 Alkynyl, C 3-7 Cyclic hydrocarbon group, one or more R 4e Substituted C 3-7 Cyclic hydrocarbon group, 3-12 membered heterocyclic hydrocarbon group, one or more R 4f Substituted 3-12 membered heterocyclic hydrocarbon group, C 6-10 Aryl, one or more R 4g Substituted C 6-10 Aryl, 5-10 membered heteroaryl or one or more R 4h substituted 5-10 membered heteroaryl, or R 4 and R 5 Combine to form an oxo group, or R 4 and R 5 Together with the carbon atom to which they are attached, they form C 3-7 Cyclic hydrocarbon group, one or more R 4i Substituted C 3-7 Cyclic hydrocarbon group, 3-12 membered heterocyclic hydrocarbon group or one or more R 4j Substituted 3-12 membered heterocyclic hydrocarbon group;
[0060] Each R 4a , R 4b , R 4c , R 4d , R 4e , R 4f , R 4g , R 4h , R 4i and R 4j are independently deuterium, hydroxyl, cyano, halogen, -N(R 8 2. C 1-6 Alkyl, -OC 1-6 Alkyl or C 3-7 Cycloalkyl;
[0061] R 6 For hydrogen, -COR 8、-COOR 8 、-CON(R 8 )2. -SOR 8 ,-SON(R 8 2. -SO2R 8 、-SO2N(R 8 2. C 1-6 Alkyl, with one or more R 6a Substituted C 1-6 Alkyl, C 2-6 Alkenyl, one or more R 6b Substituted C 2-6 Alkenyl, C 2-6 Alkynyl, with one or more R 6c Substituted C 2-6 Alkynyl, C 3-7 Cyclic hydrocarbon group, one or more R 6d Substituted C 3-7 Cyclic hydrocarbon group, 3-12 membered heterocyclic hydrocarbon group, one or more R 6e Substituted 3-12 membered heterocyclic hydrocarbon group, C 6-10 Aryl, one or more R 6f Substituted C 6-10 Aryl, 5-10 membered heteroaryl or one or more R 6g substituted 5-10 membered heteroaryl;
[0062] Each R 6a , R 6b , R 6c , R 6d , R 6e , R 6f and R 6g are independently deuterium, hydroxyl, cyano, halogen, -N(R 8 2. C 1-6 Alkyl, -OC 1-6 Alkyl or C 3-7 Cycloalkyl;
[0063] R 7 For one or more R 7a Substituted C 3-7 Cyclic hydrocarbon group, one or more R 7b substituted 3-12 membered heterocyclic hydrocarbon group, 7c Substituted C 6-10 Aryl or one or more R 7d substituted 5-10 membered heteroaryl;
[0064] Each R 7a , R 7b , R 7c and R 7dare each independently deuterium, hydroxyl, cyano, halogen, nitro, -N(R 9 )2. -SR 9 、-COR 10 、-COOR 10 、-OCOR 10 、-CON(R 9 )2.-NR 9 COR 10 、-NR 9 COOR 9 、-NR 9 CON(R 9 )2.-SON(R 9 2. -SOR 10 、-NR 9 SOR 10 、-NR 9 SON(R 9 )2、-SO2N(R 9 2. -SO2R 10 、-NR 9 S02R 10 、-NR 9 SO2N(R 9 )2, -S(=O)(=NR 9 )R 10 ,-P(=O)(R 11 2. C 1-6 Alkyl, with one or more R 7-a Substituted C 1-6 Alkyl, -OC 1-6 Alkyl, with one or more R 7-b Replaced-OC 1-6 Alkyl, C 2-6 Alkenyl, one or more R 7-c Substituted C 2-6 Alkenyl, C 2-6 Alkynyl, with one or more R 7-d Substituted C 2-6 Alkynyl, C 3-7 Cyclic hydrocarbon group, one or more R 7-e Substituted C 3-7 Cyclic hydrocarbon group, 3-12 membered heterocyclic hydrocarbon group, one or more R 7-f Substituted 3-12 membered heterocyclic hydrocarbon group, C 6-10 Aryl, one or more R 7-g Substituted C 6-10 Aryl, 5-10 membered heteroaryl, substituted by one or more R 7-h Substituted 5-10 membered heteroaryl, -OC 3-7 Cyclic hydrocarbon or one or more R 7-iReplaced-OC 3-7 Cycloalkyl; and R 7a , R 7b , R 7c and R 7d Each has at least one -SON(R 9 2. -SOR 10 、-SO2N(R 9 2. -SO2R 10 、-S(=O)(=NR 9 )R 10 or -P(=O)(R 11 )2;
[0065] Each R 7-a , R 7-b , R 7-c , R 7-d , R 7-e , R 7-f , R 7-g , R 7-h and R 7-i are each independently deuterium, hydroxyl, cyano, halogen, -N(R 12 2. C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, -OC 1-6 Alkyl, -SC 1-6 Alkyl, C 3-7 Cycloalkyl, 3-12 membered heterocyclic alkyl, C 6-10 Aryl, 5-10 membered heteroaryl, -COR 10 、-COOR 10 、-OCOR 10 、-CON(R 9 )2.-NR 9 COR 10 、-NR 9 COOR 9 、-NR 9 CON(R 9 )2.-SON(R 9 2. -SOR 10 、-NR 9 SOR 10 、-NR 9 SON(R 9 )2、-SO2N(R 9 2. -SO2R 10 、-NR 9 S02R 10 、-NR 9 SO2N(R 9 )2, -S(=O)(=NR9 )R 10 or -P(=O)(R 11 )2;
[0066] Each R 9 are independently hydrogen, cyano, -CO(C 1-6 Alkyl), C 1-6 Alkyl, with one or more R 9a Substituted C 1-6 Alkyl, C 3-7 Cyclic hydrocarbon group, one or more R 9b Substituted C 3-7 Cyclic hydrocarbon group, 3-12 membered heterocyclic hydrocarbon group or one or more R 9c Substituted 3-12 membered heterocyclic hydrocarbon group;
[0067] Each R 9a , R 9b and R 9c are each independently deuterium, hydroxyl, cyano, halogen, -N(R 12 2. C 1-6 Alkyl, -OC 1-6 Alkyl or C3-7 cycloalkyl;
[0068] Each R 10 are independently hydrogen, hydroxyl, C 1-6 Alkyl, with one or more R 10a Substituted C 1-6 Alkyl, C 3-7 Cyclic hydrocarbon group, one or more R 10b Substituted C 3-7 Cyclic hydrocarbon group, 3-12 membered heterocyclic hydrocarbon group or one or more R 10c Substituted 3-12 membered heterocyclic hydrocarbon group;
[0069] Each R 10a , R 10b and R 10c are each independently deuterium, hydroxyl, cyano, halogen, -N(R 12 2. C 1-6 Alkyl, -OC 1-6 Alkyl or C 3-7 Cycloalkyl;
[0070] Each R 11 are independently hydrogen, hydroxyl, C 1-6 Alkyl, with one or more R 11a Substituted C 1-6 Alkyl, C 3-7 Cyclic hydrocarbon group, one or more R 11b Substituted C 3-7 Cyclic hydrocarbon group, 3-12 membered heterocyclic hydrocarbon group or one or more R11c substituted 3-12 membered heterocyclic hydrocarbon group, or two R 11 Connected with them Together form a 4-8 membered heterocyclic hydrocarbon group or one or more R l1d Substituted 4-8 membered heterocyclic hydrocarbon group;
[0071] Each R 11a , R 11b , R 11c and R 11d are each independently deuterium, hydroxyl, cyano, halogen, -N(R 12 2. C 1-6 Alkyl, -OC 1-6 Alkyl or C 3-7 Cycloalkyl;
[0072] Each R 12 are independently hydrogen or C 1-6 alkyl;
[0073] In each "3-12 membered heterocyclic hydrocarbon group", the heteroatom species are each independently selected from one, two or more of N, O and S, and the number of heteroatoms is each independently 1, 2 or 3;
[0074] “Two R’s 11 Connected with them Together form a 4-8 membered heterocyclic hydrocarbon group or one or more R l1d In each of the "4-8 membered heterocyclic hydrocarbon groups" in the "substituted 4-8 membered heterocyclic hydrocarbon group", when the number of heteroatom groups is 1, the heteroatom group is P(O); when the number of heteroatoms or heteroatom groups is 2 or 3, one of the heteroatom groups is P(O), and the remaining heteroatoms are independently selected from one or two of N, O and S;
[0075] In each "5-10 membered heteroaryl", the heteroatom species are independently selected from one, two or more of N, O and S, and the number of heteroatoms is independently 1, 2 or 3;
[0076] When m is 1, R 1 Not halogen.
[0077] In one embodiment, each halogen can independently be fluorine, chlorine, bromine or iodine, for example fluorine.
[0078] In one embodiment, each halogen can independently be fluorine, chlorine, bromine or iodine, for example fluorine or chlorine.
[0079] In one scheme, each C 1-6 The alkyl group may independently be C 1-4Alkyl may be methyl, ethyl, n-propyl, isopropyl, n-butyl, tert-butyl, isobutyl or sec-butyl, for example methyl, ethyl or isopropyl, for example methyl or ethyl.
[0080] In a certain embodiment, each 3-12 membered heterocycloalkyl group can independently be a 3-12 membered heterocycloalkyl group or a 3-12 membered heterocycloalkenyl group;
[0081] The 3-12 membered heterocycloalkyl group may be a 3-6 membered monocyclic heterocycloalkyl group with 1, 2 or 3 heteroatoms selected from N, or a 6-12 membered polycyclic (e.g., cyclic, spiro or bridged) heterocycloalkyl group, for example, a 3-6 membered monocyclic heterocycloalkyl group with 1, 2 or 3 heteroatoms selected from N, or piperazinyl, morpholinyl, tetrahydropyrrolyl, oxetanyl or azetidinyl, further for example
[0082] The 3-12 membered heterocycloalkenyl group may be a 3-6 membered monocyclic heterocycloalkenyl group having 1, 2 or 3 heteroatoms selected from N or a 6-12 membered polycyclic (e.g., cyclic, spiro or bridged) heterocycloalkenyl group, for example, a 3-6 membered monocyclic heterocycloalkenyl group having 1, 2 or 3 heteroatoms selected from N, or Further example
[0083] In a certain embodiment, each 3-12 membered heterocycloalkyl group can independently be a 3-12 membered heterocycloalkyl group or a 3-12 membered heterocycloalkenyl group;
[0084] The 3-12 membered heterocycloalkyl group may be a 3-6 membered monocyclic heterocycloalkyl group with one or both heteroatoms selected from N and O, and the number of heteroatoms is 1, 2 or 3, or a 6-12 membered polycyclic (e.g., cyclic, spiro or bridged) heterocycloalkyl group, for example, a 3-6 membered monocyclic heterocycloalkyl group with one, 2 or 3 heteroatoms selected from N and O, and the number of heteroatoms is 1, 2 or 3, for example piperazinyl, morpholinyl, tetrahydropyrrolyl, oxetanyl or azetidinyl, further for example Further, for example The 6-12 membered polycyclic heterocycloalkyl may be a 6-12 membered spirocyclic heterocycloalkyl, preferably More preferred
[0085] The 3-12 membered heterocycloalkenyl group may be a 3-6 membered monocyclic heterocycloalkenyl group having one or both heteroatoms selected from N and O, and having 1, 2 or 3 heteroatoms, or a 6-12 membered polycyclic (e.g., cyclic, spiro or bridged) heterocycloalkenyl group, for example, a 3-6 membered monocyclic heterocycloalkenyl group having one, 2 or 3 heteroatoms selected from N, and having 1, 2 or 3 heteroatoms, for example Further example
[0086] In a certain embodiment, each 5-10 membered heteroaryl group can independently be a 5-6 membered monocyclic heteroaryl group or an 8-10 membered bicyclic (e.g., cyclic, spiro or bridged) heteroaryl group, wherein the heteroatom species is N and the number of heteroatoms is 1, 2 or 3, for example Another example
[0087] In a certain embodiment, each 5-10 membered heteroaryl group can be independently a 5-6 membered monocyclic heteroaryl group or an 8-10 membered bicyclic (e.g., cyclic, spiro or bridged) heteroaryl group, wherein the heteroatom species is selected from one or two of N, O and S, and the number of heteroatoms is 1, 2 or 3. The 5-6 membered monocyclic heteroaryl group is, for example, Another example The 8-10 membered bicyclic heteroaryl group is for example Another example
[0088] In a certain embodiment, each 5-10 membered heteroaryl group can independently be a 5-10 membered cycloheteroaryl group, preferably an 8-10 membered cycloheteroaryl group, and the cycloheteroaryl group is preferably a 6-membered cycloheteroaryl group, such as a 6-membered heterocycloalkylphenyl group.
[0089] In one scheme, each C 3-7 The cycloalkyl groups may independently be C 3-7 Cycloalkyl or C 3-7 Cycloalkenyl, such as C 3-7 Cycloalkyl, the C 3-7 The cycloalkyl group may be C 3-7 Monocyclic cycloalkyl or C 6-7 Polycyclic (eg, cyclopentyl, cyclobutyl, cyclopentyl or cyclohexyl) cycloalkyl, preferably cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl, such as cyclopropyl; the C 3-7 Cycloalkenyl can be C 3-7 Monocyclic cycloalkenyl or C 6-7 Polycyclic (eg, fused, spiro or bridged) cycloalkenyl.
[0090] In one scheme, each C 6-10 Aryl may independently be phenyl or naphthyl, for example phenyl.
[0091] In one scheme, each -OC 1-6 The alkyl group may independently be -OC 1-4 Alkyl may in turn be methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, sec-butoxy or tert-butoxy, for example methoxy.
[0092] In one scheme, each C 2-6The alkenyl group may independently be ethenyl, propenyl, butenyl or pentenyl.
[0093] In one scheme, each C 2-6 Alkynyl groups may independently be ethynyl, propynyl, butynyl or pentynyl.
[0094] In one scheme, each -SC 1-6 The alkyl group may independently be -SC 1-4 The alkyl group may be methylmercapto, ethylmercapto, n-propylmercapto, isopropylmercapto, n-butylmercapto, isobutylmercapto, sec-butylmercapto or tert-butylmercapto.
[0095] In one embodiment, each -CO(C 1-6 Alkyl) may independently be -CO(C 1-4 Alkyl), and may also be -C(O)CH3, -C(O)CH2CH3, -C(O)(CH2)2CH3, -C(O)CH(CH3)2 or -C(O)(CH2)3CH3.
[0096] In one scheme, each -OC 3-7 The cycloalkyl groups may independently be -OC 3-7 Cycloalkyl or -OC 3-7 Cycloalkenyl, the -OC 3-7 The cycloalkyl group may be -OC 3-7 Monocyclic cycloalkyl or -OC 6-7 Polycyclic (eg, fused, spiro or bridged) cycloalkyl, the -OC 3-7 Cycloalkenyl can be -OC 3-7 Monocyclic cycloalkenyl or -OC 6-7 Polycyclic (eg, fused, spiro or bridged) cycloalkenyl.
[0097] In a certain embodiment, each 4-8 membered heterocycloalkyl group can independently be a 4-8 membered heterocycloalkyl group or a 4-8 membered heterocycloalkenyl group;
[0098] The 4-8 membered heterocycloalkyl may be a 4-6 membered monocyclic heterocycloalkyl or a 6-8 membered bicyclic heterocycloalkyl, wherein when the number of heteroatom groups is 1, the heteroatom group is P(O), when the number of heteroatoms or heteroatom groups is 2 or 3, one of the heteroatom groups is P(O), and the remaining heteroatoms are independently selected from one or two of N, O and S; the 4-6 membered monocyclic heterocycloalkyl may be a 4-6 membered monocyclic heterocycloalkyl, wherein when the number of heteroatom groups is 1, the heteroatom group is P(O), when the number of heteroatoms or heteroatom groups is 2 or 3, one of the heteroatom groups is P(O), and the remaining heteroatoms are independently selected from N and / or O, preferably
[0099] The 4-8 membered heterocycloalkenyl group is preferably a 4-6 membered monocyclic heterocycloalkenyl group or a 6-8 membered bicyclic heterocycloalkenyl group, wherein when the number of the heteroatom groups is 1, the heteroatom group is P(O); when the number of the heteroatoms or heteroatom groups is 2 or 3, wherein one heteroatom group is P(O), and the remaining heteroatoms are independently selected from one or two of N, O and S.
[0100] In a certain aspect, each "one or more" can independently be 1, 2 or 3.
[0101] In one embodiment, X1 is CH.
[0102] In one embodiment, X2 is CH.
[0103] In one embodiment, X3 is CH.
[0104] In one embodiment, X4 is CH.
[0105] In one scheme, each R 1 are independently halogen, hydroxyl, C 1-6 Alkyl, 3-12 membered heterocyclic hydrocarbon, 1f substituted 3-12 membered heterocyclic hydrocarbon group, 5-10 membered heteroaryl group or one or more R 1h Substituted 5-10 membered heteroaryl, preferably halogen, C 1-6 Alkyl, with one or more R 1f substituted 3-12 membered heterocyclic hydrocarbon group, 5-10 membered heteroaryl group or one or more R 1h Substituted 5-10 membered heteroaryl, preferably halogen, C 1-6 Alkyl or 5-10 membered heteroaryl.
[0106] In one scheme, each R 1 are independently cyano, halogen, hydroxyl, C 1-6 Alkyl, with one or more R 1a Substituted C 1-6 Alkyl, 3-12 membered heterocyclic hydrocarbon, 1f substituted 3-12 membered heterocyclic hydrocarbon group, 5-10 membered heteroaryl group, substituted by one or more R 1h Substituted 5-10 membered heteroaryl, C 2-6 Alkynyl, -N(R 8 2. -COR 8 、-COOR 8 or-CON(R 8 )2; cyano, one or more R 1a Substituted C 1-6 Alkyl, C 2-6 Alkynyl, -N(R 82. -COR 8 、-COOR 8 or-CON(R 8 )2; preferably cyano, halogen, C 1-6 Alkyl, with one or more R 1a Substituted C 1-6 Alkyl, 3-12 membered heterocyclic hydrocarbon, 1f substituted 3-12 membered heterocyclic hydrocarbon group, 5-10 membered heteroaryl group, substituted by one or more R 1h Substituted 5-10 membered heteroaryl, C 2-6 Alkynyl, -N(R 8 2. -COR 8 、-COOR 8 or-CON(R 8 )2; preferably cyano, halogen, C 1-6 Alkyl, with one or more R 1f substituted 3-12 membered heterocyclic hydrocarbon group, 5-10 membered heteroaryl group, substituted by one or more R 1h Substituted 5-10 membered heteroaryl, C 2-6 Alkynyl or -COOR 8 ; further preferably halogen, C 1-6 Alkyl, 5-10 membered heteroaryl or -COOR 8 .
[0107] In one scheme, each R 1a are independently hydroxy or halogen.
[0108] In one scheme, each R 1f Independently for C 1-6 alkyl.
[0109] In one scheme, each R 1f are independently hydroxy, halogen or C 1-6 Alkyl, hydroxyl, or halogen.
[0110] In one scheme, each R 1h Independently for C 1-6 alkyl.
[0111] In one scheme, each R 1h Independently for C 1-6 Alkyl or one or more -CON(R 13 )2 substituted C 1-6 alkyl.
[0112] In one scheme, each R 8 are independently hydrogen, C 1-6 Alkyl or one or more R 8-1Substituted 3-12 membered heterocyclic hydrocarbon group, also C 1-6 alkyl.
[0113] In one scheme, each R 8-1 are independently halogen or C 1-6 alkyl.
[0114] In one scheme, each R 13 are independently hydrogen or C 1-6 Alkyl, also hydrogen.
[0115] In one embodiment, m is 1, 2 or 3.
[0116] In one scenario, R 2 C 1-6 Alkyl, with one or more R 2a Substituted C 1-6 Alkyl, C 3-7 Cyclic hydrocarbon or one or more R 2d Substituted C 3-7 Cycloalkyl, preferably C 1-6 Alkyl or C 3-7 Cycloalkyl, more preferably C 1-6 alkyl.
[0117] In one scheme, each R 2a are independently halogen.
[0118] In one scheme, each R 2d Independently for C 1-6 alkyl.
[0119] In one scenario, R 3 For hydroxyl, cyano, halogen, C 1-6 Alkyl or one or more R 3a Substituted C 1-6 Alkyl, preferably with one or more R 3a Substituted C 1-6 alkyl.
[0120] In one scheme, each R 3a are independently halogen.
[0121] In one scenario, R 4 and R 5 are independently hydrogen, hydroxy, cyano, halogen or C 1-6 Alkyl, preferably hydrogen.
[0122] In one scenario, R 6 For hydrogen.
[0123] In one scenario, R 7 For one or more R 7cSubstituted C 6-10 Aryl.
[0124] In one scheme, each R 7c Independently -SO2R 10 ,-P(=O)(R 11 )2 or -OC 1-6 Alkyl, with at least one R 7c SO2R 10 or -P(=O)(R 11 )2; preferably -SO2R 10 or -OC 1-6 Alkyl, and at least one R 7c SO2R 10 .
[0125] In one scheme, each R 7c Independently -SO2R 10 ,-P(=O)(R 11 )2. -OC 1-6 Alkyl, with one or more R 7-b Replaced-OC 1-6 Alkyl or one or more R 7-j Substituted -O-(3-12 membered heterocyclic hydrocarbon group), with at least one R 7c SO2R 10 or -P(=O)(R 11 )2.
[0126] In one scheme, each R 7-b is independently a 3-12 membered heterocyclic hydrocarbon group or is replaced by one or more R 7-a-1 Substituted 3-12 membered heterocyclic hydrocarbon group.
[0127] In one scheme, each R 7-a-1 Independently for C 1-6 alkyl.
[0128] In one scheme, each R 7-j Independently for C 1-6 alkyl.
[0129] In one scheme, each R 10 Independently for C 1-6 alkyl.
[0130] In one scheme, each R 11 Each independently is C 1-6 Alkyl, or two R 11 Connected with them Together form a 4-8 membered heterocyclic hydrocarbon group or one or more R l1dSubstituted 4-8 membered heterocyclic hydrocarbon group; preferably C 1-6 alkyl.
[0131] In one scheme, each R 11d are independently -N(R 12 )2 or C 1-6 alkyl.
[0132] In one scheme, each R 12 Independently for C 1-6 alkyl.
[0133] In one scheme, each R 1 Independently Fluorine or methyl, preferably Fluorine or methyl.
[0134] In one scheme, each R 1 Independently Fluorine, chlorine, cyano, Methyl, -NH2, Best Fluorine, chlorine, cyano, Methyl, -NH2,
[0135] In one scheme, each R 8 are independently hydrogen, methyl or Preferred are hydrogen, methyl,
[0136] In one scenario, R 2 for Methyl or ethyl, preferably Methyl or ethyl.
[0137] In one scenario, R 3 for
[0138] In one scheme, each R 7c are independently -OCH3, -SO2CH3, Preferred is -OCH3 or -SO2CH3.
[0139] In one scheme, each R 7-b Independently For example
[0140] In one scheme, each R 7-a-1are independently methyl.
[0141] In one scheme, each R 7-j are independently methyl.
[0142] In one scheme, each R 7c are independently -OCH3, -SO2CH3, Preferred -OCH3, Or -SO2CH3.
[0143] In one scenario, R 7 for Best
[0144] In one scenario, R 7 for Best
[0145] In one embodiment, X1 is CH;
[0146] X2 is CH;
[0147] X3 is CH;
[0148] X4 is CH;
[0149] Each R 1 are independently halogen, hydroxyl, C 1-6 Alkyl, 3-12 membered heterocyclic hydrocarbon, 1f substituted 3-12 membered heterocyclic hydrocarbon group, 5-10 membered heteroaryl group or one or more R 1h substituted 5-10 membered heteroaryl;
[0150] Each R 1f Independently for C 1-6 alkyl;
[0151] Each R 1h Independently for C 1-6 alkyl;
[0152] m is 1, 2 or 3;
[0153] R 2 C 1-6 Alkyl, with one or more R 2a Substituted C 1-6 Alkyl, C 3-7 Cyclic hydrocarbon or one or more R 2d Substituted C3-7 Cycloalkyl;
[0154] Each R 2a are independently halogen;
[0155] Each R 2d Independently for C 1-6 alkyl;
[0156] R 3 For hydroxyl, cyano, halogen, C 1-6 Alkyl or one or more R 3a Substituted C 1-6 alkyl;
[0157] Each R 3a are independently halogen;
[0158] R 4 and R 5 are independently hydrogen, hydroxy, cyano, halogen or C 1-6 alkyl;
[0159] R 6 is hydrogen;
[0160] R 7 For one or more R 7c Substituted C 6-10 Aryl;
[0161] Each R 7c Independently -SO2R 10 ,-P(=O)(R 11 )2 or -OC 1-6 Alkyl, with at least one R 7c SO2R 10 or -P(=O)(R 11 )2;
[0162] Each R 10 Independently for C 1-6 alkyl;
[0163] Each R 11 Independently for C 1-6 Alkyl, or two R 11 Connected to them Together form a 4-8 membered heterocyclic hydrocarbon group or one or more R l1d Substituted 4-8 membered heterocyclic hydrocarbon group;
[0164] Each R 11d are independently -N(R 12 )2 or C 1-6 alkyl;
[0165] Each R12 Independently for C 1-6 alkyl;
[0166] And when m is 1, R 1 Not halogen.
[0167] In one scheme, X1 is CH;
[0168] X2 is CH;
[0169] X3 is CH;
[0170] X4 is CH;
[0171] Each R 1 are independently cyano, halogen, hydroxyl, C 1-6 Alkyl, with one or more R 1a Substituted C 1-6 Alkyl, 3-12 membered heterocyclic hydrocarbon, 1f substituted 3-12 membered heterocyclic hydrocarbon group, 5-10 membered heteroaryl group, substituted by one or more R 1h Substituted 5-10 membered heteroaryl, C 2-6 Alkynyl, -N(R 8 2. -COR 8 、-COOR 8 or-CON(R 8 )2;
[0172] Each R 1a are independently hydroxy or halogen;
[0173] Each R 1f are independently hydroxy, halogen or C 1-6 alkyl;
[0174] Each R 1h Independently for C 1-6 Alkyl or one or more -CON(R 13 )2 substituted C 1-6 alkyl;
[0175] Each R 8 are independently hydrogen, C 1-6 Alkyl or one or more R 8-1 Substituted 3-12 membered heterocyclic hydrocarbon group;
[0176] Each R 8-1 are independently halogen or C 1-6 alkyl;
[0177] Each R 13 are independently hydrogen or C 1-6 alkyl;
[0178] m is 1, 2 or 3;
[0179] R 2 C 1-6 Alkyl, with one or more R 2a Substituted C 1-6 Alkyl, C 3-7 Cyclic hydrocarbon or one or more R 2d Substituted C 3-7 Cycloalkyl;
[0180] Each R 2a are independently halogen;
[0181] Each R 2d Independently for C 1-6 alkyl;
[0182] R 3 For hydroxyl, cyano, halogen, C 1-6 Alkyl or one or more R 3a Substituted C 1-6 alkyl;
[0183] Each R 3a are independently halogen;
[0184] R 4 and R 5 are independently hydrogen, hydroxy, cyano, halogen or C 1-6 alkyl;
[0185] R 6 is hydrogen;
[0186] R 7 For one or more R 7c Substituted C 6-10 Aryl;
[0187] Each R 7c Independently -SO2R 10 ,-P(=O)(R 11 )2. -OC 1-6 Alkyl, with one or more R 7-b Replaced-OC 1-6 Alkyl or one or more R 7-j Substituted -O-(3-12 membered heterocyclic hydrocarbon group), with at least one R 7c SO2R 10 or -P(=O)(R 11 )2;
[0188] Each R 7-b is independently a 3-12 membered heterocyclic hydrocarbon group or is replaced by one or more R 7-a-1 Substituted 3-12 membered heterocyclic hydrocarbon group;
[0189] Each R 7-a-1 Independently for C 1-6 alkyl;
[0190] Each R 7-j Independently for C 1-6 alkyl;
[0191] Each R 10 Independently for C 1-6 alkyl;
[0192] Each R 11 Independently for C 1-6 Alkyl, or two R 11 Connected to them Together form a 4-8 membered heterocyclic hydrocarbon group or one or more R l1d Substituted 4-8 membered heterocyclic hydrocarbon group;
[0193] Each R 11d are independently -N(R 12 )2 or C 1-6 alkyl;
[0194] Each R 12 Independently for C 1-6 alkyl;
[0195] And when m is 1, R 1 Not halogen.
[0196] In one embodiment, X1 is CH;
[0197] X2 is CH;
[0198] X3 is CH;
[0199] X4 is CH;
[0200] Each R 1 are independently halogen, C 1-6 Alkyl, with one or more R 1f substituted 3-12 membered heterocyclic hydrocarbon group, 5-10 membered heteroaryl group or one or more R 1h substituted 5-10 membered heteroaryl;
[0201] Each R 1f Independently for C 1-6 alkyl;
[0202] Each R 1h Independently for C 1-6 alkyl;
[0203] m is 1, 2 or 3;
[0204] R 2 C1-6 Alkyl, with one or more R 2a Substituted C 1-6 Alkyl, C 3-7 Cyclic hydrocarbon or one or more R 2d Substituted C 3-7 Cycloalkyl;
[0205] Each R 2a are independently halogen;
[0206] Each R 2d Independently for C 1-6 alkyl;
[0207] R 3 For one or more R 3a Substituted C 1-6 alkyl;
[0208] Each R 3a are independently halogen;
[0209] R 4 and R 5 each independently is hydrogen;
[0210] R 6 is hydrogen;
[0211] R 7 For one or more R 7c Substituted C 6-10 Aryl;
[0212] Each R 7c Independently -SO2R 10 ,-P(=O)(R 11 )2 or -OC 1-6 Alkyl, and at least one R 7c SO2R 10 or -P(=O)(R 11 )2;
[0213] Each R 10 Independently for C 1-6 alkyl;
[0214] Each R 11 Independently for C 1-6 alkyl;
[0215] And when m is 1, R 1 Not halogen.
[0216] In one scheme, X1 is CH;
[0217] X2 is CH;
[0218] X3 is CH;
[0219] X4 is CH;
[0220] Each R 1 are independently cyano, halogen, C 1-6 Alkyl, with one or more R 1a Substituted C 1-6 Alkyl, 3-12 membered heterocyclic hydrocarbon, 1f substituted 3-12 membered heterocyclic hydrocarbon group, 5-10 membered heteroaryl group, substituted by one or more R 1h Substituted 5-10 membered heteroaryl, C 2-6 Alkynyl, -N(R 8 2. -COR 8 、-COOR 8 or-CON(R 8 )2;
[0221] Each R 1a are independently hydroxy or halogen;
[0222] Each R 1f are independently hydroxy, halogen or C 1-6 alkyl;
[0223] Each R 1h Independently for C 1-6 Alkyl or one or more -CON(R 13 )2 substituted C 1-6 alkyl;
[0224] Each R 8 are independently hydrogen, C 1-6 Alkyl or one or more R 8-1 Substituted 3-12 membered heterocyclic hydrocarbon group;
[0225] Each R 8-1 are independently halogen or C 1-6 alkyl;
[0226] Each R 13 are independently hydrogen;
[0227] m is 1, 2 or 3;
[0228] R 2 C 1-6 Alkyl, with one or more R 2a Substituted C 1-6 Alkyl, C 3-7 Cyclic hydrocarbon or one or more R 2d Substituted C 3-7 Cycloalkyl;
[0229] Each R 2aare independently halogen;
[0230] Each R 2d Independently for C 1-6 alkyl;
[0231] R 3 For one or more R 3a Substituted C 1-6 alkyl;
[0232] Each R 3a are independently halogen;
[0233] R 4 and R 5 each independently is hydrogen;
[0234] R 6 is hydrogen;
[0235] R 7 For one or more R 7c Substituted C 6-10 Aryl;
[0236] Each R 7c Independently -SO2R 10 ,-P(=O)(R 11 )2. -OC 1-6 Alkyl, with one or more R 7-b Replaced-OC 1-6 Alkyl or one or more R 7-j Substituted -O-(3-12 membered heterocyclic hydrocarbon group), with at least one R 7c SO2R 10 or -P(=O)(R 11 )2;
[0237] Each R 7-b is independently a 3-12 membered heterocyclic hydrocarbon group or is replaced by one or more R 7-a-1 Substituted 3-12 membered heterocyclic hydrocarbon group;
[0238] Each R 7-a-1 Independently for C 1-6 alkyl;
[0239] Each R 7-j Independently for C 1-6 alkyl;
[0240] Each R 10 Independently for C 1-6 alkyl;
[0241] Each R 11 Independently for C 1-6 alkyl;
[0242] And when m is 1, R 1 Not halogen.
[0243] In one embodiment, X1 is CH;
[0244] X2 is CH;
[0245] X3 is CH;
[0246] X4 is CH;
[0247] Each R 1 are independently halogen, C 1-6 Alkyl, with one or more R 1f substituted 3-12 membered heterocyclic hydrocarbon group, 5-10 membered heteroaryl group or one or more R 1h substituted 5-10 membered heteroaryl;
[0248] Each R 1f Independently for C 1-6 alkyl;
[0249] Each R 1h Independently for C 1-6 alkyl;
[0250] m is 1 or 2;
[0251] R 2 C 1-6 Alkyl or C 3-7 Cycloalkyl;
[0252] R 3 For one or more R 3a Substituted C 1-6 Alkyl (e.g. ethyl substituted by 1, 2 or 3 fluorine groups);
[0253] Each R 3a are independently halogen (e.g. fluorine);
[0254] R 4 and R 5 each independently is hydrogen;
[0255] R 6 is hydrogen;
[0256] R 7 For one or more R 7c Substituted C 6-10 Aryl;
[0257] Each R 7c Independently -SO2R 10 or -OC 1-6 Alkyl (e.g. -SO2CH3 or methoxy), and at least one R7c SO2R 10 ;
[0258] Each R 10 Independently for C 1-6 Alkyl (e.g. methyl);
[0259] And when m is 1, R 1 Not halogen.
[0260] In one scheme, X1 is CH;
[0261] X2 is CH;
[0262] X3 is CH;
[0263] X4 is CH;
[0264] Each R 1 are independently cyano, halogen, C 1-6 Alkyl, with one or more R 1a Substituted C 1-6 Alkyl, 3-12 membered heterocyclic hydrocarbon, 1f substituted 3-12 membered heterocyclic hydrocarbon group, 5-10 membered heteroaryl group, substituted by one or more R 1h Substituted 5-10 membered heteroaryl, C 2-6 Alkynyl, -N(R 8 2. -COR 8 、-COOR 8 or-CON(R 8 )2;
[0265] Each R 1a are independently hydroxy or halogen;
[0266] Each R 1f are independently hydroxy, halogen or C 1-6 alkyl;
[0267] Each R 1h Independently for C 1-6 Alkyl or one or more -CON(R 13 )2 substituted C 1-6 alkyl;
[0268] Each R 8 are independently hydrogen, C 1-6 Alkyl or one or more R 8-1 Substituted 3-12 membered heterocyclic hydrocarbon group;
[0269] Each R 8-1 are independently halogen or C 1-6 alkyl;
[0270] Each R13 are independently hydrogen;
[0271] m is 1 or 2;
[0272] R 2 C 1-6 Alkyl or C 3-7 Cycloalkyl;
[0273] R 3 For one or more R 3a Substituted C 1-6 Alkyl (e.g. ethyl substituted by 1, 2 or 3 fluorine groups);
[0274] Each R 3a are independently halogen (e.g. fluorine);
[0275] R 4 and R 5 each independently is hydrogen;
[0276] R 6 is hydrogen;
[0277] R 7 For one or more R 7c Substituted C 6-10 Aryl;
[0278] Each R 7c Independently -SO2R 10 ,-P(=O)(R 11 )2 or -OC 1-6 Alkyl (e.g., -SO2CH3, -P(=O)(CH3)2 or methoxy), and at least one R 7c SO2R 10 or -P(=O)(R 11 )2;
[0279] Each R 10 Independently for C 1-6 Alkyl (e.g. methyl);
[0280] Each R 11 Independently for C 1-6 Alkyl (e.g. methyl);
[0281] And when m is 1, R 1 Not halogen.
[0282] In one embodiment, X1 is CH;
[0283] X2 is CH;
[0284] X3 is CH;
[0285] X4 is CH;
[0286] Each R 1 are independently halogen, C 1-6 Alkyl, with one or more R 1f substituted 3-12 membered heterocyclic hydrocarbon group, 5-10 membered heteroaryl group or one or more R 1h substituted 5-10 membered heteroaryl;
[0287] Each R 1f Independently for C 1-6 alkyl;
[0288] Each R 1h Independently for C 1-6 alkyl;
[0289] m is 1 or 2;
[0290] R 2 C 1-6 Alkyl (e.g. methyl);
[0291] R 3 For one or more R 3a Substituted C 1-6 Alkyl (e.g. ethyl substituted by 1, 2 or 3 fluorine groups);
[0292] Each R 3a are independently halogen (e.g. fluorine);
[0293] R 4 and R 5 each independently is hydrogen;
[0294] R 6 is hydrogen;
[0295] R 7 For one or more R 7c Substituted C 6-10 Aryl;
[0296] Each R 7c Independently -SO2R 10 or -OC 1-6 Alkyl (e.g. -SO2CH3 or methoxy), and at least one R 7c SO2R 10 ;
[0297] Each R 10 Independently for C 1-6 Alkyl (e.g. methyl);
[0298] And when m is 1, R 1 Not halogen.
[0299] In one embodiment, X1 is CH;
[0300] X2 is CH;
[0301] X3 is CH;
[0302] X4 is CH;
[0303] Each R 1 are independently cyano, halogen, C 1-6 Alkyl, with one or more R 1f substituted 3-12 membered heterocyclic hydrocarbon group, 5-10 membered heteroaryl group, substituted by one or more R 1h Substituted 5-10 membered heteroaryl, C 2-6 Alkynyl or -COOR 8 ;
[0304] Each R 1f Independently for C 1-6 alkyl;
[0305] Each R 1h Independently for C 1-6 alkyl;
[0306] Each R 8 Independently for C 1-6 alkyl;
[0307] m is 1 or 2;
[0308] R 2 C 1-6 Alkyl (e.g. methyl);
[0309] R 3 For one or more R 3a Substituted C 1-6 Alkyl (e.g. ethyl substituted by 1, 2 or 3 fluorine groups);
[0310] Each R 3a are independently halogen (e.g. fluorine);
[0311] R 4 and R 5 each independently is hydrogen;
[0312] R 6 is hydrogen;
[0313] R 7 For one or more R 7c Substituted C 6-10 Aryl;
[0314] Each R 7c Independently -SO2R 10 ,-P(=O)(R 11 )2 or -OC1-6 Alkyl (e.g., -SO2CH3, -P(=O)(CH3)2 or methoxy), and at least one R 7c SO2R 10 or -P(=O)(R 11 )2;
[0315] Each R 10 Independently for C 1-6 Alkyl (e.g. methyl);
[0316] Each R 11 Independently for C 1-6 Alkyl (e.g. methyl);
[0317] And when m is 1, R 1 Not halogen.
[0318] In one scheme, X1 is CH;
[0319] X2 is CH;
[0320] X3 is CH;
[0321] X4 is CH;
[0322] Each R 1 are independently halogen, C 1-6 Alkyl or 5-10 membered heteroaryl, R 1 The 5-10 membered heteroaryl group is connected to the 6-position of indole (i.e., connected to the ring carbon atom of X2);
[0323] m is 1 or 2;
[0324] R 2 C 1-6 Alkyl (e.g., methyl or ethyl);
[0325] R 3 For one or more R 3a Substituted C 1-6 Alkyl (e.g. ethyl substituted by 1, 2 or 3 fluorine groups);
[0326] Each R 3a are independently halogen (e.g. fluorine);
[0327] R 4 and R 5 each independently is hydrogen;
[0328] R 6 is hydrogen;
[0329] R 7 For one or more R 7c Substituted C 6-10 Aryl;
[0330] Each R 7c Independently -SO2R 10 or -OC 1-6 Alkyl (e.g. -SO2CH3 or methoxy), and at least one R 7c SO2R 10 ;
[0331] Each R 10 Independently for C 1-6 Alkyl (e.g. methyl);
[0332] And when m is 1, R 1 Not halogen.
[0333] In one embodiment, X1 is CH;
[0334] X2 is CH;
[0335] X3 is CH;
[0336] X4 is CH;
[0337] Each R 1 are independently halogen, C 1-6 Alkyl, 5-10 membered heteroaryl or -COOR 8 , when the 5-10 membered heteroaryl is an 8-10 membered bicyclic heteroaryl, R 1 The 8-10 membered bicyclic heteroaryl group is connected to the 6-position of indole (i.e., connected to the ring carbon atom of X2);
[0338] Each R 8 Independently for C 1-6 Alkyl (e.g. methyl);
[0339] m is 1 or 2;
[0340] R 2 C 1-6 Alkyl (e.g., methyl or ethyl);
[0341] R 3 For one or more R 3a Substituted C 1-6 Alkyl (e.g. ethyl substituted by 1, 2 or 3 fluorine groups);
[0342] Each R 3a are independently halogen (e.g. fluorine);
[0343] R 4 and R 5 each independently is hydrogen;
[0344] R 6 is hydrogen;
[0345] R 7 For one or more R 7c Substituted C 6-10 Aryl;
[0346] Each R 7c Independently -SO2R 10 or -OC 1-6 Alkyl (e.g. -SO2CH3 or methoxy), and at least one R 7c SO2R 10 ;
[0347] Each R 10 Independently for C 1-6 Alkyl (e.g. methyl);
[0348] And when m is 1, R 1 Not halogen.
[0349] In one embodiment, the compound represented by formula (I) is a compound represented by formula (I-1), (I-2) or (I-3):
[0350]
[0351] Among them, R 1-a For one or more R 1f substituted 3-12 membered heterocyclic hydrocarbon group, 5-10 membered heteroaryl group or one or more R 1h substituted 5-10 membered heteroaryl;
[0352] R 1-b Halogen or C 1-6 alkyl;
[0353] m' is 0, 1, 2 or 3;
[0354] m、R 1 , R 1f , R 1h , R 2 , R 3 and R 7 The definition of is as described in any embodiment of the present invention.
[0355] In one embodiment, the compound represented by formula (I) is a compound represented by formula (I-4), (I-5) or (I-6):
[0356]
[0357] Among them, R 1-c For one or more R 1f substituted 3-12 membered heterocyclic hydrocarbon group, 5-10 membered heteroaryl group, substituted by one or more R1h Substituted 5-10 membered heteroaryl or -N(R 8 )2;
[0358] R 1-d For cyano, halogen, C 1-6 Alkyl, with one or more R 1a Substituted C 1-6 Alkyl, 5-10 membered heteroaryl, 1h Substituted 5-10 membered heteroaryl, -COR 8 、-COOR 8 , C 2-6 Alkynyl, -N(R 8 )2 or -CON(R 8 )2;
[0359] R 1-e is a 5-10 membered heteroaryl group, 1h substituted 5-10 membered heteroaryl or one or more R 1f Substituted 3-12 membered heterocyclic hydrocarbon group;
[0360] R 1-f Halogen or C 1-6 alkyl;
[0361] m' is 0, 1, 2 or 3;
[0362] m、R 1 , R 1a , R 1f , R 1h , R 2 , R 3 , R 7 , R 7c and R 8 The definition of is as described in any embodiment of the present invention.
[0363] In one embodiment, the compound represented by formula (I) is any of the following compounds:
[0364]
[0365]
[0366]
[0367]
[0368]
[0369] The present invention also provides a pharmaceutical composition, which comprises (a therapeutically effective amount of) substance A and a pharmaceutically acceptable excipient, wherein the substance A is a compound as shown in formula (I) or a pharmaceutically acceptable salt thereof as described in any embodiment of the present invention.
[0370] The present invention also provides a use of a compound as shown in formula (I) or a pharmaceutically acceptable salt thereof or the above-mentioned pharmaceutical composition according to any embodiment of the present invention in the preparation of a p53 Y220C activator. In the above-mentioned application, the p53Y220C activator can be used in mammals; it can also be used in vitro, mainly for experimental purposes, for example: as a standard sample or control sample for comparison, or prepared into a kit according to conventional methods in the art to provide rapid detection of the activation effect of p53 Y220C.
[0371] The present invention also provides a use of a compound as shown in formula (I) or a pharmaceutically acceptable salt thereof or the above-mentioned pharmaceutical composition according to any embodiment of the present invention in the preparation of a drug for treating and / or preventing a disease associated with the p53 Y220C mutation; preferably, the compound as shown in formula (I) or a pharmaceutically acceptable salt thereof or the above-mentioned pharmaceutical composition is a therapeutically effective amount. The disease may be cancer, preferably ovarian cancer, breast cancer, lung cancer, colorectal cancer, gastric cancer, head and neck cancer, prostate cancer, endometrial cancer, pancreatic cancer or liver cancer, more preferably ovarian cancer, breast cancer, lung cancer, pancreatic cancer or liver cancer, such as pancreatic cancer or liver cancer.
[0372] The present invention also provides a use of a compound as shown in formula (I) or a pharmaceutically acceptable salt thereof or the above-mentioned pharmaceutical composition according to any embodiment of the present invention in the preparation of a drug for treating and / or preventing cancer; preferably, the compound as shown in formula (I) or a pharmaceutically acceptable salt thereof or the above-mentioned pharmaceutical composition is a therapeutically effective amount, and / or the cancer is preferably ovarian cancer, breast cancer, lung cancer, colorectal cancer, gastric cancer, head and neck cancer, prostate cancer, endometrial cancer, pancreatic cancer or liver cancer, more preferably ovarian cancer, breast cancer, lung cancer, pancreatic cancer or liver cancer, such as pancreatic cancer or liver cancer.
[0373] The present invention provides a method for activating p53 Y220C, the method comprising administering to a patient a compound as shown in formula (I) or a pharmaceutically acceptable salt thereof or the above-mentioned pharmaceutical composition as described in any scheme of the present invention; preferably, the compound as shown in formula (I) or a pharmaceutically acceptable salt thereof or the above-mentioned pharmaceutical composition is in a therapeutically effective amount.
[0374] The present invention provides a method for treating and / or preventing a disease associated with the p53 Y220C mutation, the method comprising administering to a patient a compound as shown in formula (I) or a pharmaceutically acceptable salt thereof or the above-mentioned pharmaceutical composition as described in any embodiment of the present invention; preferably, the compound as shown in formula (I) or a pharmaceutically acceptable salt thereof or the above-mentioned pharmaceutical composition is a therapeutically effective amount. The disease may be cancer, preferably ovarian cancer, breast cancer, lung cancer, colorectal cancer, gastric cancer, head and neck cancer, prostate cancer, endometrial cancer, pancreatic cancer or liver cancer, more preferably ovarian cancer, breast cancer, lung cancer, pancreatic cancer or liver cancer, such as pancreatic cancer or liver cancer.
[0375] The present invention provides a method for treating and / or preventing cancer, the method comprising administering to a patient a compound as shown in formula (I) or a pharmaceutically acceptable salt thereof or the above-mentioned pharmaceutical composition as described in any embodiment of the present invention; preferably, the compound as shown in formula (I) or a pharmaceutically acceptable salt thereof or the above-mentioned pharmaceutical composition is a therapeutically effective amount, and / or, the cancer is preferably ovarian cancer, breast cancer, lung cancer, colorectal cancer, gastric cancer, head and neck cancer, prostate cancer, endometrial cancer, pancreatic cancer or liver cancer, more preferably ovarian cancer, breast cancer, lung cancer, pancreatic cancer or liver cancer, such as pancreatic cancer or liver cancer.
[0376] The present invention also provides a method for preparing a compound as shown in formula (I) or a pharmaceutically acceptable salt thereof, which is Scheme 1 or Scheme 2:
[0377] Scheme 1: When the compound represented by formula (I) is a compound represented by formula (I') (ie, one R 1 For R a , the rest is R b ), which comprises the following steps: in a solvent, a compound as shown in formula (Ia) is subjected to a deprotection reaction to prepare a compound as shown in formula (I');
[0378]
[0379] in,
[0380] R a’ for R a for Ring A is a 3-12 membered heterocyclic hydrocarbon group containing at least one N or a 5-10 membered heteroaryl group containing at least one N, Y is an amino protecting group, and Y is connected to the N of ring A via a single bond;
[0381] Each R b are independently halogen or C 1-6 alkyl;
[0382] m' is 0, 1, 2 or 3;
[0383] X1, X2, X3, X4, R 2 , R 3 , R 4 , R 5 , R 6 and R 7 The definition of is as described in any embodiment of the present invention;
[0384] Preferably, the solvent is selected from aromatic hydrocarbon solvents, such as toluene;
[0385] And / or, said Y is tert-butyloxycarbonyl;
[0386] Scheme 2: When the compound represented by formula (I) is a compound represented by formula (I") (i.e., one R 1 For R c , the rest is R d ), which comprises the following steps: in a solvent, a compound as represented by formula (Ib) reacts with paraformaldehyde under the action of a reducing agent to prepare a compound as represented by formula (I”);
[0387]
[0388] Among them, R c’ for R c for Ring A is a 3-12-membered heterocyclic hydrocarbon group containing at least one N or a 5-10-membered heteroaryl group containing at least one N;
[0389] Each R d are independently halogen or C 1-6 alkyl;
[0390] m' is 0, 1, 2 or 3;
[0391] X1, X2, X3, X4, R 2 , R 3 , R 4 , R 5 , R 6 and R 7 The definition of is as described in any embodiment of the present invention;
[0392] Preferably, the solvent is selected from halogenated hydrocarbon solvents and / or alcohol solvents, preferably dichloromethane and / or methanol, such as dichloromethane and methanol;
[0393] And / or, the reaction is carried out under acidic conditions, and the acid is preferably a Lewis acid, such as acetic acid or TiCl4;
[0394] And / or, the reducing agent is sodium cyanoborohydride, sodium acetate borohydride or sodium borohydride, preferably sodium cyanoborohydride.
[0395] The present invention also provides a method for preparing the compound represented by formula (I) or a pharmaceutically acceptable salt thereof, which is Scheme 3 or Scheme 4:
[0396] Scheme 3: When the compound represented by formula (I) is a compound represented by formula (I') (ie, one R 1 For R a , the rest is R b ), which comprises the following steps: in a solvent, a compound as shown in formula (Ia) is subjected to a deprotection reaction to prepare a compound as shown in formula (I');
[0397]
[0398] in,
[0399] R a’ for R a for Ring A is a 3-12 membered heterocyclic hydrocarbon group containing at least one N, surrounded by one or more R 1f substituted 3-12-membered heterocyclic hydrocarbon group containing at least one N or 5-10-membered heteroaryl group containing at least one N; Ring A' is replaced by one or more R 8-1 A substituted 3-12-membered heterocyclic hydrocarbon group containing at least one N; Y is an amino protecting group, and Y is connected to the N of ring A or ring A' through a single bond;
[0400] Each R b are independently halogen, cyano, -N(R 8 2. -COR 8 、-COOR 8 、-CON(R 8 )2. One or more R 1a Substituted C 1-6 Alkyl, C 2-6 Alkynyl, 5-10 membered heteroaryl, substituted by one or more R 1h Substituted 5-10 membered heteroaryl or C 1-6 alkyl;
[0401] m' is 0, 1, 2 or 3;
[0402] X1, X2, X3, X4, R 1a , R 1f , R 1h , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8and R 8-1 The definition of is as described in any embodiment of the present invention;
[0403] Preferably, the solvent is selected from aromatic hydrocarbon solvents, such as toluene;
[0404] And / or, said Y is tert-butyloxycarbonyl;
[0405] Scheme 4: When the compound represented by formula (I) is a compound represented by formula (I") (i.e., one R 1 For R c , the rest is R d ), which comprises the following steps: in a solvent, a compound as represented by formula (Ib) reacts with paraformaldehyde under the action of a reducing agent to prepare a compound as represented by formula (I”);
[0406]
[0407] Among them, R c’ for R c for Ring A is a 3-12 membered heterocyclic hydrocarbon group containing at least one N or a 5-10 membered heteroaryl group containing at least one N; Ring A' is a 8-1 A substituted 3-12 membered heterocyclic hydrocarbon group containing at least one N;
[0408] Each R d are independently halogen or C 1-6 alkyl;
[0409] m' is 0, 1, 2 or 3;
[0410] X1, X2, X3, X4, R 2 , R 3 , R 4 , R 5 , R 6 , R 7 and R 8-1 The definition of is as described in any embodiment of the present invention;
[0411] Preferably, the solvent is selected from halogenated hydrocarbon solvents and / or alcohol solvents, preferably dichloromethane and / or methanol, such as dichloromethane and methanol;
[0412] And / or, the reaction is carried out under acidic conditions, and the acid is preferably a Lewis acid, such as acetic acid or TiCl4;
[0413] And / or, the reducing agent is sodium cyanoborohydride, sodium acetate borohydride or sodium borohydride, preferably sodium cyanoborohydride.
[0414] The present invention also provides a compound of formula (Ia) or formula (Ib) as shown below,
[0415]
[0416] Among them, R a’ , R b , R c’ , R d 、m'、X1、X2、X3、X4、R 2 , R 3 , R 4 , R 5 , R 6 and R 7 The definition of is as described in any embodiment of the present invention;
[0417] Preferably, the compound of formula (Ia) is the following compound:
[0418]
[0419]
[0420]
[0421] In addition to the foregoing, when used in the specification and claims of this application, unless otherwise specifically indicated, the following terms have the following meanings:
[0422] In the chemical structure of this application, the bond Indicates that the configuration is not specified. or Indicates the absolute configuration. If there are chiral isomers in the chemical structure, the bond Can be or or include both and Two configurations.
[0423] When "tran" or "cis" is contained in the chemical structure of this application, it means trans or cis. For example, It means that it is trans, that is, the substituents are located on both sides of the piperidine ring. It is cis, that is, the substituents are on the same side of the piperidine ring, which means
[0424] The term "pharmaceutically acceptable salt" refers to a salt prepared from a compound of the present invention and a relatively nontoxic, pharmaceutically acceptable acid or base. When the compound of the present invention contains a relatively acidic functional group, a base addition salt can be obtained by contacting a neutral form of such compound with a sufficient amount of a pharmaceutically acceptable base in a pure solution or a suitable inert solvent. When the compound of the present invention contains a relatively basic functional group, an acid addition salt can be obtained by contacting a neutral form of such compound with a sufficient amount of a pharmaceutically acceptable acid in a pure solution or a suitable inert solvent.
[0425] The term "halogen" refers to F, Cl, Br, I.
[0426] The term "alkyl" refers to a group having a specified number of carbon atoms (e.g., 1-6 or C1-C6, C 1-4 or C1-C4), linear or branched, saturated, monovalent hydrocarbon group. The alkyl group includes, but is not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, n-hexyl, etc.
[0427] The term "alkenyl" refers to a group having the specified number of carbon atoms (e.g., C 2-6 or C2-C6), a linear or branched, unsaturated, monovalent hydrocarbon group having a carbon-carbon sp 2 Double bond. Alkenyl groups include but are not limited to: vinyl, wait.
[0428] The term "alkynyl" refers to a radical having the specified number of carbon atoms (e.g., C 2-6 or C2-C6), a straight or branched, unsaturated, monovalent hydrocarbon group having a carbon-carbon sp 3 Triple bond. Alkynyl groups include, but are not limited to: wait.
[0429] The term "-OC 1-6 In the "alkyl" group, C 1-6 The alkyl group is as defined above.
[0430] The term "-SC 1-6 In the "alkyl" group, C 1-6 The alkyl group is as defined above.
[0431] The term “-CO(C 1-6 In the "alkyl" group, C 1-6 The alkyl group is as defined above.
[0432] The term "cycloalkyl" refers to a group having the specified number of ring carbon atoms (e.g., C 3-7or C3-C7) non-aromatic saturated or partially unsaturated cycloalkyl, including cycloalkyl and cycloalkenyl, the cycloalkyl may be monocyclic or polycyclic, and may be a cyclic, spirocyclic or bridged ring structure. The cycloalkyl includes but is not limited to: cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl.
[0433] The term "-OC 3-7 In the "cycloalkyl" group, C 3-7 The cycloalkyl group is as defined above.
[0434] The term "cycloalkyl" refers to a cycloalkyl radical having a specified number of ring carbon atoms (e.g., 3-7 or C3-C7), saturated monocyclic, spirocyclic, bridged or paracyclic cyclic groups whose ring atoms consist only of carbon atoms. Cycloalkyl includes but is not limited to cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, etc.
[0435] The term "cycloalkenyl" refers to a cycloalkenyl radical having the specified number of carbon atoms (e.g., 3-7 or C3-C7), an unsaturated monocyclic, spirocyclic, bridged or paracyclic cyclic group whose ring atoms consist only of carbon atoms, and which does not have aromaticity.
[0436] The term "heterocyclic hydrocarbon group" refers to a non-aromatic saturated or partially unsaturated cyclic group having a specified number of ring atoms (e.g., 3-12 members or 4-8 members), a specified number of heteroatoms (e.g., 1, 2, or 3), a specified heteroatom or heteroatom group type (1, 2, or 3 of N, O, S, P, S(O), S(O)2, and P(O)), including heterocyclic alkyl or heterocyclic alkenyl. The heterocyclic hydrocarbon group can be monocyclic or polycyclic, and can be a cyclic, spirocyclic, or bridged ring structure. Heterocyclic hydrocarbon groups include, but are not limited to, oxetanyl, azetidinyl, tetrahydropyrrolyl, piperazinyl, piperidinyl, morpholinyl, 1,2,3,6-tetrahydropyridinyl, wait.
[0437] In the term "-O-(3-12-membered heterocyclic hydrocarbon group)", the 3-12-membered heterocyclic hydrocarbon group is as defined above.
[0438] The term "heterocycloalkyl" refers to a saturated monocyclic, spirocyclic, bridged or paracyclic cyclic group with a specified number of ring atoms (e.g., 3-12 or 4-8 members), a specified number of heteroatoms (e.g., 1, 2 or 3), a specified heteroatom or heteroatom group type (1, 2 or 3 of N, O, S, P, S(O), S(O)2 and P(O)). When it is polycyclic, each ring is saturated. Heterocycloalkyl includes, but is not limited to, oxetanyl, azetidinyl, tetrahydropyrrolyl, piperazinyl, piperidinyl, morpholinyl, etc., for example Another example
[0439] The term "heterocycloalkenyl" refers to an unsaturated monocyclic, spirocyclic, bridged or paracyclic cyclic group having a specified number of ring atoms (e.g., 3-12 members or 4-8 members), a specified number of heteroatoms (e.g., 1, 2 or 3), a specified heteroatom or heteroatom group type (one, two or three of N, O, S, P, S(O), S(O)2 and P(O)), and having no aromaticity. Heterocycloalkenyl includes, but is not limited to, 1,2,3,6-tetrahydropyridyl, etc., for example
[0440] The term "aryl" refers to a radical having a specified number of ring carbon atoms (e.g., C 6-10 or C6-C 10 ) is an aromatic group. Examples of the aryl group include, but are not limited to, phenyl or naphthyl.
[0441] The term "heteroaryl" refers to a cyclic group having a specified number of ring atoms (e.g., 5-10 members, 5-6 members, 8-10 members), a specified number of heteroatoms (e.g., 1, 2 or 3), and a specified heteroatom type (e.g., one, two or more of N, O and S), which can be a monocyclic or bicyclic ring (e.g., a cyclic ring, a spirocyclic ring and a bridged ring), and at least one ring is aromatic (in accordance with Huckel's rule). The heteroaryl group is connected to other fragments in the molecule through an aromatic ring or a non-aromatic ring. Heteroaryl includes, but is not limited to, furanyl, pyrrolyl, thienyl, pyrazolyl, imidazolyl, oxazolyl, thiazolyl, pyridyl, pyrimidinyl, indolyl, 1,2,3,4-tetrahydroisoquinolyl, etc., for example
[0442] The term "oxo" refers to =0, an oxygen atom replacing two hydrogens on the same carbon atom, ie, replacing a methylene group with a carbonyl group.
[0443] The term "one or more" means 1, 2, 3, 4, 5, 6, 7, 8, 9 or more.
[0444] It will be understood by those skilled in the art that the structural formulas used in the present invention to describe groups are based on the conventions used in the art. It means that the corresponding group R is connected to other fragments and groups in the compound through this site.
[0445] When the structural formula of the group described in the present invention is a polycyclic structure, for example Unless otherwise specified, Indicates that the substitution site can be Any substitutable position on the two rings (e.g. ), It is connected to other fragments and groups in the compound through any substitutable site.
[0446] The term "pharmaceutically acceptable excipients" refers to excipients and additives used in the production of drugs and the preparation of prescriptions. It is all substances contained in drug preparations except active ingredients. Please refer to the Pharmacopoeia of the People's Republic of China (2020 Edition) Part IV, or Handbook of Pharmaceutical Excipients (Raymond C Rowe, 2009 Sixth Edition).
[0447] The term "treat" refers to therapeutic treatment. When referring to a specific condition, treatment means: (1) ameliorating the disease or one or more biological manifestations of the condition, (2) interfering with (a) one or more points in the biological cascade leading to or causing the condition or (b) one or more biological manifestations of the condition, (3) ameliorating one or more symptoms, effects, or side effects associated with the condition or one or more symptoms, effects, or side effects associated with the condition or its treatment, or (4) slowing the progression of the condition or one or more biological manifestations of the condition.
[0448] The term "prevent" refers to the reduction of the risk of acquiring or developing a disease or disorder.
[0449] The term "therapeutically effective amount" refers to an amount administered to a patient that is sufficient to effectively treat a disease. The therapeutically effective amount will vary depending on the type of compound, the type of disease, the severity of the disease, the age of the patient, etc., but can be adjusted by those skilled in the art as appropriate.
[0450] The term "activator" refers to a compound that can stabilize the Y220C mutated P53 protein, reactivate its function of inhibiting cancer cells, and achieve the effect of inhibiting cancer.
[0451] Without violating the common sense in the art, the above-mentioned preferred conditions can be arbitrarily combined to obtain the preferred embodiments of the present invention.
[0452] The reagents and raw materials used in the present invention are commercially available.
[0453] The positive effect of the present invention is that the compounds of the present invention can reactivate mutated p53 to restore its tumor suppressor function. The compounds of the present invention show good proliferation inhibition activity on BxPC-3 human pancreatic cancer cells and / or HuH-7 human liver cancer cells with p53 Y220C mutation. DETAILED DESCRIPTION
[0454] The present invention is further described below by way of examples, but the present invention is not limited to the scope of the examples. The experimental methods in the following examples without specifying specific conditions are carried out according to conventional methods and conditions, or selected according to the product specifications.
[0455] Example 1: 2-methoxy-N-(3-(1-methyl-6-(1,2,3,4-tetrahydroisoquinolin-7-yl)-2-(2,2,2-trifluoroethyl)-1H-indol-3-yl)prop-2-yn-1-yl)-4-(methylsulfonyl)aniline (Compound 1)
[0456]
[0457] Step 1: 6-Bromo-2-(2,2,2-trifluoroethyl)-1H-indole
[0458]
[0459] In a 100mL reaction bottle, add 6-bromo-1H-indole (3.5g, 18mmol, 1.0eq), palladium acetate (462mg, 11.55mmol, 0.15eq), dibenzoylmethane (1.6g, 7.2mmol, 0.4eq), norbornene (3.4g, 36mmol, 2.0eq), and potassium bicarbonate (3.4g, 36mmol, 2.0eq). Finally, add a solution of 1,1,1-trifluoro-2-iodoethane (1.81g, 10.83mmol, 1.5eq) in N,N-dimethylformamide (35mL). Under nitrogen protection, react at 100℃ for 16 hours. The reaction was completed after LCMS monitoring. Ethyl acetate was added for filtration, washed with ethyl acetate and water, and the filtrate was concentrated. The residue was purified by column (ethyl acetate / petroleum ether: 0-4%) to obtain: 6-bromo-2-(2,2,2-trifluoroethyl)-1H-indole (3.3 g, yield: 66%) as a brown solid.
[0460] MS m / z:278 / 280[M+H] + .
[0461] Step 2: 6-Bromo-1-methyl-2-(2,2,2-trifluoroethyl)-1H-indole
[0462]
[0463] In a 25mL reaction bottle, 6-bromo-2-(2,2,2-trifluoroethyl)-1H-indole (500mg, 1.23mmol, 1.0eq) was dissolved in N,N-dimethylformamide (5mL), sodium hydride (360mg, 1.5mmol, 60%) was added at 0℃, and the reaction was carried out at room temperature for 0.5 hours. Methyl iodide (1.26g, 13.5mmol, 1.5eq) was added at 0℃, and the reaction was carried out at room temperature for 1 hour. The reaction was monitored by LCMS. Water was added to quench, ethyl acetate was extracted and washed, the filtrate was concentrated, and the residue was purified by column (ethyl acetate / petroleum ether: 10%) to obtain: 6-bromo-1-methyl-2-(2,2,2-trifluoroethyl)-1H-indole (1.2g, yield: 70%), yellow solid.
[0464] MS m / z:292 / 294[M+H] + .
[0465] Step 3: tert-Butyl 7-(1-methyl-2-(2,2,2-trifluoroethyl)-1H-indol-6-yl)-3,4-dihydroisoquinoline-2(1H)-carboxylate
[0466]
[0467] In a 100 mL reaction bottle, 6-bromo-1-methyl-2-(2,2,2-trifluoroethyl)-1H-indole (680 mg, 2.34 mmol, 1.0 eq) and tert-butyl 7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,4-dihydroisoquinoline-2(1H)-carboxylate (839 mg, 2.34 mmol, 1.0 eq) were dissolved in 1,4-dioxane (13 mL). Tetrakis(triphenylphosphine)palladium (540 mg, 0.47 mmol, 0.2 eq) and aqueous sodium carbonate solution (2.5 g / 13 mL) were added. The reaction was carried out at 100 °C for 4 hours under nitrogen protection. The reaction was completed after monitoring by LCMS. Ethyl acetate was added to remove water, the filtrate was concentrated, and the residue was purified by column (ethyl acetate / petroleum ether: 0-20%) to obtain: tert-butyl 7-(1-methyl-2-(2,2,2-trifluoroethyl)-1H-indol-6-yl)-3,4-dihydroisoquinoline-2(1H)-carboxylate (850 mg, yield: 74%) as a yellow solid.
[0468] MS m / z:445[M+H] + .
[0469] Step 4: tert-Butyl 7-(3-iodo-1-methyl-2-(2,2,2-trifluoroethyl)-1H-indol-6-yl)-3,4-dihydroisoquinoline-2(1H)-carboxylate
[0470]
[0471] In a 25 mL reaction bottle, tert-butyl 7-(1-methyl-2-(2,2,2-trifluoroethyl)-1H-indol-6-yl)-3,4-dihydroisoquinoline-2(1H)-carboxylate (200 mg, 0.45 mmol, 1.0 eq) was dissolved in N,N-dimethylformamide (3 mL), and N-iodosuccinimide (111 mg, 0.5 mmol, 1.1 eq) was added at 0°C, and the reaction was carried out for 0.5 hours at 0°C. The reaction was monitored by LCMS. Water was added at 0°C to quench the reaction, and the mixture was washed with ethyl acetate and dried and concentrated to obtain tert-butyl 7-(3-iodo-1-methyl-2-(2,2,2-trifluoroethyl)-1H-indol-6-yl)-3,4-dihydroisoquinoline-2(1H)-carboxylate (270 mg crude product) as a yellow solid.
[0472] MS m / z:515[M-56] + .
[0473] Step 5: tert-Butyl 7-(3-(3-(2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-1-methyl-2-(2,2,2-trifluoroethyl)-1H-indol-6-yl)-3,4-dihydroisoquinoline-2(1H)-carboxylate
[0474]
[0475] In a 25 mL reaction bottle, tert-butyl 7-(3-iodo-1-methyl-2-(2,2,2-trifluoroethyl)-1H-indol-6-yl)-3,4-dihydroisoquinoline-2(1H)-carboxylate (260 mg, 0.46 mmol, 1.0 eq), 2-methoxy-4-(methylsulfonyl)-N-(prop-2-yn-1-yl)aniline (327 mg, 1.37 mmol, 3 eq) and triethylamine (1 mL) were dissolved in N,N-dimethylformamide (2 mL), tetrakis(triphenylphosphine)palladium (96 mg, 0.137 mmol, 0.3 eq) and cuprous iodide (44 mg, 0.23 mmol, 0.5 eq) were added, and the reaction was carried out at 50 °C under nitrogen protection for 16 hours. The reaction was completed after monitoring by LCMS. The reaction solution was concentrated, and the concentrated residue was purified by column (ethyl acetate / petroleum ether: 0-50%) to give: tert-butyl 7-(3-(3-(2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-1-methyl-2-(2,2,2-trifluoroethyl)-1H-indol-6-yl)-3,4-dihydroisoquinoline-2(1H)-carboxylate (100 mg, yield: 41%) as a brown solid.
[0476] MS m / z:682[M+H] + .
[0477] Step 6: 2-methoxy-N-(3-(1-methyl-6-(1,2,3,4-tetrahydroisoquinolin-7-yl)-2-(2,2,2-trifluoroethyl)-1H-indol-3-yl)prop-2-yn-1-yl)-4-(methylsulfonyl)aniline
[0478]
[0479] In a 25 mL reaction bottle, dissolve tert-butyl 7-(3-(3-(2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-1-methyl-2-(2,2,2-trifluoroethyl)-1H-indol-6-yl)-3,4-dihydroisoquinoline-2(1H)-carboxylate (70 mg, 0.151 mmol, 1.0 eq) in anhydrous toluene (10 mL), add 200-300 mesh silica gel (3 g), react at 110 ° C for 5 hours, and monitor the reaction completion by LCMS. The solvent was spin-dried and washed with dichloromethane / methanol = 10:1 to give a crude product, which was sent to HPLC to obtain: 2-methoxy-N-(3-(1-methyl-6-(1,2,3,4-tetrahydroisoquinolin-7-yl)-2-(2,2,2-trifluoroethyl)-1H-indol-3-yl)prop-2-yn-1-yl)-4-(methylsulfonyl)aniline (24 mg, yield: 27%) as a white solid.
[0480] MS m / z:582.2[M+H] + .
[0481] 1 H NMR(400MHz, DMSO-d6)δ7.78(d,J=18.1Hz,1H),7.49(t,J=8.8Hz,2H),7.47–7.31(m ,3H),7.26(d,J=1.9Hz,1H),7.15(d,J=8.0Hz,1H),6.96(d,J=8.4Hz,1H),6.49(t,J =6.1Hz,1H),4.34(d,J=6.1Hz,2H),3.98(d,J=10.7Hz,2H),3.93(s,2H),3.90(s,3H ),3.83(d,J=7.5Hz,3H),3.10(s,3H),2.98(t,J=5.8Hz,2H),2.73(d,J=6.3Hz,2H).
[0482] Example 2: 2-methoxy-N-(3-(1-methyl-6-(2-methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-2-(2,2,2-trifluoroethyl)-1H-indol-3-yl)prop-2-yn-1-yl)-4-(methylsulfonyl)aniline (Compound 2)
[0483]
[0484] Step 1: 2-methoxy-N-(3-(1-methyl-6-(2-methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-2-(2,2,2-trifluoroethyl)-1H-indol-3-yl)prop-2-yn-1-yl)-4-(methylsulfonyl)aniline (Compound 2)
[0485] In a 25 mL reaction bottle, 2-methoxy-N-(3-(1-methyl-6-(1,2,3,4-tetrahydroisoquinolin-7-yl)-2-(2,2,2-trifluoroethyl)-1H-indol-3-yl)prop-2-yn-1-yl)-4-(methylsulfonyl)aniline (20 mg, 0.034 mmol, 1.0 eq), paraformaldehyde (10 mg, 0.34 mmol, 10 eq), acetic acid (2 mg, 0.034 mmol, 1.0 eq) were dissolved in dichloromethane / methanol (2 mL / 2 mL), sodium cyanoborohydride (4.3 mg, 0.068 mmol, 2.0 eq) was added and reacted at room temperature for 2 hours. The reaction was monitored by LCMS to be complete. The reaction solution was quenched by adding 0.1 mL of a saturated sodium bicarbonate solution, extracted with dichloromethane, and concentrated. The product was separated by HPLC to give: 2-methoxy-N-(3-(1-methyl-6-(2-methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-2-(2,2,2-trifluoroethyl)-1H-indol-3-yl)prop-2-yn-1-yl)-4-(methylsulfonyl)aniline (7 mg, yield: 34%) as a white solid.
[0486] MS m / z:596.2[M+H] + .
[0487] 1H NMR(400MHz, DMSO-d6)δ7.76(t,J=1.0Hz,1H),7.55–7.48(m,2H),7.47–7.37(m,3H ),7.26(d,J=2.0Hz,1H),7.19(d,J=8.0Hz,1H),6.96(d,J=8.4Hz,1H),6.48(t,J=6. 2Hz,1H),4.35(d,J=6.1Hz,2H),3.98(q,J=10.8Hz,2H),3.90(s,3H),3.82(s,3H),3 .56(s,2H),3.10(s,3H),2.85(t,J=6.0Hz,2H),2.62(t,J=5.9Hz,2H),2.37(s,3H).
[0488] Example 3: N-(3-(1-ethyl-6-(1,2,3,4-tetrahydroisoquinolin-6-yl)-2-(2,2,2-trifluoroethyl)-1H-indol-3-yl)prop-2-yn-1-yl)-2-methoxy-4-(methylsulfonyl)aniline (Compound 3)
[0489]
[0490] The synthetic route of Example 3 refers to Example 1, wherein:
[0491] Step 2: 6-Bromo-1-ethyl-2-(2,2,2-trifluoroethyl)-1H-indole
[0492]
[0493] During the synthesis, methyl iodide was replaced by ethyl iodide.
[0494] Step 3: tert-Butyl 6-(1-ethyl-2-(2,2,2-trifluoroethyl)-1H-indol-6-yl)-3,4-dihydroisoquinoline-2(1H)-carboxylate
[0495]
[0496] The starting material tert-butyl 7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,4-dihydroisoquinoline-2(1H)-carboxylate was replaced with tert-butyl 6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,4-dihydroisoquinoline-2(1H)-carboxylate.
[0497] The reaction was then carried out through various steps to prepare N-(3-(1-ethyl-6-(1,2,3,4-tetrahydroisoquinolin-6-yl)-2-(2,2,2-trifluoroethyl)-1H-indol-3-yl)prop-2-yn-1-yl)-2-methoxy-4-(methylsulfonyl)aniline (compound 3).
[0498] MS m / z:596.2[M+H] + .
[0499] 1 H NMR(400MHz,DMSO-d6)δ7.75(d,J=1.5Hz,1H),7.55–7.39(m,5H),7.26(d,J=2 .0Hz,1H),7.10(d,J=8.0Hz,1H),6.95(d,J=8.5Hz,1H),6.48(t,J=6.2Hz,1H) ,4.35(d,J=6.5Hz,4H),3.95(d,J=10.7Hz,2H),3.90(s,3H),3.88(s,2H),3.1 0(s,3H),2.98(t,J=5.8Hz,2H),2.78(t,J=5.7Hz,2H),1.27(t,J=7.0Hz,3H).
[0500] Example 4: N-(3-(1-cyclopropyl-6-(1,2,3,4-tetrahydroisoquinolin-6-yl)-2-(2,2,2-trifluoroethyl)-1H-indol-3-yl)prop-2-yn-1-yl)-2-methoxy-4-(methylsulfonyl)aniline (Compound 4)
[0501]
[0502] The synthetic route of Example 4 is based on Example 1, wherein:
[0503] Step 2: 6-Bromo-1-cyclopropyl-2-(2,2,2-trifluoroethyl)-1H-indole
[0504]
[0505] In a 100 mL reaction bottle, 6-bromo-2-(2,2,2-trifluoroethyl)-1H-indole (1.2 g, 4.33 mmol, 1.0 eq), cyclopropylboric acid (740 mg, 8.66 mmol, 2.0 eq) and sodium carbonate (918 mg, 8.66 mmol, 2.0 eq) were dissolved in 1,2-dichloroethane (15 mL). A solution of copper acetate monohydrate (688 mg, 3.44 mmol, 1.0 eq) and 2,2-bipyridine (537 mg, 3.44 mmol, 1.0 eq) in hot 1,2-dichloroethane (15 mL) were added. The mixture was reacted at 70 °C for 5 hours. The reaction was completed after monitoring by LCMS. The reaction solution was filtered through celite and concentrated. The concentrated residue was purified by column chromatography (ethyl acetate / petroleum ether: 0-8%) to obtain: 6-bromo-1-cyclopropyl-2-(2,2,2-trifluoroethyl)-1H-indole (970 mg, yield: 71%) as a yellow solid.
[0506] MS m / z:318 / 320[M+H] +
[0507] Step 3: tert-Butyl 6-(1-cyclopropyl-2-(2,2,2-trifluoroethyl)-1H-indol-6-yl)-3,4-dihydroisoquinoline-2(1H)-carboxylate
[0508]
[0509] The starting material tert-butyl 7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,4-dihydroisoquinoline-2(1H)-carboxylate was replaced with tert-butyl 6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,4-dihydroisoquinoline-2(1H)-carboxylate.
[0510] The reaction was then continued through various steps to obtain N-(3-(1-cyclopropyl-6-(1,2,3,4-tetrahydroisoquinolin-6-yl)-2-(2,2,2-trifluoroethyl)-1H-indol-3-yl)prop-2-yn-1-yl)-2-methoxy-4-(methylsulfonyl)aniline (compound 4).
[0511] MS m / z:608.2[M+H] + .
[0512] 1H NMR(400MHz,DMSO-d6)δ7.76(d,J=1.5Hz,1H),7.57–7.36(m,5H),7.26(d,J=2.0Hz,1H) ,7.11(d,J=7.9Hz,1H),6.95(d,J=8.4Hz,1H),6.49(t,J=6.2Hz,1H),4.35(d,J=6.1Hz,2 H),3.97(t,J=10.7Hz,2H),3.90(s,3H),3.88(s,2H),3.25(d,J=3.7Hz,2H),3.11(s,3H) ,2.98(t,J=5.8Hz,2H),2.78(t,J=5.8Hz,2H),1.26(m,J=5.1Hz,2H),1.11–0.98(m,2H).
[0513] Example 5: 2-methoxy-N-(3-(1-methyl-6-(1,2,3,4-tetrahydroisoquinolin-6-yl)-2-(2,2,2-trifluoroethyl)-1H-indol-3-yl)prop-2-yn-1-yl)-4-(methylsulfonyl)aniline (Compound 5)
[0514]
[0515] The synthetic route of Example 5 is as described in Example 1, wherein:
[0516] Step 3: tert-Butyl 6-(1-methyl-2-(2,2,2-trifluoroethyl)-1H-indol-6-yl)-3,4-dihydroisoquinoline-2(1H)-carboxylate
[0517]
[0518] The starting material tert-butyl 7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,4-dihydroisoquinoline-2(1H)-carboxylate was replaced with tert-butyl 6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,4-dihydroisoquinoline-2(1H)-carboxylate.
[0519] The reaction was then continued in various steps to prepare 2-methoxy-N-(3-(1-methyl-6-(1,2,3,4-tetrahydroisoquinolin-6-yl)-2-(2,2,2-trifluoroethyl)-1H-indol-3-yl)prop-2-yn-1-yl)-4-(methylsulfonyl)aniline (Compound 5).
[0520] MS m / z:582[M+H] + .
[0521] 1H NMR (400MHz, DMSO-d6) δ7.76(d,J=1.5Hz,1H),7.58-7.38(m,5H),7.26(d,J=2.0Hz,1H),7.09(d,J=7.9Hz,1H),6.96(d,J=8.4Hz,1H),6.48(t,J=6.2Hz ,1H),4.35(d,J=6.1Hz,2H),3.98(q,J=10.7Hz,2H),3.90(s,3H),3.87(s,2 H),3.82(s,3H),3.10(s,3H),2.97(t,J=5.8Hz,2H),2.77(t,J=5.8Hz,2H).
[0522] Example 6: 2-methoxy-N-(3-(1-methyl-6-(2-methyl-1,2,3,4-tetrahydroisoquinolin-6-yl)-2-(2,2,2-trifluoroethyl)-1H-indol-3-yl)prop-2-yn-1-yl)-4-(methylsulfonyl)aniline (Compound 6)
[0523]
[0524] The synthetic route of Example 6 refers to Example 2, wherein the substrate compound 1 is replaced by compound 5, and the reaction is performed to prepare 2-methoxy-N-(3-(1-methyl-6-(2-methyl-1,2,3,4-tetrahydroisoquinolin-6-yl)-2-(2,2,2-trifluoroethyl)-1H-indol-3-yl)prop-2-yn-1-yl)-4-(methylsulfonyl)aniline (Compound 6).
[0525] MS m / z:596[M+H] + .
[0526] 1 H NMR(400MHz,DMSO-d6)δ7.77(d,J=1.5Hz,1H),7.55-7.46(m,3H),7.44-7.41(m,2H ),7.26(d,J=2.0Hz,1H),7.13(d,J=8.5Hz,1H),6.96(d,J=8.4Hz,1H),6.48(t,J=6. 2Hz,1H),4.35(d,J=6.1Hz,2H),3.98(q,J=10.7Hz,2H),3.90(s,3H),3.82(s,3H),3 .51(s,2H),3.10(s,3H),2.91(t,J=5.9Hz,2H),2.62(t,J=5.9Hz,2H),2.36(s,3H).
[0527] Example 7: N-(3-(5-fluoro-1-methyl-6-(1,2,3,4-tetrahydroisoquinolin-6-yl)-2-(2,2,2-trifluoroethyl)-1H-indol-3-yl)prop-2-yn-1-yl)-2-methoxy-4-(methylsulfonyl)aniline (Compound 7)
[0528]
[0529] The synthetic route of Example 7 refers to Example 1, wherein:
[0530] Step 1: 6-Bromo-5-fluoro-2-(2,2,2-trifluoroethyl)-1H-indole
[0531]
[0532] The substrate 6-bromo-1H-indole was replaced by 6-bromo-5-fluoro-1H-indole.
[0533] Step 3: tert-Butyl 6-(5-fluoro-1-methyl-2-(2,2,2-trifluoroethyl)-1H-indol-6-yl)-3,4-dihydroisoquinoline-2(1H)-carboxylate
[0534]
[0535] The starting material tert-butyl 7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,4-dihydroisoquinoline-2(1H)-carboxylate was replaced with tert-butyl 6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,4-dihydroisoquinoline-2(1H)-carboxylate.
[0536] The reaction was then continued through various steps to obtain N-(3-(5-fluoro-1-methyl-6-(1,2,3,4-tetrahydroisoquinolin-6-yl)-2-(2,2,2-trifluoroethyl)-1H-indol-3-yl)prop-2-yn-1-yl)-2-methoxy-4-(methylsulfonyl)aniline (Compound 7).
[0537] MS m / z:600[M+H] + .
[0538] 1H NMR(400MHz,DMSO-d6)δ7.60(d,J=6.4Hz,1H),7.42(dd,J=8.4,2.0Hz,1H),7.3 3-7.28(m,2H),7.25-7.22(m,2H),7.10(d,J=7.9Hz,1H),6.96(d,J=8.4Hz,1H), 6.48(t,J=6.2Hz,1H),4.33(d,J=6.1Hz,2H),3.97(q,J=10.8Hz,2H),3.89-3.88 (m,5H),3.79(s,3H),3.09(s,3H),2.97(t,J=5.8Hz,2H),2.74(t,J=5.9Hz,2H).
[0539] Example 8: N-(3-(5-fluoro-1-methyl-6-(2-methyl-1,2,3,4-tetrahydroisoquinolin-6-yl)-2-(2,2,2-trifluoroethyl)-1H-indol-3-yl)prop-2-yn-1-yl)-2-methoxy-4-(methylsulfonyl)aniline (Compound 8)
[0540]
[0541] The synthetic route of Example 8 refers to Example 2, wherein the substrate compound 1 is replaced by compound 7, and the reaction is performed to prepare N-(3-(5-fluoro-1-methyl-6-(2-methyl-1,2,3,4-tetrahydroisoquinolin-6-yl)-2-(2,2,2-trifluoroethyl)-1H-indol-3-yl)prop-2-yn-1-yl)-2-methoxy-4-(methylsulfonyl)aniline (Compound 8).
[0542] MS m / z:614[M+H] + .
[0543] 1 H NMR(400MHz,DMSO-d6)δ7.62(d,J=6.4Hz,1H),7.42(dd,J=8.3,2.0Hz,1H),7.33-7.3 1(m,2H),7.28-7.21(m,2H),7.14(d,J=8.5Hz,1H),6.96(d,J=8.4Hz,1H),6.48(t,J= 6.2Hz,1H),4.33(d,J=6.1Hz,2H),3.97(q,J=10.7Hz,2H),3.89(s,3H),3.79(s,3H), 3.52(s,2H),3.09(s,3H),2.88(t,J=6.0Hz,2H),2.61(t,J=5.9Hz,2H),2.35(s,3H).
[0544] Example 9: N-(3-(5-fluoro-1-methyl-6-(1-methyl-1,2,3,6-tetrahydropyridin-4-yl)-2-(2,2,2-trifluoroethyl)-1H-indol-3-yl)prop-2-yn-1-yl)-2-methoxy-4-(methylsulfonyl)aniline (Compound 9)
[0545]
[0546] The synthetic route of Example 9 has 7 steps in total, and steps 1-6 refer to steps 1-6 of Example 7, wherein:
[0547] Step 3: tert-Butyl 4-(5-fluoro-1-methyl-2-(2,2,2-trifluoroethyl)-1H-indol-6-yl)-3,6-dihydropyridine-1(2H)carboxylate
[0548]
[0549] The substrate tert-butyl 6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolin-2-yl)-3,4-dihydroisoquinoline-2(1H)-carboxylate was replaced by tert-butyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,6-dihydropyridine-1(2H)-carboxylate.
[0550] Then, step 4-6 is reacted to prepare N-(3-(5-fluoro-1-methyl-6-(1,2,3,6-tetrahydropyridin-4-yl)-2-(2,2,2-trifluoroethyl)-1H-indol-3-yl)prop-2-yn-1-yl)-2-methoxy-4-(methylsulfonyl)aniline, the structure of which is as follows:
[0551]
[0552] MS m / z:550[M+H] + .
[0553] Step 7: N-(3-(5-fluoro-1-methyl-6-(1-methyl-1,2,3,6-tetrahydropyridin-4-yl)-2-(2,2,2-trifluoroethyl)-1H-indol-3-yl)prop-2-yn-1-yl)-2-methoxy-4-(methylsulfonyl)aniline
[0554]
[0555] In a 100 mL reaction bottle, N-(3-(5-fluoro-1-methyl-6-(1,2,3,6-tetrahydropyridin-4-yl)-2-(2,2,2-trifluoroethyl)-1H-indol-3-yl)prop-2-yn-1-yl)-2-methoxy-4-(methylsulfonyl)aniline (47 mg, 0.1 mmol, 1.0 eq) and paraformaldehyde (26 mg, 0.9 mmol, 10.0 eq) were dissolved in dichloromethane / methanol (1 mL / 1 mL), sodium cyanoborohydride (11 mg, 0.2 mmol, 2.0 eq) and acetic acid (5 mg, 0.1 mmol, 1.0 eq) were added, and the mixture was reacted at 30 °C for 3 hours. The reaction was complete when monitored by LCMS. Saturated sodium bicarbonate solution was added, extracted with dichloromethane, washed with saturated brine, and dried over anhydrous sodium sulfate. After filtration, the filtrate was concentrated and the residue was separated and purified by HPLC preparative chromatography to obtain: N-(3-(5-fluoro-1-methyl-6-(1-methyl-1,2,3,6-tetrahydropyridin-4-yl)-2-(2,2,2-trifluoroethyl)-1H-indol-3-yl)prop-2-yn-1-yl)-2-methoxy-4-(methylsulfonyl)aniline (Compound 9, 19.4 mg, yield: 40%) as a white solid.
[0556] MS m / z:564[M+H] + .
[0557] 1 H NMR (400MHz, CDCl3) δ7.54(dd,J=8.4,2.0Hz,1H),7.27(d,J=2.1Hz,1H),7.21(d,J=1 0.9Hz,1H),7.14(d,J=5.9Hz,1H),6.86(d,J=8.4Hz,1H),5.93-5.92(m,1H),5.15(t, J=6.1Hz,1H),4.34(d,J=6.1Hz,2H),3.93(s,3H),3.69(s,3H),3.63(q,J=10.0Hz,2H ),3.23-3.14(m,2H),3.03(s,3H),2.75-2.73(m,2H),2.69-2.62(m,2H),2.47(s,2H).
[0558] Example 10: N-(3-(5-fluoro-1-methyl-6-(1-methylpiperidin-4-yl)-2-(2,2,2-trifluoroethyl)-1H-indol-3-yl)prop-2-yn-1-yl)-2-methoxy-4-(methylsulfonyl)aniline (Compound 10)
[0559]
[0560] The synthetic route of Example 10 has 8 steps in total, and steps 1-3 and 5-8 refer to steps 1-3 and 4-7 of Example 9, wherein:
[0561] Step 4 was added after step 3: tert-butyl 4-(5-fluoro-1-methyl-2-(2,2,2-trifluoroethyl)-1H-indol-6-yl)piperidine-1-carboxylate
[0562]
[0563] In a 100mL reaction bottle, tert-butyl 4-(5-fluoro-1-methyl-2-(2,2,2-trifluoroethyl)-1H-indol-6-yl)-3,6-dihydropyridine-1(2H)-carboxylate (530mg, 1.3mmol, 1.0eq) was dissolved in ethanol (5mL), and platinum dioxide (53mg) was added. The reaction was allowed to proceed for 16 hours under a hydrogen atmosphere. LCMS monitored the reaction to be complete. The mixture was filtered and the filtrate was concentrated to give the crude product: tert-butyl 4-(5-fluoro-1-methyl-2-(2,2,2-trifluoroethyl)-1H-indol-6-yl)piperidine-1-carboxylate (250.0mg, yield: 47%), as a light yellow solid.
[0564] The subsequent steps 5-8 refer to step 4-7 of Example 9, and the raw material 4-(5-fluoro-1-methyl-2-(2,2,2-trifluoroethyl)-1H-indol-6-yl)-3,6-dihydropyridine-1(2H)carboxylic acid tert-butyl ester is replaced with 4-(5-fluoro-1-methyl-2-(2,2,2-trifluoroethyl)-1H-indol-6-yl)piperidine-1-carboxylic acid tert-butyl ester, and N-(3-(5-fluoro-1-methyl-6-(1-methylpiperidin-4-yl)-2-(2,2,2-trifluoroethyl)-1H-indol-3-yl)prop-2-yn-1-yl)-2-methoxy-4-(methylsulfonyl)aniline (Compound 10) is prepared by reaction.
[0565] MS m / z:566[M+H] + .
[0566] 1H NMR (400MHz, DMSO-d6) δ7.44(d,J=6.1Hz,1H),7.40(dd,J=8.4,2.0Hz,1H),7.24( d,J=2.0Hz,1H),7.11(d,J=10.6Hz,1H),6.93(d,J=8.4Hz,1H),6.46(t,J=6.2Hz, 1H),4.31(d,J=6.2Hz,2H),3.97-3.89(m,5H),3.74(s,3H),3.09(s,3H),2.89-2. 87(m,2H),2.82-2.74(m,1H),2.20(s,3H),2.01-1.95(m,2H),1.85-1.70(m,4H).
[0567] Example 11: N-(3-(6-bromo-1-methyl-2-(2,2,2-trifluoroethyl)-1H-indol-3-yl)prop-2-yn-1-yl)-2-methoxy-4-(methylsulfonyl)aniline (Compound 11)
[0568]
[0569] 6-bromo-1-methyl-2-(2,2,2-trifluoroethyl)-1H-indole was prepared by referring to steps 1 and 2 of Example 1, and then 6-bromo-1-methyl-2-(2,2,2-trifluoroethyl)-1H-indole was directly used as a raw material to react by referring to steps 4 and 5 of Example 1, and finally N-(3-(6-bromo-1-methyl-2-(2,2,2-trifluoroethyl)-1H-indol-3-yl)prop-2-yn-1-yl)-2-methoxy-4-(methylsulfonyl)aniline (Compound 11) was prepared.
[0570] MS m / z:528.8[M+H] + .
[0571] 1 H NMR(400MHz, DMSO-d6)δ7.82(d,J=1.7Hz,1H),7.44–7.37(m,2H),7.31–7.21(m,2H),6.94(d,J=8.4Hz, 1H), 6.46 (t, J = 6.1Hz, 1H), 4.33 (d, J = 6.1Hz, 2H), 3.97 (m, 2H), 3.89 (s, 3H), 3.75 (s, 3H), 3.10 (s, 3H).
[0572] Example 12: 2-methoxy-N-(3-(1-methyl-7-(1,2,3,4-tetrahydroisoquinolin-6-yl)-2-(2,2,2-trifluoroethyl)-1H-indol-3-yl)prop-2-yn-1-yl)-4-(methylsulfonyl)aniline (Compound 12)
[0573]
[0574] The synthetic route of Example 12 is based on Example 3, wherein:
[0575] Step 1: 7-Bromo-2-(2,2,2-trifluoroethyl)-1H-indole
[0576]
[0577] The reaction was carried out using 7-bromo-1H-indole instead of 6-bromo-1H-indole.
[0578] Then, 2-methoxy-N-(3-(1-methyl-7-(1,2,3,4-tetrahydroisoquinolin-6-yl)-2-(2,2,2-trifluoroethyl)-1H-indol-3-yl)prop-2-yn-1-yl)-4-(methylsulfonyl)aniline (Compound 12) was prepared by the reaction of each step.
[0579] MS m / z:581.9[M+H] + .
[0580] 1 H NMR (400MHz, DMSO-d6) δ7.48(dd,J=7.9,1.3Hz,1H),7.42(dd,J=8.3,2.0Hz,1H),7.26(d,J=2.0Hz,1H),7.20–7.08(m,4H),6.97 (t,J=7.4Hz,2H),6.49(t,J=6.2Hz,1H),4.35(d,J=6.2Hz,2H),3.93(m,7H),3.24(s,3H),3.10(s,3H),3.02(m,2H),2.76(m,2H).
[0581] Example 13: N-(3-(1,7-dimethyl-6-(1,2,3,4-tetrahydroisoquinolin-6-yl)-2-(2,2,2-trifluoroethyl)-1H-indol-3-yl)prop-2-yn-1-yl)-2-methoxy-4-(methylsulfonyl)aniline (Compound 13)
[0582]
[0583] The synthetic route of Example 13 refers to Example 3, wherein:
[0584] Step 1: 6-Bromo-7-methyl-2-(2,2,2-trifluoroethyl)-1H-indole
[0585]
[0586] The reaction was carried out using 6-bromo-7-methylindole instead of 6-bromo-1H-indole.
[0587] The reaction was then continued through various steps to obtain N-(3-(1,7-dimethyl-6-(1,2,3,4-tetrahydroisoquinolin-6-yl)-2-(2,2,2-trifluoroethyl)-1H-indol-3-yl)prop-2-yn-1-yl)-2-methoxy-4-(methylsulfonyl)aniline (Compound 13).
[0588] MS m / z:595.9[M+H] + .
[0589] 1 H NMR (400MHz, DMSO-d6) δ7.41(dd,J=8.4,2.0Hz,1H),7.30(d,J=8.1Hz,1H),7.25(d,J=2.0Hz,1H),7.09–6.92(m,5H),6.48(t,J=6.2Hz,1H), 4.34(d,J=6.1Hz,2H),3.98(d,J=17.2Hz,5H),3.89(d,J=4.3Hz,5H),3.10(s,3H),2.97(t,J=5.9Hz,2H),2.73(t,J=5.9Hz,2H),2.60(s,3H).
[0590] Example 14: 3-(3-{[2-methoxy-4-(methyldioxy- 6 -thio)phenyl]amino}prop-1-ynyl)-1-methyl-6-(1,2,3,4-tetrahydroisoquinolin-6-yl)-2-(2,2,2-trifluoroethyl)indole-5-carboxylic acid methyl ester (Compound 14)
[0591]
[0592] Step 1: 2-Methylpropan-2-yl 6-bromo-5-methylindole-1-carboxylate
[0593]
[0594] In a 100mL eggplant-shaped bottle, di-tert-butyl dicarbonate (623mg, 2.86mmol, 2eq), triethylamine (0.397mL, 2.86mmol, 2eq), 4-dimethylaminopyridine (209mg, 1.71mmol, 1.2eq), 6-bromo-5-methyl-1H-indole (300mg, 1.43mmol 1eq) and tetrahydrofuran (5mL) were added and stirred at room temperature for 3 hours. TLC showed that the raw materials were basically reacted and the target product was generated. The reaction system was directly spin-dried and purified by column chromatography (pure petroleum ether) to obtain the product 6-bromo-5-methylindole-1-carboxylic acid-2-methylprop-2-yl ester (409mg, 92%) as a colorless oil.
[0595] Step 2: 2-methylpropan-2-yl 6-bromo-5-(bromomethyl)indole-1-carboxylate
[0596]
[0597] Add the reactant 6-bromo-5-methylindole-1-carboxylic acid 2-methylpropane-2-yl ester (350mg, 1.13mmol, 1eq), carbon tetrachloride (5mL), N-bromosuccinimide (221mg, 1.24mmol, 1.1eq), azobisisobutyronitrile (28mg, 0.17mmol, 0.15mg) to a 100mL eggplant-shaped bottle, and react at 80℃ for 3 hours under argon protection. TLC shows that some of the raw materials remain and the target product is generated. The reaction solution is cooled to room temperature, the reaction solution is spin-dried and the sample is purified by silica gel column chromatography (ethyl acetate-petroleum ether, 0-3% gradient elution) to obtain the product 6-bromo-5-(bromomethyl)indole-1-carboxylic acid 2-methylpropane-2-yl ester (398mg, 91%), a yellow oil.
[0598] Step 3: (6-Bromo-1H-indol-5-yl)methanol
[0599]
[0600] Add the reactants 6-bromo-5-(bromomethyl)indole-1-carboxylic acid-2-methylpropane-2-yl ester (395 mg, 1.02 mmol, 1 eq), potassium carbonate (702 mg, 5.08 mmol, 5 eq), sodium hydroxide (244 mg, 6.09 mmol, 6 eq) and dioxane (3 mL), water (3 mL) into a 50 mL eggplant-shaped bottle. Under argon protection, the reaction solution was stirred at 100 ° C overnight. LCMS results showed that the reaction was complete. The reaction solution was cooled to room temperature, diluted with water, and extracted and washed with ethyl acetate and saturated brine. The organic phase was dried, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (ethyl acetate-petroleum ether, 0-50% gradient elution) to obtain the product (6-bromo-1H-indol-5-yl) methanol (62 mg, 27%), a yellow oil.
[0601] Step 4: 6-Bromo-1H-indole-5-carbaldehyde
[0602]
[0603] Add the reactant (6-bromo-1H-indol-5-yl)methanol (62 mg, 0.27 mmol, 1 eq) and dichloromethane (10 mL) into a 100 mL eggplant-shaped flask, and add Dess-Martin periodinane (140 mg, 0.33 mmol, 1.2 eq) at 0°C, and react at room temperature for 30 minutes.
[0604] TLC results showed that the reaction was complete. The reaction solution was diluted with water and quenched, and extracted and washed with dichloromethane and saturated brine. The organic phase was dried, filtered and concentrated, and the residue was purified by silica gel column chromatography (ethyl acetate-petroleum ether, 0-20% gradient elution) to obtain the product 6-bromo-1H-indole-5-carboxaldehyde (52 mg, 0.23 mmol, 85%) as a yellow solid.
[0605] Step 5: 6-Bromo-1H-indole-5-carboxylic acid
[0606]
[0607] In a 25 mL eggplant-shaped bottle, add reactants 6-bromo-1H-indole-5-carboxaldehyde (185 mg, 0.46 mmol), tetrahydrofuran (1.2 mL), tert-butyl alcohol (1.2 mL), sodium dihydrogen phosphate (223 mg, 1.86 mmol), 2-methyl-2-butene (814 mg, 11.60 mmol), water (0.4 mL), sodium chlorite (79 mg, 0.70 mmol) at 0°C, and react at room temperature for 2 hours. LCMS showed that the reaction was complete.
[0608] Add 2 drops of 2M (M = mol / L) hydrochloric acid to the reaction solution, and extract with ethyl acetate and saturated brine. Dry the organic phase, filter and concentrate under reduced pressure to obtain 6-bromo-1H-indole-5-carboxylic acid (110 mg, crude product) as a yellow oil.
[0609] MS m / z:238[MH] +
[0610] Step 6: Methyl 6-bromo-1H-indole-5-carboxylate
[0611]
[0612] Dissolve 6-bromo-1H-indole-5-carboxylic acid (90 mg, 0.37 mmol, 1 eq) in N,N-dimethylformamide (3 mL), add potassium carbonate (54 mg, 0.39 mmol, 1.05 eq), add iodomethane (0.032 mL, 0.39 mmol, 1.05 eq) at 0°C, and stir at room temperature for 5 hours. LCMS shows that the raw material is basically reacted and the target product is generated. After adding 10 ml of water to quench the reaction solution, it is extracted and washed with ethyl acetate and saturated brine. The organic phase is dried, filtered, and concentrated under reduced pressure. The residue is purified by silica gel column chromatography (ethyl acetate-petroleum ether, 0-50% gradient elution) to obtain the product 6-bromo-1H-indole-5-carboxylic acid methyl ester (55 mg, 0.22 mmol, 57.74%) as a gray solid
[0613] MS m / z:252[MH] +
[0614] Step 7: Methyl 6-bromo-2-(2,2,2-trifluoroethyl)-1H-indole-5-carboxylate
[0615]
[0616] Add the reactants 6-bromo-1H-indole-5-carboxylic acid methyl ester, potassium bicarbonate (11 mg, 0.11 mmol, 2 eq), dibenzoylmethane (7 mg, 0.03 mmol, 0.6 eq), di(acetylacetone) palladium (10 mg, 0.03 mmol, 0.6), norbornene (10 mg, 0.11 mmol, 2 eq), N, N-dimethylformamide (2 mL) and 1,1,1-trifluoro-2-iodoethane (328 mg, 1.09 mmol, 28 eq) to a 100 mL eggplant-shaped bottle. Under argon protection, the reaction solution was microwaved at 160 ° C for 12 hours. LCMS results showed that the reaction was complete. The reaction solution was diluted with water and extracted with ethyl acetate and saturated brine. The organic phase was dried over sodium, filtered, concentrated, and the residue was purified by silica gel column chromatography (ethyl acetate-petroleum ether, 0-10% gradient elution) to obtain the crude product, which was then sent for preparative purification and lyophilized to give methyl 6-bromo-2-(2,2,2-trifluoroethyl)-1H-indole-5-carboxylate (3 mg, 16%) as a yellow solid.
[0617] MS m / z:336[M+H] +
[0618] Step 8: Methyl 6-bromo-1-methyl-2-(2,2,2-trifluoroethyl)indole-5-carboxylate
[0619]
[0620] Add the reactants 6-bromo-2-(2,2,2-trifluoroethyl)-1H-indole-5-carboxylic acid methyl ester (40 mg, 0.12 mmol, 1 eq) and N,N-dimethylformamide (2 mL) to a 25 mL eggplant-shaped bottle, add sodium hydrogen (5.7 mg, 0.14 mmol, 1.2 eq) at 0°C, react at room temperature for 30 minutes under N2 protection, add iodomethane (0.011 mL, 0.13 mmol, 1.1 eq) at 0°C, and react at room temperature overnight under N2 protection. TLC shows that the raw materials are basically reacted and the target product is generated. Dilute the reaction solution with water, extract with ethyl acetate and wash with saturated brine. The organic phase was dried over sodium, filtered, concentrated, and the residue was purified by silica gel column chromatography (ethyl acetate-petroleum ether, 0-10% gradient elution) to give the product methyl 6-bromo-1-methyl-2-(2,2,2-trifluoroethyl)indole-5-carboxylate (40 mg, 96.0%) as a yellow solid.
[0621] Step 9: 1-methyl-6-(2-{[(2-methylpropan-2-yl)oxy]carbonyl}-1,2,3,4-tetrahydroisoquinolin-6-yl)-2-(2,2,2-trifluoroethyl)indole-5-carboxylic acid methyl ester
[0622]
[0623] Add the reactants 6-bromo-2-(2,2,2-trifluoroethyl)-1H-indole-5-carboxylic acid methyl ester (21 mg, 0.06 mmol, 1 eq), 6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,2,3,4-tetrahydroisoquinoline-2-carboxylic acid-2-methylpropan-2-yl ester (26 mg, 0.07 mmol, 1.2 eq), [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium (4 mg, 0.01 mmol, 0.1 eq), sodium carbonate (64 mg, 0.6 mmol, 10 eq), water (1 mL) and dioxane (1 mL) into a 25 mL eggplant-shaped bottle. Under argon protection, the reaction solution was stirred at 100 ° C for 1 hour. LCMS showed that the reaction was complete. The reaction solution was quenched by adding water and extracted with ethyl acetate and saturated brine. The organic phase was dried, filtered, and concentrated, and the residue was purified by column chromatography (ethyl acetate / petroleum ether: 0-20%) to give the product, 1-methyl-6-(2-{[(2-methylpropan-2-yl)oxy]carbonyl}-1,2,3,4-tetrahydroisoquinolin-6-yl)-2-(2,2,2-trifluoroethyl)indole-5-carboxylic acid methyl ester, a yellow oil (105 mg, yield 79%).
[0624] MS m / z:403[M-100+H] +
[0625] Step 10: 3-iodo-1-methyl-6-(2-{[(2-methylpropan-2-yl)oxy]carbonyl}-1,2,3,4-tetrahydroisoquinolin-6-yl)-2-(2,2,2-trifluoroethyl)indole-5-carboxylic acid methyl ester
[0626]
[0627] Add the reactants 1-methyl-6-(2-{[(2-methylpropan-2-yl)oxy]carbonyl}-1,2,3,4-tetrahydroisoquinolin-6-yl)-2-(2,2,2-trifluoroethyl)indole-5-carboxylic acid methyl ester (10 mg, 0.04 mmol, 1 eq) and N,N-dimethylformamide (1 mL) to a 25 mL eggplant-shaped bottle, add N-iodosuccinimide (9 mg, 0.04 mmol, 1.1 eq) at 0°C, react at 0°C for 0.5 hours, and react at room temperature overnight. LCMS results show that the reaction is basically complete. Add water to the reaction solution to quench, and extract with ethyl acetate and saturated brine. The organic phase was dried, filtered, concentrated, and concentrated under reduced pressure to give the product, 3-iodo-1-methyl-6-(2-{[(2-methylpropan-2-yl)oxy]carbonyl}-1,2,3,4-tetrahydroisoquinolin-6-yl)-2-(2,2,2-trifluoroethyl)indole-5-carboxylic acid methyl ester (41 mg, crude) as a brown oil.
[0628] MS m / z:496[M-100+H] +
[0629] Step 11: 3-(3-{[2-methoxy-4-(methyldioxy- 6 -6-(2-{[(2-methylpropan-2-yl)oxy]carbonyl}-1,2,3,4-tetrahydroisoquinolin-6-yl)-2-(2,2,2-trifluoroethyl)indole-5-carboxylic acid methyl ester
[0630]
[0631] Add the reactants [2-methoxy-4-(methyldioxy-λ 6 -sulfuryl)phenyl](prop-2-ynyl)amine (34mg0.14mmol, 3eq), 3-iodo-1-methyl-6-(2-{[(2-methylprop-2-yl)oxy]carbonyl}-1,2,3,4-tetrahydroisoquinolin-6-yl)-2-(2,2,2-trifluoroethyl)indole-5-carboxylic acid methyl ester (30mg, 0.05mmol, 1eq), bistriphenylphosphine palladium dichloride (10mg, 0.01mmol, 0.3eq), cuprous iodide (5mg, 0.02mmol, 0.5eq), triethylamine (1.5mL) and N,N-dimethylformamide (3mL). Under argon protection, the reaction solution was stirred at 50°C for 12 hours. LCMS results showed that the reaction was complete.
[0632] The reaction solution was cooled to room temperature and diluted with water, extracted with ethyl acetate and saturated brine, dried, filtered, concentrated, and purified by column chromatography (ethyl acetate-petroleum ether, 0-33%) to obtain the product 3-(3-{[2-methoxy-4-(methyldioxy- 6 -thio)phenyl]amino}prop-1-ynyl)-1-methyl-6-(2-{[(2-methylprop-2-yl)oxy]carbonyl}-1,2,3,4-tetrahydroisoquinolin-6-yl)-2-(2,2,2-trifluoroethyl)indole-5-carboxylic acid methyl ester (17 mg, yield 48%).
[0633] MS m / z:640[M-100+H] +
[0634] Step 12: 3-(3-{[2-methoxy-4-(methyldioxy- 6 -thio)phenyl]amino}prop-1-ynyl)-1-methyl-6-(1,2,3,4-tetrahydroisoquinolin-6-yl)-2-(2,2,2-trifluoroethyl)indole-5-carboxylic acid methyl ester
[0635]
[0636] 3-(3-{[2-methoxy-4-(methyldioxy- 6 -thio)phenyl]amino}prop-1-ynyl)-1-methyl-6-(2-{[(2-methylprop-2-yl)oxy]carbonyl}-1,2,3,4-tetrahydroisoquinolin-6-yl)-2-(2,2,2-trifluoroethyl)indole-5-carboxylic acid methyl ester (17 mg, 0.02 mmol, 1 eq), silica gel (1000 mg), and toluene (10 mL) were mixed, replaced with N2, and reacted at 110° C. for 2 hours.
[0637] TLC results showed that the reaction was complete. After the reaction solution was cooled to room temperature, the toluene was dried and filtered, and the filter cake was washed with a mixed solvent of dichloromethane (DCM): methanol (MeOH): triethylamine (Et3N) of 10:1:0.01, and the organic phases were combined, filtered and concentrated under reduced pressure. The residue was purified by preparative HPLC to obtain 2.5 mg of the product, with a yield of 17%.
[0638] MS m / z:640[M+H] +
[0639] 1 H NMR(400MHz,DMSO-d6)δ7.90(s,1H),7.51(s,1H),7.42(dd,J=8.4,2.0Hz,1 H),7.26(d,J=2.0Hz,1H),7.07–6.95(m,4H),6.50(t,J=6.2Hz,1H),4.36(d ,J=6.1Hz,2H),4.01(q,J=10.6Hz,2H),3.90(s,3H),3.88(s,2H),3.80(s,3 H),3.64(s,3H),3.09(s,3H),2.97(t,J=5.8Hz,2H),2.73(t,J=5.8Hz,2H).
[0640] Example 15: [3-(3-{[2-methoxy-4-(methyldioxy- 6 -thio)phenyl]amino}prop-1-ynyl)-1-methyl-6-(1,2,3,4-tetrahydroisoquinolin-6-yl)-2-(2,2,2-trifluoroethyl)indol-5-yl]methanol (Compound 15)
[0641]
[0642] Step 1: [6-Bromo-1-methyl-2-(2,2,2-trifluoroethyl)indol-5-yl]methanol
[0643]
[0644] Add the reactant 6-bromo-1-methyl-2-(2,2,2-trifluoroethyl)indole-5-carboxylic acid methyl ester (300mg, 0.86mmol, 1eq) and anhydrous tetrahydrofuran (2mL) to a 50mL round-bottom flask. Under argon protection, add diisobutylaluminum hydride tetrahydrofuran solution (1M, 6.85ml, 8eq) at -78°C. LCMS results show that the reaction is complete. After the reaction solution is quenched by adding 2M hydrochloric acid, it is extracted and washed with ethyl acetate and saturated brine. The organic phase is dried, filtered, and concentrated under reduced pressure to obtain the crude product [6-bromo-1-methyl-2-(2,2,2-trifluoroethyl)indol-5-yl]methanol (250mg, 0.78mmol) as a yellow solid.
[0645] MS m / z:322[M+H] +
[0646] Step 2: 6-[5-(Hydroxymethyl)-1-methyl-2-(2,2,2-trifluoroethyl)indol-6-yl]-1,2,3,4-tetrahydroisoquinoline-2-carboxylic acid-2-methylpropan-2-yl ester
[0647]
[0648] Add reactants [6-bromo-1-methyl-2-(2,2,2-trifluoroethyl)indol-5-yl]methanol (210 mg, 0.65 mmol, 1 eq), 6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,2,3,4-tetrahydroisoquinoline-2-carboxylic acid-2-methylpropane-2-yl ester (234 mg, 0.65 mmol, 1 eq), [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium (47.7 mg, 0.07 mmol, 0.1 eq), sodium carbonate (691 mg, 6.52 mmol, 10 eq), water (5 mL) and dioxane (5 mL) into a 25 mL eggplant-shaped bottle. Under argon protection, the reaction solution was stirred at 100 ° C for 3 hours. TLC showed that the reaction was complete. The reaction solution was quenched by adding water and extracted with ethyl acetate and saturated brine. The organic phase was dried, filtered, and concentrated, and the residue was purified by column chromatography (ethyl acetate / petroleum ether: 0-50%) to give the product 6-[5-(hydroxymethyl)-1-methyl-2-(2,2,2-trifluoroethyl)indol-6-yl]-1,2,3,4-tetrahydroisoquinoline-2-carboxylic acid-2-methylpropan-2-yl ester as a yellow oil (43 mg, yield 82%).
[0649] Step 3: 6-[5-(Hydroxymethyl)-3-iodo-1-methyl-2-(2,2,2-trifluoroethyl)indol-6-yl]-1,2,3,4-tetrahydroisoquinoline-2-carboxylic acid-2-methylpropan-2-yl ester
[0650]
[0651] Add the reactant 6-[5-(hydroxymethyl)-1-methyl-2-(2,2,2-trifluoroethyl)indol-6-yl]-1,2,3,4-tetrahydroisoquinoline-2-carboxylic acid-2-methylpropane-2-yl ester (86 mg, 0.07 mmol, 1 eq) and N,N-dimethylformamide (2 mL) to a 25 mL eggplant-shaped bottle, add N-iodosuccinimide (45 mg, 0.07 mmol, 1.1 eq) at 0°C, and react at room temperature for 1 hour. LCMS results show that the reaction is basically complete. The reaction solution is quenched by adding water and extracted with ethyl acetate and saturated brine. The organic phase was dried, filtered, concentrated, and concentrated under reduced pressure to give the product 6-[5-(hydroxymethyl)-3-iodo-1-methyl-2-(2,2,2-trifluoroethyl)indol-6-yl]-1,2,3,4-tetrahydroisoquinoline-2-carboxylic acid-2-methylpropan-2-yl ester (105 mg, crude) as a brown oil.
[0652] Step 4: 6-[5-(hydroxymethyl)-3-(3-{[2-methoxy-4-(methyldioxy- 6 -1-methyl-2-(2,2,2-trifluoroethyl)indol-6-yl)-1,2,3,4-tetrahydroisoquinoline-2-carboxylic acid 2-methylpropan-2-yl ester
[0653]
[0654] Add the reactants [2-methoxy-4-(methyldioxy-λ 6-sulfuryl)phenyl](prop-2-ynyl)amine (126mg, 0.52mmol, 3eq), 6-[5-(hydroxymethyl)-3-iodo-1-methyl-2-(2,2,2-trifluoroethyl)indol-6-yl]-1,2,3,4-tetrahydroisoquinoline-2-carboxylic acid-2-methylprop-2-yl ester (105mg, 0.17mmol, 1eq), bistriphenylphosphine palladium dichloride (37mg, 0.05mmol, 0.3eq), cuprous iodide (17mg, 0.09mmol, 0.5eq), triethylamine (1.5mL) and N,N-dimethylformamide (3mL). Under argon protection, the reaction solution was stirred at 50°C for 12 hours. LCMS results showed that the reaction was complete. The reaction solution was cooled to room temperature and diluted with water, extracted with ethyl acetate and saturated brine, dried, filtered, concentrated, and purified by column chromatography (ethyl acetate-petroleum ether, 0-50%) to obtain the product 6-[5-(hydroxymethyl)-3-(3-{[2-methoxy-4-(methyldioxy- 6 -thio)phenyl]amino}prop-1-ynyl)-1-methyl-2-(2,2,2-trifluoroethyl)indol-6-yl]-1,2,3,4-tetrahydroisoquinoline-2-carboxylic acid-2-methylprop-2-yl ester (75 mg, yield 60%).
[0655] MS m / z:712[M+H] +
[0656] Step 5: [3-(3-{[2-methoxy-4-(methyldioxy- 6 -thio)phenyl]amino}prop-1-ynyl)-1-methyl-6-(1,2,3,4-tetrahydroisoquinolin-6-yl)-2-(2,2,2-trifluoroethyl)indol-5-yl]methanol
[0657]
[0658] 6-[5-(hydroxymethyl)-3-(3-{[2-methoxy-4-(methyldioxy- 6 -sulfuryl)phenyl]amino}prop-1-ynyl)-1-methyl-2-(2,2,2-trifluoroethyl)indol-6-yl]-1,2,3,4-tetrahydroisoquinoline-2-carboxylic acid-2-methylprop-2-yl ester (35 mg, 0.05 mmol, 1 eq), silica gel (3000 mg, 9.03 mmol), toluene (10 mL) were mixed, replaced with nitrogen, and reacted at 110 ° C for 2 hours. LCMS results showed that the reaction was complete. After the reaction solution was cooled to room temperature, the toluene was dried and filtered, and the filter cake was washed with a mixed solvent of DCM:MeOH:Et3N of 10:1:0.01, and the organic phases were combined, filtered and concentrated under reduced pressure. The residue was purified by preparative-HPLC to obtain 3 mg of the product with a yield of 10%.
[0659] LCMS: MS m / z: 612 [M+H] +
[0660] 1 H NMR (400MHz, DMSO-d6) δ7.69(s,1H),7.42(dd,J=8.4,2.0Hz,1H),7.29(s,1H),7.25(d,J=2.0Hz,1H ),7.14(dd,J=7.6,1.7Hz,1H),7.10(s,1H),7.05(d,J=7.8Hz,1H),6.96(d,J=8.4Hz,1H),6.48(t,J =6.2Hz,1H),5.06(t,J=5.4Hz,1H),4.45(d,J=5.3Hz,2H),4.36(d,J=6.2Hz,2H),3.97(d,J=10.7Hz ,2H),3.89(d,J=5.3Hz,5H),3.74(s,3H),3.09(s,3H),2.97(t,J=5.8Hz,2H),2.73(t,J=5.8Hz,2H).
[0661] Example 16: 6-{3-[3-({4-[dimethyl(carbonyl)-λ 5 -phosphoalkyl]-2-methoxyphenyl}amino)prop-1-ynyl]-1-methyl-2-(2,2,2-trifluoroethyl)indol-6-yl}-1,2,3,4-tetrahydroisoquinoline (Compound 16)
[0662]
[0663] Example 16 The synthetic route is as in Example 5, wherein:
[0664] Step 5: 6-{3-[3-({4-[dimethyl(oxy)-λ 5- [(2-methoxyphenyl)amino]prop-1-ynyl]-1-methyl-2-(2,2,2-trifluoroethyl)indol-6-yl]-1,2,3,4-tetrahydroisoquinoline-2-carboxylic acid-2-methylprop-2-yl ester
[0665]
[0666] During the synthesis process, the raw material 2-methoxy-4-(methylsulfonyl)-N-(prop-2-yn-1-yl)aniline in step 5 of Example 5 was replaced by {4-[dimethyl(oxy)-λ 5-methylphosphino]-2-methoxyphenyl}(prop-2-ynyl)amine (for the specific synthesis process, refer to Example 1 of patent WO2023025324), and then through each step of reaction to obtain 6-{3-[3-({4-[dimethyl(carbonyl)-λ 5 -phosphoalkyl]-2-methoxyphenyl}amino)prop-1-ynyl]-1-methyl-2-(2,2,2-trifluoroethyl)indol-6-yl}-1,2,3,4-tetrahydroisoquinoline.
[0667] MS m / z:580[M+H] +
[0668] 1 H NMR(400MHz,DMSO-d6)δ7.75(s,1H),7.49-7.40(m,4H),7.27-7.21(m,1H),7.14( d,J=11.9,1H),7.09(d,J=7.9Hz,1H),6.91(dd,J=8.0,3.1Hz,1H),5.99(t,J=6.3H z,1H),4.30(d,J=6.3Hz,2H),3.94(q,J=10.7Hz,2H),3.87(s,2H),3.85(s,3H),3. 81(s,3H),2.97(t,J=5.9Hz,2H),2.76(t,J=5.9Hz,2H),1.60(s,3H),1.56(s,3H).
[0669] Example 17 1-[3-(3-{[2-methoxy-4-(methyldioxy- 6 -thio)phenyl]amino}prop-1-ynyl)-1-methyl-6-(1,2,3,4-tetrahydroisoquinolin-6-yl)-2-(2,2,2-trifluoroethyl)indol-5-yl]ethan-1-one (Compound 17)
[0670]
[0671] Step 1: 6-Bromo-1-methyl-2-(2,2,2-trifluoroethyl)indole-5-carboxylic acid
[0672]
[0673] Add the reactants 6-bromo-1-methyl-2-(2,2,2-trifluoroethyl)indole-5-carboxylic acid methyl ester (214 mg, 0.61 mmol, 1 eq), sodium hydroxide (122 mg, 3.06 mmol, 5 eq) and methanol (2 mL), water (1 mL) into a 50 mL round-bottom flask. Under argon protection, the reaction solution was stirred at 40 ° C for 1 hour. LCMS results showed that the reaction was complete. The reaction solution was added with 2M hydrochloric acid to adjust the pH to 6, and then extracted and washed with dichloromethane and saturated brine. The organic phase was dried, filtered, and concentrated under reduced pressure to obtain the crude product 6-bromo-1-methyl-2-(2,2,2-trifluoroethyl)indole-5-carboxylic acid (255 mg, 0.76 mmol), a light yellow oil.
[0674] MS m / z:335[M+H] +
[0675] Step 2: 6-Bromo-N-methoxy-1,N-dimethyl-2-(2,2,2-trifluoroethyl)indole-5-carboxamide
[0676]
[0677] In a 100mL reaction bottle, 6-bromo-1-methyl-2-(2,2,2-trifluoroethyl)indole-5-carboxylic acid (34mg, 0.1mmol, 1.0eq), N,O-dimethylhydroxylamine hydrochloride (20mg, 0.2mmol, 2.0eq), N,N-diisopropylethylamine (52mg, 0.4mmol, 4.0eq) were dissolved in N,N-dimethylformamide (2mL) and reacted at room temperature for 8 hours. LCMS monitored the reaction to be complete. Water was added to quench the reaction, and the mixture was extracted with ethyl acetate and dried over anhydrous sodium sulfate. The filtrate was filtered, concentrated, and the residue was purified by column (ethyl acetate / petroleum ether: 5-50%) to obtain: 6-bromo-N-methoxy-1,N-dimethyl-2-(2,2,2-trifluoroethyl)indole-5-carboxamide (38mg, yield: 99%), a light yellow oil.
[0678] MS m / z:379[M+H] +
[0679] Step 3: 1-[6-Bromo-1-methyl-2-(2,2,2-trifluoroethyl)indol-5-yl]ethan-1-one
[0680]
[0681] In a 100mL reaction bottle, 6-bromo-N-methoxy-1,N-dimethyl-2-(2,2,2-trifluoroethyl)indole-5-carboxamide (28mg, 0.07mmol, 1.0eq) was dissolved in tetrahydrofuran (2mL). Methylmagnesium chloride (0.07mL, 0.22mmol, 3.0eq) was added under ice bath. The reaction was carried out at 0℃ for 1 hour and then at room temperature for 1 hour. LCMS monitored that the raw material reaction was complete. The reaction was quenched by adding saturated ammonium chloride solution, extracted with ethyl acetate, and dried over anhydrous sodium sulfate. Filtered, the filtrate was concentrated, and the residue was purified by column (ethyl acetate / petroleum ether: 5-50%) to obtain: 1-[6-bromo-1-methyl-2-(2,2,2-trifluoroethyl)indol-5-yl]ethan-1-one (24mg, yield: 97%), a light yellow oil.
[0682] MS m / z:334[M+H] +
[0683] The subsequent synthesis steps refer to Example 1, wherein:
[0684] Step 4 Referring to step 3 of Example 1, tert-butyl 7-(1-methyl-2-(2,2,2-trifluoroethyl)-1H-indol-6-yl)-3,4-dihydroisoquinoline-2(1H)-carboxylate was replaced with 1-[6-bromo-1-methyl-2-(2,2,2-trifluoroethyl)indol-5-yl]ethan-1-one, and the following 4 steps were followed to obtain compound 17, 1-[3-(3-{[2-methoxy-4-(methyldioxy-λ 6 -thio)phenyl]amino}prop-1-ynyl)-1-methyl-6-(1,2,3,4-tetrahydroisoquinolin-6-yl)-2-(2,2,2-trifluoroethyl)indol-5-yl]ethan-1-one.
[0685] MS m / z:624[M+H] +
[0686] 1 H NMR(400MHz,DMSO-d6)δ7.70(s,1H),7.49(s,1H),7.42-7.40(m,1H),7.24(s, 1H),7.08-7.05(m,2H),7.03-7.00(m,1H),6.97(d,J=8.4Hz,1H),6.48(t,J=6. 2Hz,1H),4.35(d,J=5.9Hz,2H),4.00(q,J=10.6Hz,3H),3.89-3.88(m,5H),3. 80(s,3H),3.09(s,3H),2.96(t,J=5.9Hz,2H),2.74-2.72(m,2H),2.10(s,3H).
[0687] Example 18: 6-[3-(3-{[2-methoxy-4-(methyldicarbonyl-λ 6- [(4-(2 ...
[0688]
[0689] Step 1: 6-Bromo-1-methyl-2-(2,2,2-trifluoroethyl)indole-5-carbaldehyde
[0690]
[0691] In a 100mL reaction bottle, methyl 6-bromo-1-methyl-2-(2,2,2-trifluoroethyl)indol-5-yl]methanol (148mg, 0.46mmol, 1.0eq) was dissolved in dichloromethane (3mL). Dess-Martin periodinane (253mg, 0.60mmol, 1.3eq) was added under ice bath. The reaction was allowed to proceed for 30 minutes under ice bath. The reaction was complete as monitored by LCMS. The reaction was quenched by adding saturated sodium bicarbonate solution, extracted with ethyl acetate, and dried over anhydrous sodium sulfate. The filtrate was filtered, concentrated, and the residue was purified by column (ethyl acetate / petroleum ether: 5-10%) to obtain: 6-bromo-1-methyl-2-(2,2,2-trifluoroethyl)indole-5-carboxaldehyde (98mg, yield: 67%), a light yellow solid.
[0692] MS m / z:320[M+H] +
[0693] Step 2: 6-Bromo-1-methyl-5-(1,3-oxazol-5-yl)-2-(2,2,2-trifluoroethyl)indole
[0694]
[0695] In a 100mL reaction bottle, 6-bromo-1-methyl-2-(2,2,2-trifluoroethyl)indole-5-carboxaldehyde (50mg, 0.16mmol, 1.0eq), potassium carbonate (43mg, 0.32mmol, 2.0eq), p-toluenesulfonylmethyl isocyanide (31mg, 0.16mmol, 1.0eq) were dissolved in methanol (2mL) and reacted at 75°C for 2 hours. LCMS monitored the reaction to be complete. Water was added to quench the reaction, and the mixture was extracted with ethyl acetate and dried over anhydrous sodium sulfate. The filtrate was filtered, concentrated, and the residue was purified by column (ethyl acetate / petroleum ether: 5-30%) to obtain: 6-bromo-1-methyl-5-(1,3-oxazol-5-yl)-2-(2,2,2-trifluoroethyl)indole (32mg, yield: 57%), a light yellow solid.
[0696] MS m / z:359[M+H] +
[0697] The subsequent synthesis steps refer to Example 3, wherein,
[0698] Step 3: The raw material 6-bromo-1-ethyl-2-(2,2,2-trifluoroethyl)indole is replaced with 6-bromo-1-methyl-5-(1,3-oxazol-5-yl)-2-(2,2,2-trifluoroethyl)indole, and 6-[3-(3-{[2-methoxy-4-(methyldicarbonyl-λ 6-
[0063] In the invention, the invention relates to 1-methyl-5-(1,3-oxazol-5-yl)-2-(2,2,2-trifluoroethyl)indol-6-yl)-1,2,3,4-tetrahydroisoquinoline.
[0699] MS m / z:649[M+H] +
[0700] 1 H NMR (400MHz, DMSO-d6) δ8.28(s,1H),7.79(s,1H),7.48(s,1H),7.44(dd,J= 8.4,1.9Hz,1H),7.25(d,J=2.0Hz,1H),7.05-6.94(m,4H),6.50(t,J=6.1Hz, 1H),6.23(s,1H),4.36(d,J=6.1Hz,2H),4.00(q,J=10.7Hz,2H),3.89-3.88 (m,5H),3.78(s,3H),3.08(s,3H),2.96(t,J=5.8Hz,2H),2.70-2.66(m,2H).
[0701] Example 19: 6-[7-(difluoromethyl)-3-(3-{[2-methoxy-4-(methyldioxy- 6 -thio)phenyl]amino}prop-1-ynyl)-1-methyl-2-(2,2,2-trifluoroethyl)indol-6-yl]-1,2,3,4-tetrahydroisoquinoline (Compound 19)
[0702]
[0703] Step 1: 6-Bromo-1-methyl-2-(2,2,2-trifluoroethyl)indole-7-carbaldehyde
[0704]
[0705] The synthesis of 6-bromo-2-(2,2,2-trifluoroethyl)-1H-indole-7-carbaldehyde follows the synthetic route of 6-bromo-1H-indole-5-carbaldehyde in Example 14, except that the raw material 6-bromo-5-methyl-1H-indole is replaced with 6-bromo-7-methyl-1H-indole and the product is synthesized through a four-step reaction.
[0706] Add the reactants 6-bromo-2-(2,2,2-trifluoroethyl)-1H-indole-7-carbaldehyde (63 mg, 0.21 mmol) and N,N-dimethylformamide (2 mL) to a 25 mL eggplant-shaped bottle, add sodium hydrogen (10 mg, 0.25 mmol) under ice bath, react at room temperature for 1 hour, add iodomethane (32 mg, 0.23 mmol) under ice bath, react at room temperature for 1 hour under argon protection. LCMS monitors the reaction to be complete. Add water to the reaction solution, extract with ethyl acetate and saturated brine. The organic phase is dried, filtered and concentrated, and the residue is purified by column chromatography (ethyl acetate / petroleum ether, 20%) to obtain the product 6-bromo-1-methyl-2-(2,2,2-trifluoroethyl) indole-7-carbaldehyde, a yellow oil (47 mg, yield 61%).
[0707] MS m / z:320[M+H] +
[0708] Step 2: 6-Bromo-7-(difluoromethyl)-1-methyl-2-(2,2,2-trifluoroethyl)indole
[0709]
[0710] In a 25 mL eggplant-shaped bottle, add the reactant 6-bromo-1-methyl-2-(2,2,2-trifluoroethyl)indole-7-carbaldehyde (18 mg, 0.06 mmol), dichloromethane (2 mL), diethylaminosulfur trifluoride (483.57 mg, 3.00 mmol), a drop of methanol (0.002 mL, 0.06 mmol), and react at room temperature for 16 hours under argon protection. LCMS monitoring reaction is complete. The reaction solution is diluted with saturated sodium bicarbonate solution and extracted with dichloromethane and saturated brine. The organic phase is dried, filtered and concentrated, and the residue is purified by preparative-TLC (ethyl acetate / petroleum ether, 5%) to obtain the product 6-bromo-7-(difluoromethyl)-1-methyl-2-(2,2,2-trifluoroethyl)indole, a yellow oil (12 mg, yield 62%).
[0711] MS m / z:342[M+H] +
[0712] Step 3: 6-[7-(Difluoromethyl)-1-methyl-2-(2,2,2-trifluoroethyl)indol-6-yl]-1,2,3,4-tetrahydroisoquinoline-2-carboxylic acid-2-methylpropan-2-yl ester
[0713]
[0714] The reactants 6-bromo-7-(difluoromethyl)-1-methyl-2-(2,2,2-trifluoroethyl)indole, 6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,2,3,4-tetrahydroisoquinoline-2-carboxylic acid-2-methylpropane-2-yl ester (11.03 mg, 0.03 mmol), tetrakis(triphenylphosphine)palladium) (7.09 mg, 0.01 mmol), sodium carbonate (32.53 mg, 0.31 mmol), water (1 mL) and dioxane (1 mL) were added to a 25 mL eggplant-shaped bottle. Under argon protection, the reaction solution was stirred at 100 ° C for 4 hours. LCMS showed that the reaction was complete. The reaction solution was quenched by adding water and extracted with ethyl acetate and saturated brine. The organic phase was dried, filtered, and concentrated, and the residue was purified by column chromatography (ethyl acetate / petroleum ether: 0-50%) and separated by HPLC to obtain the product 6-[7-(difluoromethyl)-1-methyl-2-(2,2,2-trifluoroethyl)indol-6-yl]-1,2,3,4-tetrahydroisoquinoline-2-carboxylic acid-2-methylpropan-2-yl ester, a yellow oil (9.2 mg, yield 61%).
[0715] MS m / z:395[M-100+H] +
[0716] Step 4: 6-[7-(Difluoromethyl)-3-iodo-1-methyl-2-(2,2,2-trifluoroethyl)indol-6-yl]-1,2,3,4-tetrahydroisoquinoline-2-carboxylic acid-2-methylpropan-2-yl ester
[0717]
[0718] Add the reactant 6-[7-(difluoromethyl)-1-methyl-2-(2,2,2-trifluoroethyl)indol-6-yl]-1,2,3,4-tetrahydroisoquinoline-2-carboxylic acid-2-methylpropane-2-yl ester (9.1 mg, 0.02 mmol) and N,N-dimethylformamide (1 mL) to a 25 mL eggplant-shaped bottle, add N-iodosuccinimide (4.55 mg, 0.02 mmol) at 0°C, and react at room temperature for 3 hours. LCMS results show that the reaction is basically complete. The reaction solution is quenched by adding water and extracted with ethyl acetate and saturated brine. The organic phase was dried, filtered, concentrated, and concentrated under reduced pressure to give the product 6-[7-(difluoromethyl)-3-iodo-1-methyl-2-(2,2,2-trifluoroethyl)indol-6-yl]-1,2,3,4-tetrahydroisoquinoline-2-carboxylic acid-2-methylpropan-2-yl ester (12 mg, crude) as a brown oil.
[0719] MS m / z:621[M+H] +
[0720] Step 5: 6-[7-(difluoromethyl)-3-(3-{[2-methoxy-4-(methyldioxy- 6 -1-methyl-2-(2,2,2-trifluoroethyl)indol-6-yl)-1,2,3,4-tetrahydroisoquinoline-2-carboxylic acid 2-methylpropan-2-yl ester
[0721]
[0722] Add the reactants [2-methoxy-4-(methyldioxy-λ 6-sulfuryl)phenyl](prop-2-ynyl)amine (14.36 mg, 0.06 mmol), 6-[7-(difluoromethyl)-3-iodo-1-methyl-2-(2,2,2-trifluoroethyl)indol-6-yl]-1,2,3,4-tetrahydroisoquinoline-2-carboxylic acid-2-methylprop-2-yl ester (11 mg, 0.02 mmol), bistriphenylphosphine palladium dichloride (3.73 mg, 0.01 mmol), cuprous iodide (1.69 mg, 0.01 mmol), triethylamine (0.25 mL) and N,N-dimethylformamide (0.25 mL). Under argon protection, the reaction solution was stirred at 50 ° C for 24 hours. LCMS results showed that the reaction was complete. The reaction solution was cooled to room temperature and diluted with water, extracted with ethyl acetate and saturated brine, dried, filtered, concentrated, and purified by preparative-TLC (ethyl acetate / petroleum ether, 33%) to obtain the product 6-[7-(difluoromethyl)-3-(3-{[2-methoxy-4-(methyldioxy- 6 -thio)phenyl]amino}prop-1-ynyl)-1-methyl-2-(2,2,2-trifluoroethyl)indol-6-yl]-1,2,3,4-tetrahydroisoquinoline-2-carboxylic acid-2-methylprop-2-yl ester (4.9 mg, yield 38%).
[0723] MS m / z:632[M-100+H] +
[0724] Step 6: 6-[7-(difluoromethyl)-3-(3-{[2-methoxy-4-(methyldioxy- 6 -1-methyl-2-(2,2,2-trifluoroethyl)indol-6-yl)-1,2,3,4-tetrahydroisoquinoline
[0725]
[0726] 6-[7-(difluoromethyl)-3-(3-{[2-methoxy-4-(methyldioxy- 6-sulfuryl)phenyl]amino}prop-1-ynyl)-1-methyl-2-(2,2,2-trifluoroethyl)indol-6-yl]-1,2,3,4-tetrahydroisoquinoline-2-carboxylic acid-2-methylprop-2-yl ester (4.9 mg, 0.01 mmol), silica gel (2000 mg, 9.03 mmol), toluene (10 mL) were mixed, nitrogen was replaced, and the reaction was carried out at 110°C for 4 hours. LCMS results showed that the reaction was complete. After the reaction solution was cooled to room temperature, the toluene was dried and filtered, and the filter cake was washed with a mixed solvent of DCM:MeOH:Et3N of 10:1:0.01. The organic phases were combined, filtered and concentrated under reduced pressure. The residue was purified by preparative-TLC to obtain the product 6-[7-(difluoromethyl)-3-(3-{[2-methoxy-4-(methyldioxy- 6 -thio)phenyl]amino}prop-1-ynyl)-1-methyl-2-(2,2,2-trifluoroethyl)indol-6-yl]-1,2,3,4-tetrahydroisoquinoline (1.8 mg, yield 43%).
[0727] MS m / z:632[M+H] +
[0728] 1 H NMR(400MHz,DMSO-d6)δ7.71(d,J=8.1Hz,1H),7.42(dd,J=8.5,2.0Hz,1H),7.3 7(d,J=7.9Hz,1H),7.28–7.21(m,3H),7.14(d,J=8.2Hz,1H),6.97(d,J=8.4Hz, 1H),6.83(m,1H)6.50(t,J=6.2Hz,1H),4.37(d,J=6.2Hz,2H),4.33(s,2H),4.0 8(q,J=10.6Hz,2H),3.90(d,J=4.1Hz,6H),3.41(d,J=6.2Hz,2H),3.09(m,5H).
[0729] Example 20: [3-(3-{[2-methoxy-4-(methyldioxy- 6 -thio)phenyl]amino}prop-1-ynyl)-1-methyl-6-(1,2,3,4-tetrahydroisoquinolin-6-yl)-2-(2,2,2-trifluoroethyl)indol-7-yl]methanol (Compound 20)
[0730]
[0731] Step 1: [6-Bromo-1-methyl-2-(2,2,2-trifluoroethyl)indol-7-yl]methanol
[0732]
[0733] Add reactant 6-bromo-1-methyl-2-(2,2,2-trifluoroethyl)indole-7-carboxaldehyde (18 mg, 0.06 mmol) and ethanol (1 mL) to a 25 mL eggplant-shaped bottle, add NaBH4 (18.91 mg, 0.50 mmol) at 0°C, react at room temperature for 1 hour, LCMS shows that the raw material reaction is complete and the target product is generated. Add water to quench the reaction solution, and extract with ethyl acetate and saturated brine. The organic phase is dried, filtered, and concentrated to obtain the product [6-bromo-1-methyl-2-(2,2,2-trifluoroethyl)indole-7-yl]methanol, a brown oil (600 mg, crude product).
[0734] MS m / z:304[M+H] +
[0735] The subsequent synthetic route refers to Example 15. In step 2, the raw material [6-bromo-1-methyl-2-(2,2,2-trifluoroethyl)indol-5-yl]methanol is replaced with [6-bromo-1-methyl-2-(2,2,2-trifluoroethyl)indol-7-yl]methanol, and after 4 steps of reaction, [3-(3-{[2-methoxy-4-(methyldioxy-λ 6 -thio)phenyl]amino}prop-1-ynyl)-1-methyl-6-(1,2,3,4-tetrahydroisoquinolin-6-yl)-2-(2,2,2-trifluoroethyl)indol-7-yl]methanol.
[0736] MS m / z:612[M+H] +
[0737] 1 H NMR (400MHz, DMSO-d6) δ7.45–7.39(m,2H),7.25(d,J=1.9Hz,1H),7.16(d,J=9.7H z,1H),7.11(s,1H),7.05(d,J=7.7Hz,1H),6.99(d,J=8.1Hz,1H),6.96(d,J=8.3Hz ,1H),6.48(t,J=6.0Hz,1H),4.68(s,2H),4.35(d,J=6.2Hz,2H),4.12(s,3H),4.0 0(d,J=10.7Hz,2H),3.90(s,5H),3.10(s,3H),2.97(s,2H),2.74(d,J=5.8Hz,2H).
[0738] Example 21: 3-(3-{[2-methoxy-4-(methyldioxy- 6-thio)phenyl]amino}prop-1-ynyl)-1-methyl-6-(1,2,3,4-tetrahydroisoquinolin-6-yl)-2-(2,2,2-trifluoroethyl)indole-7-carbonitrile (Compound 21)
[0739]
[0740] Step 1: 6-Bromo-1-methyl-2-(2,2,2-trifluoroethyl)indole-7-carboxylic acid
[0741]
[0742] Add the reactants 6-bromo-1-methyl-2-(2,2,2-trifluoroethyl)indole-7-carbaldehyde (185mg, 0.46mmol, 1eq), tetrahydrofuran (1.2mL), tert-butyl alcohol (1.2mL), sodium dihydrogen phosphate (554.81mg, 4.62mmol, 8eq), 2-methyl-2-butene (2026.79mg, 28.90mmol, 50eq), water (0.4mL) to a 25mL eggplant-shaped bottle, add sodium chlorite (196.00mg, 1.73mmol, 3eq) at 0℃, and react at room temperature for 2 hours. TLC shows that the reaction is complete. Add 2 drops of 2M hydrochloric acid to the reaction solution, and extract with ethyl acetate and saturated brine. Dry the organic phase, filter, and concentrate under reduced pressure to obtain a crude product.
[0743] MS m / z:334[MH]+
[0744] Step 2: 6-Bromo-2-(2,2,2-trifluoroethyl)-1-methylindole-7-carboxamide
[0745]
[0746] Add the reactants 6-bromo-1-methyl-2-(2,2,2-trifluoroethyl)indole-7-carboxylic acid (231 mg, 0.72 mmol, 1 eq), ammonium chloride (385.13 mg, 7.20 mmol, 10 eq), N,N,N′,N′-tetramethyl-O-(7-azabenzotriazole-1-yl)urea hexafluorophosphate (328.53 mg, 0.86 mmol, 1.2 eq), N,N-diisopropylethylamine (930.60 mg, 7.20 mmol, 10 eq) and N,N-dimethylformamide (5 mL) to a 50 mL round-bottom flask. Under argon protection, the reaction solution was reacted at 40 ° C for 5 hours. LCMS results showed that the reaction was complete. The reaction solution was cooled to room temperature, diluted with water (30 mL), and washed with ethyl acetate and saturated brine. The organic phase was dried, filtered and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (ethyl acetate / petroleum ether, 0-50%) to give the product 6-bromo-1-methyl-2-(2,2,2-trifluoroethyl)indole-7-carboxamide (245 mg, crude) as a yellow solid.
[0747] MS m / z:335[M+H] +
[0748] Step 3: 6-Bromo-1-methyl-2-(2,2,2-trifluoroethyl)indole-7-carbonitrile
[0749]
[0750] Add N,N-dimethylformamide (3mL) to a 25ml eggplant-shaped bottle, add phosphorus oxychloride (0.6mL) dropwise under ice bath, add 6-bromo-1-methyl-2-(2,2,2-trifluoroethyl)indole-7-carboxamide (150mg, 0.45mmol), and react at room temperature for 20 minutes. LCMS shows that the reaction is complete. Add the reaction solution to saturated sodium bicarbonate solution and stir for 20 minutes, extract with ethyl acetate and saturated brine. The organic phase is dried, filtered and concentrated under reduced pressure. The residue is purified by silica gel column chromatography (ethyl acetate / petroleum ether, 0-50%) to obtain the product 6-bromo-1-methyl-2-(2,2,2-trifluoroethyl)indole-7-carbonitrile (97mg, yield 68%) as a yellow solid.
[0751] MS m / z:316[M+H] +
[0752] The subsequent synthetic route refers to Specific Example 5, wherein in step 4, the raw material 6-bromo-1-methyl-2-(2,2,2-trifluoroethyl)indole is replaced with 6-bromo-1-methyl-2-(2,2,2-trifluoroethyl)indole-7-carbonitrile and then reacted in each step to prepare 3-(3-{[2-methoxy-4-(methyldioxy- 6-thio)phenyl]amino}prop-1-ynyl)-1-methyl-6-(1,2,3,4-tetrahydroisoquinolin-6-yl)-2-(2,2,2-trifluoroethyl)indole-7-carbonitrile.
[0753] MS m / z:607[M+H] +
[0754] 1 H NMR (400MHz, DMSO-d6) δ7.80(d,J=8.2Hz,1H),7.42(dd,J=8.3,2.0Hz,1H),7.36–7.24(m,4H),7.18(d,J=7.9Hz,1H),6.96(d,J=8.4Hz,1H),6.50(t ,J=6.2Hz,1H),4.36(d,J=6.1Hz,2H),4.06(d,J=20.1Hz,5H),3.96(s,2H ),3.89(s,3H),3.10(s,3H),3.03(t,J=5.9Hz,2H),2.79(t,J=5.8Hz,2H).
[0755] Example 22: 3-(3-{[2-methoxy-4-(methyldioxy- 6 -thio)phenyl]amino}prop-1-ynyl)-1,N,N-trimethyl-6-(1,2,3,4-tetrahydroisoquinolin-6-yl)-2-(2,2,2-trifluoroethyl)indole-5-carboxamide (Compound 22)
[0756]
[0757] Step 1: 6-Bromo-1,N,N-trimethyl-2-(2,2,2-trifluoroethyl)indole-5-carboxamide
[0758]
[0759] Add the reactants 6-bromo-1-methyl-2-(2,2,2-trifluoroethyl)indole-5-carboxylic acid (110 mg, 0.33 mmol, 1 eq), N,N-dimethylformamide (2 mL), N,N-diisopropylethylamine (126.90 mg, 0.98 mmol, 3 eq), 2-(7-azobenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate (149.33 mg, 0.39 mmol, 1.2 eq), dimethylamine hydrochloride (40.03 mg, 0.49 mmol, 1.5 eq) to a 50 mL eggplant-shaped bottle. Stir the reaction solution at room temperature for 1 hour. LCMS results show that the reaction is complete. Add water (10 mL) to dilute and extract with ethyl acetate (3×20 mL). Combine the organic phases and extract with ethyl acetate and saturated brine. The organic phase was dried, filtered, and concentrated, and the residue was purified by column chromatography (ethyl acetate / petroleum ether: 0-50%) to give the product 6-bromo-1, N, N-trimethyl-2-(2,2,2-trifluoroethyl)indole-5-carboxamide (40 mg, 0.11 mmol, 33.65%) as a yellow solid.
[0760] MS m / z:363[M+H] +
[0761] The subsequent synthesis process is referred to Example 5, wherein:
[0762] Step 2 Referring to step 3 of Example 5, the raw material 6-bromo-1-methyl-2-(2,2,2-trifluoroethyl)indole was replaced with 6-bromo-1,N,N-trimethyl-2-(2,2,2-trifluoroethyl)indole-5-carboxamide, and 3-(3-{[2-methoxy-4-(methyldioxy-λ 6 -thio)phenyl]amino}prop-1-ynyl)-1,N,N-trimethyl-6-(1,2,3,4-tetrahydroisoquinolin-6-yl)-2-(2,2,2-trifluoroethyl)indole-5-carboxamide.
[0763] MS m / z:653[M+H] +
[0764] 1H NMR (400MHz, DMSO-d6) δ7.55(s,1H),7.39(d,J=9.9Hz,2H),7.25(d,J=2.0Hz,1H ),7.17(d,J=7.0Hz,2H),7.06(d,J=8.2Hz,1H),6.96(d,J=8.4Hz,1H),6.49(t,J =6.1Hz,1H),4.34(d,J=6.1Hz,2H),4.00(d,J=11.1Hz,2H),3.90(s,5H),3.81(s ,3H),3.10(s,3H),2.99(t,J=5.8Hz,2H),2.80(s,3H),2.74(s,2H),2.45(s,3H).
[0765] Example 23: 6-[5-chloro-3-(3-{[2-methoxy-4-(methyldioxy- 6 -thio)phenyl]amino}prop-1-ynyl)-1-methyl-2-(2,2,2-trifluoroethyl)indol-6-yl]-1,2,3,4-tetrahydroisoquinoline (Compound 23)
[0766]
[0767] Example 23 Synthesis route Refer to Example 5, wherein in step 1, the raw material 6-bromo-1H-indole is replaced with 6-bromo-5-chloro-1H-indole, and 6-[5-chloro-3-(3-{[2-methoxy-4-(methyldioxy-λ 6 -thio)phenyl]amino}prop-1-ynyl)-1-methyl-2-(2,2,2-trifluoroethyl)indol-6-yl]-1,2,3,4-tetrahydroisoquinoline.
[0768] LCMS:MS m / z:616[M+H] +
[0769] 1H NMR (400MHz, DMSO-d6) δ7.55(d,J=5.4Hz,2H),7.42(dd,J=8.3,2.0Hz,1H),7.26(d,J =2.0Hz,1H),7.20–7.16(m,1H),7.14(s,1H),7.08(d,J=7.9Hz,1H),6.97(d,J=8.4Hz ,1H),6.49(t,J=6.2Hz,1H),4.35(d,J=6.1Hz,2H),3.99(q,J=10.7Hz,2H),3.90(d,J =5.1Hz,5H),3.77(s,3H),3.09(s,3H),2.97(t,J=5.9Hz,2H),2.74(t,J=5.7Hz,2H).
[0770] Example 24: 2-{4-[3-(3-{[2-methoxy-4-(methyldioxy- 6 -thio)phenyl]amino}prop-1-ynyl)-1-methyl-6-(1,2,3,4-tetrahydroisoquinolin-6-yl)-2-(2,2,2-trifluoroethyl)indol-5-yl]pyrazol-1-yl}acetamide (Compound 24)
[0771]
[0772] Step 1: 6-{5-[1-(formamidomethyl)pyrazol-4-yl]-3-(3-{[2-methoxy-4-(methyldioxy- 6- 2-Methylpropan-2-yl)-1-methyl-2-(2,2,2-trifluoroethyl)indol-6-yl}-1,2,3,4-tetrahydroisoquinoline-2-carboxylate
[0773]
[0774] In a 25 mL round bottom flask, add the reactants 6-[5-chloro-3-(3-{[2-methoxy-4-(methyldioxy- 6-thio)phenyl]amino}prop-1-ynyl)-1-methyl-2-(2,2,2-trifluoroethyl)indol-6-yl]-1,2,3,4-tetrahydroisoquinoline-2-carboxylic acid-2-methylprop-2-yl ester (30 mg, 0.04 mmol, 1 eq), 2-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazol-1-yl]acetamide (21 mg, 0.08 mmol, 2 eq), Chloro(2-dicyclohexylphosphino-2',4',6'-triisopropyl-1,1'-biphenyl)[2-(2-aminoethylphenyl)]palladium(II) (3 mg, 0.01 mmol, 0.1 eq), potassium phosphate (13 mg, 0.06 mmol, 1.5 eq), 2-dicyclohexylphosphino-2',4',6'-triisopropylbiphenyl (4 mg, 0.01 mmol, 0.2 eq), water (0.5 mL) and dioxane (5 mL). Under argon protection, the reaction solution was stirred at 100°C for 3 hours. LCMS showed that the reaction was complete. The reaction solution was cooled to room temperature and diluted with water, extracted with ethyl acetate and saturated brine, dried, filtered, concentrated, and purified by column chromatography (methanol-dichloromethane, 0-10%) to obtain the product 6-{5-[1-(formamidomethyl)pyrazol-4-yl]-3-(3-{[2-methoxy-4-(methyldioxy- 6 -thio)phenyl]amino}prop-1-ynyl)-1-methyl-2-(2,2,2-trifluoroethyl)indol-6-yl}-1,2,3,4-tetrahydroisoquinoline-2-carboxylic acid-2-methylprop-2-yl ester (20 mg, yield 60%).
[0775] MS m / z:805[M+H] +
[0776] Step 2: 2-{4-[3-(3-{[2-methoxy-4-(methyldioxy- 6 -thio)phenyl]amino}prop-1-ynyl)-1-methyl-6-(1,2,3,4-tetrahydroisoquinolin-6-yl)-2-(2,2,2-trifluoroethyl)indol-5-yl]pyrazol-1-yl}acetamide
[0777]
[0778] The reactants 6-{5-[1-(formamidomethyl)pyrazol-4-yl]-3-(3-{[2-methoxy-4-(methyldioxy- 6-sulfur)phenyl]amino}prop-1-ynyl)-1-methyl-2-(2,2,2-trifluoroethyl)indol-6-yl}-1,2,3,4-tetrahydroisoquinoline-2-carboxylic acid-2-methylprop-2-yl ester (45 mg, 0.06 mmol), 2,6-lutidine (0.162 mL, 1.40 mmol) and dichloromethane (2 mL). The reaction solution was stirred for 1 hour with trimethylsilyl trifluoromethanesulfonate (248.23 mg, 1.12 mmol) at room temperature. LCMS showed that the reaction was complete. After the reaction solution was cooled to room temperature, toluene was dried and filtered, and the filter cake was washed with a mixed solvent of DCM:MeOH:Et3N of 10:1:0.01, and the organic phases were combined, filtered and concentrated under reduced pressure. The residue was purified by preparative-HPLC to obtain 2-{4-[3-(3-{[2-methoxy-4-(methyldioxy- 6 -thio)phenyl]amino}prop-1-ynyl)-1-methyl-6-(1,2,3,4-tetrahydroisoquinolin-6-yl)-2-(2,2,2-trifluoroethyl)indol-5-yl]pyrazol-1-yl}acetamide (5.6 mg, yield 14%).
[0779] MS m / z:705[M+H] +
[0780] 1 H NMR(400MHz, DMSO-d6)δ7.51(d,J=6.2Hz,2H),7.46–7.38(m,2H),7.34–7.23(m,3H),7.05–6.87(m,4H),6.49(t,J=6.2Hz,1H),4.69 (s,2H),4.35(d,J=6.1Hz,2H),3.98(q,J=10.8Hz,2H),3.89(s,5H),3.76(s,3H),3.07(s,3H),2.95(s,2H),2.71(d,J=37.1Hz,2H).
[0781] Example 25: 3-(3-{[2-methoxy-4-(methyldicarbonyl-λ 6 -sulfanyl)phenyl]amino}prop-1-ynyl)-1-methyl-6-(1,2,3,4-tetrahydroisoquinolin-6-yl)-2-(2,2,2-trifluoroethyl)indole-7-carbaldehyde (Compound 25)
[0782]
[0783] The synthetic route is as follows: Steps 3-6 of Example 5, wherein:
[0784] Step 1 Referring to step 3 of Example 5, the raw material 6-bromo-1H-indole was replaced with 6-bromo-1-methyl-2-(2,2,2-trifluoroethyl)indole-7-carbaldehyde, and 3-(3-{[2-methoxy-4-(methyldicarbonyl-λ 6 -sulfanyl)phenyl]amino}prop-1-ynyl)-1-methyl-6-(1,2,3,4-tetrahydroisoquinolin-6-yl)-2-(2,2,2-trifluoroethyl)indole-7-carbaldehyde.
[0785] MS m / z:610[M+H] +
[0786] 1 H NMR (400MHz, DMSO-d6) δ10.04(s,1H),8.06(s,1H),7.76(d,J=8.1Hz,1H),7.41(dd,J= 8.3,2.1Hz,1H),7.35-7.33(m,1H),7.28(s,1H),7.26-7.25(m,1H),7.17-7.15(m,1H) ,6.96(d,J=8.4Hz,1H),6.50(t,J=6.2Hz,1H),4.34(d,J=11.1Hz,2H),4.04(q,J=10.6 Hz,2H),3.89(s,3H),3.68(s,2H),3.50(s,3H),3.10-3.04(m,5H),2.68-2.66(m,2H).
[0787] Example 26: 6-[7-ethynyl-3-(3-{[2-methoxy-4-(methyldioxy- 6 -thio)phenyl]amino}prop-1-ynyl)-1-methyl-2-(2,2,2-trifluoroethyl)indol-6-yl]-1,2,3,4-tetrahydroisoquinoline (Compound 26)
[0788]
[0789] Step 1: 6-[7-ethynyl-3-(3-{[2-methoxy-4-(methyldioxy- 6 -1-methyl-2-(2,2,2-trifluoroethyl)indol-6-yl)-1,2,3,4-tetrahydroisoquinoline-2-carboxylic acid 2-methylpropan-2-yl ester
[0790]
[0791] In a 100 mL reaction bottle, 6-[7-formyl-3-(3-{[2-methoxy-4-(methyldioxy-6 [-sulfuryl)phenyl]amino}prop-1-ynyl)-1-methyl-2-(2,2,2-trifluoroethyl)indol-6-yl]-1,2,3,4-tetrahydroisoquinoline-2-carboxylic acid-2-methylprop-2-yl ester (27 mg, 0.04 mmol, 1.0 eq), potassium carbonate (55 mg, 0.40 mmol, 10.0 eq) were dissolved in methanol (5 mL), and dimethyl (1-diazo-2-oxopropyl)phosphonate (54 mg, 0.28 mmol, 7.0 eq) was added dropwise at room temperature. The reaction was carried out at room temperature for 8 hours, and the reaction of the raw material was completed by TLC monitoring. The reaction solution was diluted with water and extracted with ethyl acetate. The organic phases were combined and washed with saturated brine. The organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by column chromatography (ethyl acetate / petroleum ether: 5-50%) to obtain: 6-[7-ethynyl-3-(3-{[2-methoxy-4-(methyldioxy- 6 -thio)phenyl]amino}prop-1-ynyl)-1-methyl-2-(2,2,2-trifluoroethyl)indol-6-yl]-1,2,3,4-tetrahydroisoquinoline-2-carboxylic acid-2-methylprop-2-yl ester (20 mg, yield: 74%), light yellow solid.
[0792] MS m / z:606[M-100] +
[0793] Step 2: 6-[7-ethynyl-3-(3-{[2-methoxy-4-(methyldioxy- 6 -1-methyl-2-(2,2,2-trifluoroethyl)indol-6-yl)-1,2,3,4-tetrahydroisoquinoline
[0794]
[0795] In a 100 mL reaction bottle, 6-[7-ethynyl-3-(3-{[2-methoxy-4-(methyldioxy- 6 2-(2-(2-(2-((2-((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((( 6-thio)phenyl]amino}prop-1-ynyl)-1-methyl-2-(2,2,2-trifluoroethyl)indol-6-yl]-1,2,3,4-tetrahydroisoquinoline (1.0 mg, yield: 6%), light yellow solid.
[0796] MS m / z:606[M+H] +
[0797] 1 H NMR(400MHz, DMSO-d6)δ7.51(d,J=8.1Hz,1H),7.41(dd,J=8.4,2.0Hz,1H),7.25-7.22( m,2H),7.17(s,1H),7.10(d,J=8.1Hz,1H),7.04(d,J=7.9Hz,1H),6.94(d,J=8.4Hz,1H) ,6.48(t,J=6.1Hz,1H),4.40(s,1H),4.34(d,J=6.1Hz,2H),4.14(s,3H),3.98(q,J=10. 6Hz,3H),3.89-3.87(m,5H),3.09(s,3H),2.96(t,J=5.8Hz,2H),2.72(t,J=5.8Hz,2H).
[0798] Examples 27 and 28: (Cis)-2-methylpropane-2-yl-3-fluoro-4-[(3-{5-[2-methoxy-4-(methyldicarbonyl-λ 6 -sulfanyl)phenyl]-2,2-dimethyl-4-carbonyl-5-aza-3-oxaoct-7-yn-8-yl}-1-methyl-2-(2,2,2-trifluoroethyl)indol-6-yl)amino]piperidin-1-carboxylate and (trans)-2-methylpropane-2-yl-3-fluoro-4-[(3-{5-[2-methoxy-4-(methyldicarbonyl-λ 6 [-sulfanyl)phenyl]-2,2-dimethyl-4-carbonyl-5-aza-3-oxaoct-7-yn-8-yl}-1-methyl-2-(2,2,2-trifluoroethyl)indol-6-yl)amino]piperidin-1-carboxylate (Compounds 27 and 28)
[0799]
[0800] Step 1: ({3-[6-bromo-1-methyl-2-(2,2,2-trifluoroethyl)indol-3-yl]prop-2-ynyl}[2-methoxy-4-(methyldioxy- 6 -2-Methylpropan-2-yl]-thio)phenyl]amino)methane
[0801] The synthesis process refers to step 4 of Example 11, wherein the raw material [2-methoxy-4-(methyldioxy- 6 -thio)phenyl](prop-2-ynyl)amine was replaced by {[2-methoxy-4-(methyldioxy-λ 6 -Methylprop-2-yl](-thio)phenyl](prop-2-ynyl)amino}methanoate
[0802] Step 2: (Cis)-2-methylpropane-2-yl-3-fluoro-4-[(3-{5-[2-methoxy-4-(methyldicarbonyl-λ 6 -sulfanyl)phenyl]-2,2-dimethyl-4-carbonyl-5-aza-3-oxaoct-7-yn-8-yl}-1-methyl-2-(2,2,2-trifluoroethyl)indol-6-yl)amino]piperidin-1-carboxylate and (trans)-2-methylpropane-2-yl--3-fluoro-4-[(3-{5-[2-methoxy-4-(methyldicarbonyl-λ 6 [-(2,2,2-trifluoroethyl)indol-6-yl)amino]piperidin-1-carboxylate
[0803]
[0804] In a 100 mL reaction bottle, ({3-[6-bromo-1-methyl-2-(2,2,2-trifluoroethyl)indol-3-yl]prop-2-ynyl}[2-methoxy-4-(methyldioxy- 6 2-Methylpropane-2-yl]-thiophenyl]amino)methane acid-2-methylpropane-2-yl ester (560 mg, 0.89 mmol, 1.0 eq), 2-methylpropane-2-yl 4-amino-3-fluorohexahydropyridine-1-carboxylate (233 mg, 1.07 mmol, 1.2 eq), 2-dicyclohexylphosphine-2',6'-diisopropoxy-1,1'-biphenyl (83 mg, 0.18 mmol, 0.2 eq), tris(dibenzylideneacetone)dipalladium (81 mg, 0.09 mmol, 0.1 eq) and sodium tert-butoxide (171 mg, 1.78 mmol, 2.0 eq) were dissolved in 1,4-dioxane (10 mL). The reaction was carried out at 110°C for 5 hours under nitrogen protection. The reaction was complete when monitored by LCMS. The reaction solution was cooled to room temperature, filtered, the filtrate was concentrated, and the residue was purified by column (ethyl acetate / petroleum ether: 5-50%) to obtain a pair of diastereoisomers 80 mg and 45 mg as yellow oil.
[0805] MS m / z:767[M+H] +
[0806] The subsequent synthesis process refers to step 6 of Example 5 and step 1 of Example 6, wherein the raw material 7-(3-(3-(2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-1-methyl-2-(2,2,2-trifluoroethyl)-1H-indol-6-yl)-3,4-dihydroisoquinoline-2(1H)-carboxylic acid tert-butyl ester is replaced by (Cis)-3-fluoro-4-[(3-{5-[2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-1-methyl-2-(2,2,2-trifluoroethyl)-1H-indol-6-yl)-3,4-dihydroisoquinoline-2(1H)-carboxylic acid tert-butyl ester, respectively. 6 -(2,2,2-trifluoroethyl)indol-6-yl)amino]piperidin-1-carboxylic acid-2-methylpropan-2-yl ester and (Trans)-3-fluoro-4-[(3-{5-[2-methoxy-4-(methyldioxy)indol-7-yne-8-yl}-1-methyl-2-(2,2,2-trifluoroethyl)indol-6-yl)amino]piperidin-1-carboxylic acid-2-methylpropan-2-yl ester 6 [(3-{5-[2-methoxy-4-(methyldicarbonyl-λ-yl)phenyl]-2,2-dimethyl-4-oxyde-5-aza-3-oxaoctan-7-yn-8-yl}-1-methyl-2-(2,2,2-trifluoroethyl)indol-6-yl)amino]piperidin-1-carboxylic acid-2-methylpropan-2-yl ester] was subjected to deprotection of the Boc protecting group and reductive amination to give (Cis)-2-methylpropane-2-yl-3-fluoro-4-[(3-{5-[2-methoxy-4-(methyldicarbonyl-λ-yl)phenyl]-2,2-dimethyl-4-oxyde-5-aza-3-oxaoctan-7-yn-8-yl}-1-methyl-2-(2,2,2-trifluoroethyl)indol-6-yl)amino]piperidin-1-carboxylic acid-2-methylpropan-2-yl ester] 6 -sulfanyl)phenyl]-2,2-dimethyl-4-carbonyl-5-aza-3-oxaoct-7-yn-8-yl}-1-methyl-2-(2,2,2-trifluoroethyl)indol-6-yl)amino]piperidin-1-carboxylate and (trans)-2-methylpropane-2-yl-3-fluoro-4-[(3-{5-[2-methoxy-4-(methyldicarbonyl-λ 6
[0045] -2,2-dimethyl-4-carbonyl-5-aza-3-oxaoct-7-yn-8-yl}-1-methyl-2-(2,2,2-trifluoroethyl)indol-6-yl)amino]piperidine-1-carboxylate.
[0807] Compound 27: LCMS retention time 2.556 minutes; MS m / z: 581 [M+H] +
[0808] 1H NMR (400MHz, DMSO-d6) δ7.40(dd,J=8.4,2.0Hz,1H),7.24(d,J=2.0Hz,1H),7.13(d,J=8.3Hz,1H),6. 92(d,J=8.5Hz,1H),6.65-6.62(m,2H),6.44(t,J=6.1Hz,1H),5.39(d,J=9.3Hz,1H),4.80(d,J=49.4H z,1H),4.30(d,J=6.2Hz,2H),3.89-3.79(m,5H),3.60(s,3H),3.09(s,3H),3.05-2.99(m,1H),2.79-2 .76(m,1H),2.34-2.26(m,1H),2.19(s,3H),2.12-2.06(m,1H),1.76-1.70(m,2H),1.27-1.21(m,1H).
[0809] Compound 28: LCMS retention time 2.634 minutes; MS m / z: 581 [M+H] +
[0810] 1 H NMR(400MHz, DMSO-d6)7.39(dd,J=8.4,2.0Hz,1H),7.24(d,J=2.0Hz,1H),7.12(d,J=9.0Hz,1H),6 .91(d,J=8.4Hz,1H),6.57-6.54(m,2H),6.42(t,J=6.3Hz,1H),5.56(d,J=8.3Hz,1H),4.54-4.36(m 1H),4.29(d,J=6.1Hz,2H),3.88(s,3H),3.82(q,J=10.8Hz,2H),3.59(s,3H),3.50-3.40(m,1H),3.09(s, 3H), 3.01(td,J=10.5,4.4Hz,1H),2.67-2.63(m,1H),2.22(s,3H),2.18-1.99(m,3H),1.43-1.33(m,1H).
[0811] LCMS method:
[0812] Column: SunFire Prep C18 OBDTM 5μm, 19*250mm Column;
[0813] Flow rate: 25 mL / min;
[0814] Mobile phase: [A (ammonia / water 1 / 999)-B (acetonitrile)]; B%: 25%-38% (v / v), 8 min.
[0815] Example 29: 6-[3-(3-{[2-methoxy-4-(methyldicarbonyl-λ 6 -sulfanyl)phenyl]amino}prop-1-ynyl)-1-methyl-5-(1,3-thiazol-5-yl)-2-(2,2,2-trifluoroethyl)indol-6-yl]-1,2,3,4-tetrahydroisoquinoline (Compound 29)
[0816]
[0817] The synthetic route refers to Example 24, wherein in step 1, the raw material 2-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazol-1-yl]acetamide is replaced with 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,3-thiazole, and 6-[3-(3-{[2-methoxy-4-(methyldicarbonyl-λ 6 -sulfanyl)phenyl]amino}prop-1-ynyl)-1-methyl-5-(1,3-thiazol-5-yl)-2-(2,2,2-trifluoroethyl)indol-6-yl]-1,2,3,4-tetrahydroisoquinoline.
[0818] MS m / z:665[M+H] +
[0819] 1 H NMR(400MHz,DMSO-d6)δ8.92(s,1H),7.61(s,1H),7.58(s,1H),7.52(s,1H),7 .39(dd,J=8.4,2.0Hz,1H),7.24(d,J=2.0Hz,1H),6.99-6.86(m,4H),6.49(t, J=6.1Hz,1H),4.34(d,J=6.2Hz,2H),4.00(q,J=10.7Hz,2H),3.88(s,3H),3.8 3(s,2H),3.79(s,3H),3.07(s,3H),2.92(t,J=5.8Hz,2H),2.67-2.62(m,2H).
[0820] Example 30: 6-[3-(3-{[2-methoxy-4-(methyldicarbonyl-λ 6 -sulfanyl)phenyl]amino}prop-1-ynyl)-1-methyl-5-(thiophen-3-yl)-2-(2,2,2-trifluoroethyl)indol-6-yl]-1,2,3,4-tetrahydroisoquinoline (Compound 30)
[0821]
[0822] The synthetic route refers to Example 24, wherein in step 1, the raw material 2-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazol-1-yl]acetamide is replaced with 4,4,5,5-tetramethyl-2-(thiophen-3-yl)-1,3,2-dioxaborolan, and 6-[3-(3-{[2-methoxy-4-(methyldicarbonyl-λ 6 -sulfanyl)phenyl]amino}prop-1-ynyl)-1-methyl-5-(thiophen-3-yl)-2-(2,2,2-trifluoroethyl)indol-6-yl]-1,2,3,4-tetrahydroisoquinoline.
[0823] MS m / z:664[M+H] +
[0824] 1 H NMR(400MHz,DMSO-d6)δ7.49(s,1H),7.46(s,1H),7.41-7.36(m,2H),7.24-7.21 (m,2H),6.97-6.95(m,2H),6.88-6.82(m,2H),6.63(dd,J=4.9,1.3Hz,1H),6.48( t,J=6.1Hz,1H),4.33(d,J=6.2Hz,2H),3.99(q,J=10.6Hz,2H),3.88(s,3H),3.8 1(s,2H),3.78(s,3H),3.06(s,3H),2.91(t,J=5.8Hz,2H),2.60(t,J=5.8Hz,2H).
[0825] Example 31: 6-[3-(3-{[2-methoxy-4-(methyldioxy- 6 -thio)phenyl]amino}prop-1-ynyl)-1-methyl-5-(thiophen-2-yl)-2-(2,2,2-trifluoroethyl)indol-6-yl]-1,2,3,4-tetrahydroisoquinoline (Compound 31)
[0826]
[0827] The synthetic route refers to Example 24, wherein in step 1, the raw material 2-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazol-1-yl]acetamide is replaced with 4,4,5,5-tetramethyl-2-(thiophen-2-yl)-1,3,2-dioxaborolan and the subsequent reaction is performed to obtain 6-[3-(3-{[2-methoxy-4-(methyldioxy- 6 -thio)phenyl]amino}prop-1-ynyl)-1-methyl-5-(thiophen-2-yl)-2-(2,2,2-trifluoroethyl)indol-6-yl]-1,2,3,4-tetrahydroisoquinoline.
[0828] MS m / z:664[M+H] +
[0829] 1 H NMR(400MHz,DMSO-d6)δ7.54(s,1H),7.47(s,1H),7.43-7.39(m,2H),7.25(d,J =2.0Hz,1H),7.00-6.94(m,3H),6.89(s,2H),6.72(dd,J=3.6,1.2Hz,1H),6.50 (t,J=6.2Hz,1H),4.35(d,J=6.2Hz,2H),4.00(q,J=10.7Hz,2H),3.89(s,3H),3 .83(s,2H),3.79(s,3H),3.06(s,3H),2.93(t,J=5.8Hz,2H),2.65-2.62(m,2H).
[0830] Example 32: 6-[3-(3-{[2-methoxy-4-(methyldioxy- 6 -thio)phenyl]amino}prop-1-ynyl)-1-methyl-5-(1,3-oxazacyclopentyl-2-yl)-2-(2,2,2-trifluoroethyl)indol-6-yl]-1,2,3,4-tetrahydroisoquinoline (Compound 32)
[0831]
[0832] Step 1: 6-Bromo-1-methyl-2-(2,2,2-trifluoroethyl)indole-5-carboxamide
[0833]
[0834] Add reactants 6-bromo-1-methyl-2-(2,2,2-trifluoroethyl)indole-5-carboxylic acid (230 mg, 0.68 mmol, 1.0 eq), N,N-dimethylformamide (3 mL), N,N-diisopropylethylamine (265.34 mg, 2.05 mmol, 3.0 eq), 2-(7-azobenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate (312.24 mg, 0.82 mmol, 1.2 eq), and ammonium chloride (65.89 mg, 1.23 mmol, 1.8 eq) to a 50 mL eggplant-shaped flask. Stir the reaction solution at room temperature for 1 hour. LCMS detected that the raw material reacted completely. Add water (10 mL) to dilute and extract with ethyl acetate (3×20 mL). Combine the organic phases and wash with water (3×10 mL) and saturated brine (10 mL). The organic phase was dried over anhydrous sodium sulfate and filtered. The reduced pressure residue was purified by silica gel column chromatography (ethyl acetate / petroleum ether, 0-50% gradient elution) to give: 6-bromo-1-methyl-2-(2,2,2-trifluoroethyl)indole-5-carboxamide (250 mg, yield: 99%) as a yellow solid.
[0835] MS m / z:334.9[M+H] +
[0836] Step 2: 6-Bromo-1-methyl-5-(1,3-oxazacyclopentyl-2-yl)-2-(2,2,2-trifluoroethyl)indole
[0837]
[0838] The reactants 6-bromo-1-methyl-2-(2,2,2-trifluoroethyl)indole-5-carboxamide (235 mg, 0.70 mmol, 1.0 eq) and 2-bromo-1,1-diethoxyethane (5.5 g, 28.0 mmol, 40.0 eq) were added to a 50 mL round-bottom flask. Under argon protection, the reaction solution was stirred at 130 ° C in a sealed tank for 4 hours. LCMS detected that the raw material reaction was complete. The reaction solution was spin-dried, wet-loaded, and purified by silica gel column chromatography (ethyl acetate / petroleum ether, 0-50% gradient elution) to obtain: 6-bromo-1-methyl-5-(1,3-oxazacyclopentyl-2-yl)-2-(2,2,2-trifluoroethyl)indole (110 mg, yield: 43%), a red solid.
[0839] MS m / z:360.9[M+H] +
[0840] The subsequent steps refer to Example 5, wherein in step 3, the raw material 6-bromo-1-methyl-2-(2,2,2-trifluoroethyl)indole is replaced with 6-bromo-1-methyl-5-(1,3-oxazacyclopentane-2-yl)-2-(2,2,2-trifluoroethyl)indole, and the compound 6-[3-(3-{[2-methoxy-4-(methyldioxy-λ 6 -thio)phenyl]amino}prop-1-ynyl)-1-methyl-5-(1,3-oxazacyclopentyl-2-yl)-2-(2,2,2-trifluoroethyl)indol-6-yl]-1,2,3,4-tetrahydroisoquinoline.
[0841] MS m / z:649.1[M+H] +
[0842] 1 H NMR(400MHz, DMSO-d6)δ7.97(s,1H),7.91(s,1H),7.57(s,1H),7.44–7.39(m,1H),7.34–7.19(m,2H),7.05–6.90(m,3H),6.89–6.81(m, 1H),6.59–6.41(m,1H),4.35(d,J=6.0Hz,2H),4.11–3.97(m,2H),3.92–3.80(m,8H),3.07(s,3H),3.02–2.93(m,2H),2.73–2.64(m,2H).
[0843] Example 33: 6-[5-(isoxazol-4-yl)-3-(3-{[2-methoxy-4-(methyldioxy- 6 -thio)phenyl]amino}prop-1-ynyl)-1-methyl-2-(2,2,2-trifluoroethyl)indol-6-yl]-1,2,3,4-tetrahydroisoquinoline (Compound 33)
[0844]
[0845] Step 1: 2-(Trimethylsilyl)ethyl {[6-bromo-1-methyl-2-(2,2,2-trifluoroethyl)indol-5-yl]amino}formate
[0846]
[0847] In a 100 mL reaction bottle, 6-bromo-1-methyl-2-(2,2,2-trifluoroethyl)indole-5-carboxylic acid (2400 mg, 7.14 mmol, 1.0 eq), diphenylphosphoryl azide (2161 mg, 7.85 mmol, 1.1 eq), triethylamine (795 mg, 7.85 mmol, 1.1 eq), 2-(trimethylsilyl)ethanol (1688 mg, 14.28 mmol, 2.0 eq) were dissolved in toluene (30 mL). The mixture was reacted at 100 ° C under nitrogen protection for 4 hours. LCMS monitored the complete reaction of the raw materials. The reaction solution was cooled to room temperature, concentrated, diluted with dichloromethane, washed with sodium bicarbonate and saturated brine in sequence, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated. The residue was purified by column (ethyl acetate / petroleum ether: 5-30%) to give: 2-(trimethylsilyl)ethyl {[6-bromo-1-methyl-2-(2,2,2-trifluoroethyl)indol-5-yl]amino}carboxylate (2400 mg, yield: 74%) as a light yellow solid.
[0848] MS m / z:451[M+H] +
[0849] Step 2: 6-Bromo-1-methyl-2-(2,2,2-trifluoroethyl)indol-5-amine
[0850]
[0851] In a 100mL reaction bottle, 2-(trimethylsilyl)ethyl{[6-bromo-1-methyl-2-(2,2,2-trifluoroethyl)indol-5-yl]amino}formate (2400mg, 5.32mmol, 1.0eq) was dissolved in tetrahydrofuran (5mL), and tetrabutylammonium fluoride tetrahydrofuran solution (10mL, 1M, 1.9eq) was added under ice bath. After the addition was complete, the reaction was carried out under ice bath for 1 hour. LCMS monitored that the raw material reacted completely. The reaction solution was diluted with ethyl acetate, and then washed with water and saturated brine in turn. Drying over anhydrous sodium sulfate, filtering, and concentrating the filtrate to obtain the crude product: 6-bromo-1-methyl-2-(2,2,2-trifluoroethyl)indol-5-amine (1600mg, yield: 98%), a light yellow solid.
[0852] MS m / z:307[M+H] +
[0853] Step 3: 2-Methylpropan-2-yl 6-[5-amino-1-methyl-2-(2,2,2-trifluoroethyl)indol-6-yl]-1,2,3,4-tetrahydroisoquinoline-2-carboxylate
[0854]
[0855] In a 100 mL reaction bottle, 6-bromo-1-methyl-2-(2,2,2-trifluoroethyl)indole-5-amine (1600 mg, 5.21 mmol, 1.0 eq), 6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,2,3,4-tetrahydroisoquinoline-2-carboxylic acid-2-methylpropane-2-yl ester (2246 mg, 6.25 mmol, 1.2 eq), 1,1-bis(diphenylphosphino)diferronichloridopalladium (381 mg, 0.52 mmol, 0.1 eq), potassium carbonate (1440 mg, 10.42 mmol, 2.0 eq) were dissolved in 1,4-dioxane / water (10 mL / 3 mL). The reaction was carried out at 80 ° C under nitrogen protection for 2 hours. LCMS monitored the reaction of the raw materials. The reaction solution was cooled to room temperature, filtered, the filtrate was concentrated, and the residue was purified by column (ethyl acetate / petroleum ether: 5-40%) to obtain: 2-methylpropane-2-yl 6-[5-amino-1-methyl-2-(2,2,2-trifluoroethyl)indol-6-yl]-1,2,3,4-tetrahydroisoquinoline-2-carboxylate (1500 mg, yield: 63%), a colorless oil.
[0856] MS m / z:460[M+H] +
[0857] Step 4: 2-Methylpropan-2-yl 6-[5-bromo-1-methyl-2-(2,2,2-trifluoroethyl)indol-6-yl]-1,2,3,4-tetrahydroisoquinoline-2-carboxylate
[0858]
[0859] In a 50mL three-necked flask, 2-methylpropane-2-yl 6-[5-amino-1-methyl-2-(2,2,2-trifluoroethyl)indol-6-yl]-1,2,3,4-tetrahydroisoquinoline-2-carboxylate (50mg, 0.11mmol, 1.0eq) was dissolved in acetonitrile (3mL). Under nitrogen protection, tert-butyl nitrite (23mg, 0.22mmol, 2.0eq) and cuprous bromide (24mg, 0.16mmol, 1.5eq) were added in turn under ice bath. First, react under ice bath for 30 minutes, then react at room temperature for 30 minutes, and finally rise to 50℃ for 1 hour. LCMS monitored the complete reaction of the raw materials. The reaction solution was cooled to room temperature, diluted with water, extracted with ethyl acetate, and dried over anhydrous sodium sulfate. Filter, concentrate the filtrate, and purify the residue by column (ethyl acetate / petroleum ether: 5-50%) to obtain: 2-methylpropan-2-yl 6-[5-bromo-1-methyl-2-(2,2,2-trifluoroethyl)indol-6-yl]-1,2,3,4-tetrahydroisoquinoline-2-carboxylate (20 mg, yield: 35%) as an off-white solid.
[0860] MS m / z:467[M-56] +
[0861] Step 5 and Step 6 refer to Step 4 and 5 of Example 5, wherein the raw material 6-[1-methyl-2-(2,2,2-trifluoroethyl)indol-6-yl]-1,2,3,4-tetrahydroisoquinoline-2-carboxylic acid-2-methylpropan-2-yl ester is replaced with 2-methylpropane-2-yl 6-[5-bromo-1-methyl-2-(2,2,2-trifluoroethyl)indol-6-yl]-1,2,3,4-tetrahydroisoquinoline-2-carboxylate, and 2-methylpropane-2-yl 6-[5-bromo-3-(3-{[2-methoxy-4-(methyldicarbonyl-λ 6 -sulfanyl)phenyl]amino}prop-1-ynyl)-1-methyl-2-(2,2,2-trifluoroethyl)indol-6-yl]-1,2,3,4-tetrahydroisoquinoline-2-carboxylate.
[0862] Step 7: 2-methylpropane-2-yl 6-[5-(isoxazol-4-yl)-3-(3-{[2-methoxy-4-(methyldicarbonyl-λ 6 -1-methyl-2-(2,2,2-trifluoroethyl)indol-6-yl)-1,2,3,4-tetrahydroisoquinoline-2-carboxylate
[0863]
[0864] In a 100 mL reaction bottle, 2-methylpropane-2-yl 6-[5-bromo-3-(3-{[2-methoxy-4-(methyldicarbonyl-λ 6
[0045] 1,4-dioxane / water (3mL / 1mL) was added with 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)isoxazole (5mg, 0.02mmol, 1.2eq), 1,1-bis(diphenylphosphino)diferronichloride palladium (2mg, 0.01mmol, 0.1eq), potassium carbonate (5mg, 0.04mmol, 2.0eq) and 1,4-dioxane / water (3mL / 1mL). The reaction was carried out at 80°C under nitrogen protection for 2 hours. The reaction of the raw material was completed by LCMS monitoring. The reaction solution was cooled to room temperature, filtered, the filtrate was concentrated, and the residue was purified by column chromatography (ethyl acetate / petroleum ether: 5-30%) to obtain: 2-methylpropane-2-yl 6-[5-(isoxazol-4-yl)-3-(3-{[2-methoxy-4-(methyldicarbonyl-λ 6
[0134]
[0135] 1-(4-(2 ...
[0865] MS m / z:749[M+H] +
[0866] Step 8: 6-[5-(isoxazol-4-yl)-3-(3-{[2-methoxy-4-(methyldicarbonyl-λ 6 -sulfanyl)phenyl]amino}prop-1-ynyl)-1-methyl-2-(2,2,2-trifluoroethyl)indol-6-yl]-1,2,3,4-tetrahydroisoquinoline
[0867]
[0868] In a 100 mL reaction bottle, 2-methylpropane-2-yl 6-[5-(isoxazol-4-yl)-3-(3-{[2-methoxy-4-(methyldicarbonyl-λ 6 -sulfanyl)phenyl]amino}prop-1-ynyl)-1-methyl-2-(2,2,2-trifluoroethyl)indol-6-yl]-1,2,3,4-tetrahydroisoquinoline-2-carboxylate (8 mg, 0.01 mmol, 1.0 eq) and 2,6-dimethylpyridine (7 mg, 0.06 mmol, 6.0 eq) were dissolved in dichloromethane (2 mL). Trimethylsilyl trifluoromethanesulfonate (10 mg, 0.04 mmol, 4.0 eq) was added at room temperature and reacted at room temperature for 15 minutes. LCMS monitored the complete reaction of the raw material. Saturated sodium bicarbonate solution was added to quench the reaction, and the mixture was extracted with dichloromethane and dried over anhydrous sodium sulfate. Filtered, the filtrate was concentrated, and the residue was separated and purified by HPLC preparative chromatography to obtain: 6-[5-(isoxazol-4-yl)-3-(3-{[2-methoxy-4-(methyldicarbonyl-λ 6 -sulfanyl)phenyl]amino}prop-1-ynyl)-1-methyl-2-(2,2,2-trifluoroethyl)indol-6-yl]-1,2,3,4-tetrahydroisoquinoline (0.8 mg, yield: 12%), white solid.
[0869] MS m / z:649[M+H] +
[0870] 1H NMR(400MHz,DMSO-d6)δ8.67(s,1H),8.10(s,1H),7.60(s,1H),7.49(s,1H),7 .40(dd,J=8.4,2.0Hz,1H),7.24(d,J=2.0Hz,1H),7.00-6.89(m,4H),6.46(t, J=6.1Hz,1H),4.34(d,J=6.1Hz,2H),3.98(q,J=10.7Hz,2H),3.89(s,3H),3.8 6(s,2H),3.78(s,3H),3.06(s,3H),2.94(t,J=5.8Hz,2H),2.68-2.66(m,2H).
[0871] Example 34: 6-[3-(3-{[2-methoxy-4-(methyldioxy- 6 -thio)phenyl]amino}prop-1-ynyl)-1-methyl-5-(1,3,4-oxadiazacyclopentyl-2-yl)-2-(2,2,2-trifluoroethyl)indol-6-yl]-1,2,3,4-tetrahydroisoquinoline (Compound 34)
[0872]
[0873] Step 1: 6-Bromo-1-methyl-2-(2,2,2-trifluoroethyl)indole-5-carboxylic acid hydrazide
[0874]
[0875] In a 100mL reaction bottle, 6-bromo-1-methyl-2-(2,2,2-trifluoroethyl)indole-5-carboxylic acid (206mg, 0.61mmol, 1.0eq), hydrazine hydrate (34mg, 0.67mmol, 1.1eq), N,N-diisopropylethylamine (237mg, 1.84mmol, 3.0eq), 2-(7-azobenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate (349mg, 0.92mmol, 1.5eq) were dissolved in N,N-dimethylformamide (5mL) and reacted for 8 hours at room temperature under nitrogen protection. LCMS monitored the reaction to be complete. Dilute with water, extract with ethyl acetate, then backwash with water, wash with saturated brine, and dry over anhydrous sodium sulfate. Filter, concentrate the filtrate, and purify the residue by column (ethyl acetate / petroleum ether: 5-90%) to obtain: 6-bromo-1-methyl-2-(2,2,2-trifluoroethyl)indole-5-carboxyhydrazide (200 mg, yield: 93%), a light yellow oil.
[0876] MS m / z:350[M+H] +
[0877] Step 2: 6-Bromo-1-methyl-5-(1,3,4-oxadiazol-2-yl)-2-(2,2,2-trifluoroethyl)indole
[0878]
[0879] In a 100mL reaction bottle, 6-bromo-1-methyl-2-(2,2,2-trifluoroethyl)indole-5-carboxylic acid hydrazide (190mg, 0.5mmol, 1.0eq) was dissolved in triethyl orthoformate (3mL), and the reaction was carried out at 120℃ under nitrogen protection for 2 hours. LCMS monitored the reaction to be complete. The reaction solution was concentrated and the residue was purified by column (ethyl acetate / petroleum ether: 5-50%) to obtain: 6-bromo-1-methyl-5-(1,3,4-oxadiazol-2-yl)-2-(2,2,2-trifluoroethyl)indole (107mg, yield: 55%), a light yellow oil.
[0880] MS m / z:360[M+H] +
[0881] The subsequent synthesis steps refer to Example 5, wherein the raw material 6-bromo-1-methyl-2-(2,2,2-trifluoroethyl)indole in step 3 is replaced by 6-bromo-1-methyl-5-(1,3,4-oxadiazol-2-yl)-2-(2,2,2-trifluoroethyl)indole, and the subsequent reaction steps give 6-[3-(3-{[2-methoxy-4-(methyldicarbonyl-λ 6 -sulfanyl)phenyl]amino}prop-1-ynyl)-1-methyl-5-(1,3,4-oxadiazol-2-yl)-2-(2,2,2-trifluoroethyl)indol-6-yl]-1,2,3,4-tetrahydroisoquinoline.
[0882] MS m / z:650[M+H] +
[0883] 1 H NMR(400MHz,DMSO-d6)δ9.11(s,1H),7.96(s,1H),7.65(s,1H),7.39(dd,J=8.3,2 .0Hz,1H),7.24(d,J=2.0Hz,1H),7.01-7.00(m,1H),6.98-6.95(m,2H),6.87-6.85 (m,1H),6.48(t,J=6.2Hz,1H),4.36(d,J=6.1Hz,2H),4.03(q,J=10.6Hz,2H),3.89 (s,3H),3.84-3.82(m,5H),3.08(s,3H),2.94(t,J=5.8Hz,2H),2.68-2.65(m,2H).
[0884] Example 35: 6-[3-(3-{[2-methoxy-4-(methyldicarbonyl-λ 6 -sulfanyl)phenyl]amino}prop-1-ynyl)-1-methyl-5-(1-methylpyrazol-4-yl)-2-(2,2,2-trifluoroethyl)indol-6-yl]-1,2,3,4-tetrahydroisoquinoline (Compound 35)
[0885]
[0886] The synthesis steps are as follows: Steps 7 and 8 of Example 33, wherein:
[0887] Step 1 Referring to step 7 of Example 33, the raw material 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)isoxazole was replaced with 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazole, and 6-[3-(3-{[2-methoxy-4-(methyldicarbonyl-λ 6 -sulfanyl)phenyl]amino}prop-1-ynyl)-1-methyl-5-(1-methylpyrazol-4-yl)-2-(2,2,2-trifluoroethyl)indol-6-yl]-1,2,3,4-tetrahydroisoquinoline.
[0888] MS m / z:662[M+H] +
[0889] 1 H NMR (400MHz, DMSO-d6) δ7.50-7.46(m,2H),7.42-7.37(m,2H),7.24(s,1H),6.99-6.93(m,3H),6.89-6.82(m,2H),6.48(t,J=6.1Hz,1H),4.34(d, J=6.1Hz,2H),3.97(q,J=10.7Hz,2H),3.89(s,3H),3.86-3.85(m,2H),3 .77-3.75(m,5H),3.05(s,1H),2.94(t,J=5.8Hz,1H),2.68-2.65(m,1H).
[0890] Example 36: 6-{3-[3-({4-[dimethyl(carbonyl)-λ 5 -phosphoalkyl]-2-methoxyphenyl}amino)prop-1-ynyl]-1-methyl-5-(1,3-oxazol-5-yl)-2-(2,2,2-trifluoroethyl)indol-6-yl}-1,2,3,4-tetrahydroisoquinoline (Compound 36)
[0891]
[0892] Example 36 Synthesis steps refer to specific example 18, wherein step 5 is to use the raw material [2-methoxy-4-(methyldioxy- 6 -thio)phenyl](prop-2-ynyl)amine was replaced by {4-[dimethyl(oxyylidene)-λ 5- 6-{3-[3-({4-[dimethyl(carbonyl)-λ 5 -phosphoalkyl]-2-methoxyphenyl}amino)prop-1-ynyl]-1-methyl-5-(1,3-oxazol-5-yl)-2-(2,2,2-trifluoroethyl)indol-6-yl}-1,2,3,4-tetrahydroisoquinoline.
[0893] MS m / z:647[M+H] +
[0894] 1 H NMR(400MHz,DMSO-d6)δ8.43(s,1H),7.79(s,1H),7.48(s,1H),7.32-7.26(m,1H),7. 13(dd,J=11.9,1.6Hz,1H),7.05-7.01(m,2H),6.98-6.95(m,2H),6.20(s,1H),6.05( t,J=6.2Hz,1H),4.32(d,J=6.2Hz,2H),3.99(q,J=10.6Hz,2H),3.90(s,2H),3.85(s, 3H),3.78(s,3H),2.97(t,J=5.8Hz,2H),2.71-2.67(m,2H),1.58(s,3H),1.54(s,3H).
[0895] Example 37: 6-[5-(1H-pyrazol-4-yl)-3-(3-{[2-methoxy-4-(methyldioxy- 6 -thio)phenyl]amino}prop-1-ynyl)-1-methyl-2-(2,2,2-trifluoroethyl)indol-6-yl]-1,2,3,4-tetrahydroisoquinoline (Compound 37)
[0896]
[0897] Example 37 Synthesis steps refer to steps 7 and 8 of Example 33, wherein,
[0898] Step 1 Referring to step 7 of Example 33, the raw material 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)isoxazole was replaced with 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole, and 6-[5-(1H-pyrazol-4-yl)-3-(3-{[2-methoxy-4-(methyldioxy-λ 6 -thio)phenyl]amino}prop-1-ynyl)-1-methyl-2-(2,2,2-trifluoroethyl)indol-6-yl]-1,2,3,4-tetrahydroisoquinoline.
[0899] MS m / z:647.7[M+H] +
[0900] 1 H NMR(400MHz,DMSO-d6)δ7.52(s,1H),7.42–7.40(m,1H),7.40–7.36(m,1H),7.30–7.14(m,3H),7.01–6.92(m,3H),6.91–6.86(m,1H),6.51–6.4 5(m,1H),4.35(d,J=6.1Hz,2H),4.03–3.92(m,3H),3.89(s,3H),3.87( s,2H),3.75(s,3H),3.06(s,3H),3.01–2.92(m,2H),2.71–2.63(m,2H).
[0901] Example 38: 6-[5-(1H-pyrazol-5-yl)-3-(3-{[2-methoxy-4-(methyldioxy- 6 -thio)phenyl]amino}prop-1-ynyl)-1-methyl-2-(2,2,2-trifluoroethyl)indol-6-yl]-1,2,3,4-tetrahydroisoquinoline (Compound 38)
[0902]
[0903] The synthesis steps of Example 38 refer to steps 7 and 8 of Example 33, wherein:
[0904] Step 1 Referring to step 7 of Example 33, the raw material 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)isoxazole was replaced with 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole, and 6-[5-(1H-pyrazol-5-yl)-3-(3-{[2-methoxy-4-(methyldioxy-1-yl)-λ 6-thio)phenyl]amino}prop-1-ynyl)-1-methyl-2-(2,2,2-trifluoroethyl)indol-6-yl]-1,2,3,4-tetrahydroisoquinoline.
[0905] MS m / z:648.1[M+H] +
[0906] 1 H NMR(400MHz,DMSO-d6)δ12.64(s,1H),7.74(s,1H),7.57–7.32(m,3H),7.2 3(d,J=2.0Hz,1H),7.01–6.93(m,2H),6.93–6.82(m,2H),6.50–6.42(m,1H ),5.61(s,1H),4.35(d,J=6.0Hz,2H),4.01–3.93(m,2H),3.89(s,3H),3.8 4(s,2H),3.77(s,3H),3.05(s,3H),3.00–2.87(m,2H),2.68–2.58(m,2H).
[0907] Example 39: 3-(3-{[2-methoxy-4-(methyldioxy- 6 -thio)phenyl]amino}prop-1-ynyl)-1-methyl-6-(1,2,3,4-tetrahydroisoquinolin-6-yl)-2-(2,2,2-trifluoroethyl)indol-5-amine (Compound 39)
[0908]
[0909] Step 1: 2-methylpropan-2-yl 6-{1-methyl-5-[(trifluoroacetyl)amino]-2-(2,2,2-trifluoroethyl)indol-6-yl}-1,2,3,4-tetrahydroisoquinoline-2-carboxylate
[0910]
[0911] Add the reactant 6-[5-amino-1-methyl-2-(2,2,2-trifluoroethyl)indol-6-yl]-1,2,3,4-tetrahydroisoquinoline-2-carboxylic acid-2-methylpropane-2-yl ester (100 mg, 0.22 mmol, 1.0 eq), triethylamine (0.181 mL, 1.31 mmol, 6.0 eq) to a 25 mL eggplant-shaped flask, and add trifluoroacetic anhydride (0.091 mL, 0.33 mmol, 1.5 eq) and dichloromethane (3 mL) at 0°C. React at room temperature for 1 hour under nitrogen protection. LCMS detected that the raw material reacted completely. Add water (10 mL) to dilute and extract with dichloromethane (3×20 mL).
[0912] The organic phases were combined, washed with water (5 mL) and saturated brine (5 mL). The organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to give: 6-{1-methyl-5-[(trifluoroacetyl)amino]-2-(2,2,2-trifluoroethyl)indol-6-yl}-1,2,3,4-tetrahydroisoquinoline-2-carboxylic acid-2-methylpropan-2-yl ester (115 mg, yield: 95.13%) as a white solid.
[0913] MS m / z:456.1[M-100] +
[0914] Step 2: 6-{3-iodo-1-methyl-5-[(trifluoroacetyl)amino]-2-(2,2,2-trifluoroethyl)indol-6-yl}-1,2,3,4-tetrahydroisoquinoline-2-carboxylic acid-2-methylpropan-2-yl ester
[0915]
[0916] Add the reactants 6-{1-methyl-5-[(trifluoroacetyl)amino]-2-(2,2,2-trifluoroethyl)indol-6-yl}-1,2,3,4-tetrahydroisoquinoline-2-carboxylic acid-2-methylpropane-2-yl ester (95 mg, 0.17 mmol, 1.0 eq) and N,N-dimethylformamide (2 mL) to a 25 mL eggplant-shaped bottle, add N-iodosuccinimide (42.32 mg, 0.19 mmol, 1.1 eq) at 0°C, and react at room temperature for 1 hour. LCMS detected that the raw material reacted completely. Add water (10 mL) to dilute and extract with ethyl acetate (3×20 mL). Combine the organic phases, wash with water (15 mL) and saturated brine (15 mL). The organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to give: 6-{3-iodo-1-methyl-5-[(trifluoroacetyl)amino]-2-(2,2,2-trifluoroethyl)indol-6-yl}-1,2,3,4-tetrahydroisoquinoline-2-carboxylic acid-2-methylpropan-2-yl ester (110 mg, yield: 94.40%), a red oil.
[0917] MS m / z:582.0[M-100] +
[0918] Step 3: 6-[3-(3-{[2-methoxy-4-(methyldioxy- 6 -1-methyl-5-[(trifluoroacetyl)amino]-2-(2,2,2-trifluoroethyl)indol-6-yl]-1,2,3,4-tetrahydroisoquinoline-2-carboxylic acid 2-methylpropan-2-yl ester
[0919]
[0920] In a 50 mL eggplant flask, add the reactants 6-{3-iodo-1-methyl-5-[(trifluoroacetyl)amino]-2-(2,2,2-trifluoroethyl)indol-6-yl}-1,2,3,4-tetrahydroisoquinoline-2-carboxylic acid-2-methylpropan-2-yl ester (110 mg, 0.16 mmol, 1.0 eq), [2-methoxy-4-(methyldioxy- 6 -sulfuryl)phenyl](prop-2-ynyl)amine (77.26mg, 0.32mmol, 2.0eq), bis(triphenylphosphine)palladium dichloride (33.99mg, 0.05mmol, 0.3eq), cuprous iodide (15.37mg, 0.08mmol, 0.5eq), triethylamine (1mL), N,N-dimethylformamide (2mL). Replaced with argon three times, the reaction solution was stirred at 50°C for 12 hours. LCMS detected that the raw material reaction was complete. The reaction solution was cooled to room temperature, diluted with water (10mL), and extracted with ethyl acetate (3×10mL). The organic phases were combined and washed with water (10mL) and saturated brine (10mL). The organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by column chromatography (ethyl acetate-petroleum ether, 50%) to obtain: 6-[3-(3-{[2-methoxy-4-(methyldioxy- 6 -thio)phenyl]amino}prop-1-ynyl)-1-methyl-5-[(trifluoroacetyl)amino]-2-(2,2,2-trifluoroethyl)indol-6-yl]-1,2,3,4-tetrahydroisoquinoline-2-carboxylic acid-2-methylprop-2-yl ester (75 mg, yield: 58.60%), white solid.
[0921] Step 4: 6-[5-amino-3-(3-{[2-methoxy-4-(methyldioxy- 6 -1-methyl-2-(2,2,2-trifluoroethyl)indol-6-yl)-1,2,3,4-tetrahydroisoquinoline-2-carboxylic acid 2-methylpropan-2-yl ester
[0922]
[0923] In a 50 mL round bottom flask, add 6-[3-(3-{[2-methoxy-4-(methyldioxy- 6-sulfuryl)phenyl]amino}prop-1-ynyl)-1-methyl-5-[(trifluoroacetyl)amino]-2-(2,2,2-trifluoroethyl)indol-6-yl]-1,2,3,4-tetrahydroisoquinoline-2-carboxylic acid-2-methylprop-2-yl ester (65 mg, 0.08 mmol, 1.0 eq), potassium carbonate (113.31 mg, 0.82 mmol, 10.0 eq), methanol (2 mL), water (0.5 mL). React at 80 ° C for 3 hours. LCMS detected that the raw material reacted completely. The reaction solution was cooled to room temperature, diluted with water (10 mL), and extracted with ethyl acetate (3×10 mL). Combine the organic phases, wash with water (10 mL) and saturated brine (10 mL). The organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by column chromatography (ethyl acetate-petroleum ether, 50%) to give: 6-[5-amino-3-(3-{[2-methoxy-4-(methyldioxy- 6 -thio)phenyl]amino}prop-1-ynyl)-1-methyl-2-(2,2,2-trifluoroethyl)indol-6-yl]-1,2,3,4-tetrahydroisoquinoline-2-carboxylic acid-2-methylprop-2-yl ester (26 mg, yield: 45.51%), red solid.
[0924] MS m / z:697.1[M+H] +
[0925] Step 5: 3-(3-{[2-methoxy-4-(methyldioxy- 6 -thio)phenyl]amino}prop-1-ynyl)-1-methyl-6-(1,2,3,4-tetrahydroisoquinolin-6-yl)-2-(2,2,2-trifluoroethyl)indol-5-amine
[0926]
[0927] The reactants 6-[5-amino-3-(3-{[2-methoxy-4-(methyldioxy- 6-sulfuryl)phenyl]amino}prop-1-ynyl)-1-methyl-2-(2,2,2-trifluoroethyl)indol-6-yl]-1,2,3,4-tetrahydroisoquinoline-2-carboxylic acid-2-methylprop-2-yl ester (16 mg, 0.02 mmol, 1.0 eq), 2,6-lutidine (0.011 mL, 0.09 mmol, 4.0 eq) and dichloromethane (2 mL). Under argon protection, the reaction solution was added with trimethylsilyl trifluoromethanesulfonate (10.20 mg, 0.05 mmol, 2.0 eq) at room temperature and stirred for 1 hour. LCMS detected that the raw material reacted completely. Spin dry and dissolve with N,N-dimethylformamide, and send to HPLC for preparative chromatography for separation and purification. Obtain: 3-(3-{[2-methoxy-4-(methyldioxy-sub-λ 6 -thio)phenyl]amino}prop-1-ynyl)-1-methyl-6-(1,2,3,4-tetrahydroisoquinolin-6-yl)-2-(2,2,2-trifluoroethyl)indol-5-amine (4 mg, yield: 25.40%), white solid.
[0928] MS m / z:597.1[M+H] +
[0929] 1 H NMR (400MHz, DMSO-d6) δ7.45–7.39(m,1H),7.29–7.15(m,4H),7.15–7.03(m,2H),6.92(d,J=8.4Hz,1H),6.83(s,1H),6.4 8–6.42(m,1H),4.31(d,J=6.0Hz,2H),3.93–3.84(m,7H),3.64(s,3H),3.09(s,3H),3.01–2.92(m,2H),2.77–2.70(m,2H)
[0930] Example 40: 4-[5-fluoro-3-(3-{[2-methoxy-4-(methyldioxy- 6 -thio)phenyl]amino}prop-1-ynyl)-1-methyl-2-(2,2,2-trifluoroethyl)indol-6-yl]hexahydropyridin-3-ol (Compound 40)
[0931]
[0932] Step 1: 4-[5-Fluoro-1-methyl-2-(2,2,2-trifluoroethyl)indol-6-yl]-3-hydroxypiperidin-1-carboxylic acid 2-methylpropan-2-yl ester
[0933] In a 100mL reaction bottle, tert-butyl 4-(5-fluoro-1-methyl-2-(2,2,2-trifluoroethyl)-1H-indol-6-yl)-3,6-dihydropyridine-1(2H)-carboxylate (2.2g, 5.3mmol, 1.0eq) was dissolved in tetrahydrofuran (40mL). Borane tetrahydrofuran solution (21.3mL, 1M, 4.0eq) was added dropwise under ice bath. After the addition was completed, the mixture was reacted at room temperature for 16 hours. Under ice bath, sodium hydroxide aqueous solution (8.0mL, 2M, 3.0eq) and hydrogen peroxide (5.6mL, 10.0eq) were added dropwise in sequence. The mixture was heated to room temperature and reacted for 1 hour. The reaction was complete when monitored by TLC. The reaction was quenched with 10% sodium thiosulfate aqueous solution, extracted with ethyl acetate, and dried over anhydrous sodium sulfate. Filter, concentrate the filtrate, and purify the residue by column (ethyl acetate / petroleum ether: 5-70%) to obtain: 4-[5-fluoro-1-methyl-2-(2,2,2-trifluoroethyl)indol-6-yl]-3-hydroxypiperidin-1-carboxylic acid-2-methylpropan-2-yl ester (1.6 g, yield: 72%) as a white solid.
[0934] MS m / z:429[MH] -
[0935] The subsequent synthesis steps 2-4 refer to steps 4-6 of Example 9, wherein:
[0936] Step 2 Referring to Step 4 of Example 9, the raw material 4-[5-fluoro-1-methyl-2-(2,2,2-trifluoroethyl)indol-6-yl]-1,2,3,6-tetrahydropyridine-1-carboxylic acid-2-methylpropan-2-yl ester was replaced with 4-[5-fluoro-1-methyl-2-(2,2,2-trifluoroethyl)indol-6-yl]-3-hydroxyhexahydropyridine-1-carboxylic acid-2-methylpropan-2-yl ester, and one of a pair of diastereomers was obtained by subsequent reaction, 4-[5-fluoro-3-(3-{[2-methoxy-4-(methyldioxy-λ 6 -thio)phenyl]amino}prop-1-ynyl)-1-methyl-2-(2,2,2-trifluoroethyl)indol-6-yl]hexahydropyridin-3-ol.
[0937] MS m / z:568[M+H] +
[0938] 1H NMR (400MHz, DMSO-d6) δ7.51-7.32(m,2H),7.24(d,J=2.0Hz,1H),7.09(d,J=10.5Hz ,1H),6.94(d,J=8.4Hz,1H),6.46(t,J=6.2Hz,1H),4.32(d,J=6.1Hz,2H),3.98-3.89 (m,5H),3.81-3.80(m,1H),3.74(s,3H),3.19-3.15(m,1H),3.09(s,3H),3.02-2.99 (m,1H),2.88-2.82(m,2H),2.65-2.58(m,1H),2.47-2.42(m,1H),1.77-1.67(m,2H).
[0939] Example 41: 4-[5-fluoro-3-(3-{[2-methoxy-4-(methyldioxy- 6 -thio)phenyl]amino}prop-1-ynyl)-1-methyl-2-(2,2,2-trifluoroethyl)indol-6-yl]-1-methylhexahydropyridin-3-ol (Compound 41)
[0940]
[0941] Step 1: 4-[5-fluoro-3-(3-{[2-methoxy-4-(methyldioxy- 6 -1-methyl-2-(2,2,2-trifluoroethyl)indol-6-yl)-1-methylpiperidin-3-ol
[0942] In a 100 mL reaction bottle, compound 40 (20 mg, 0.04 mmol, 1.0 eq) and paraformaldehyde (11 mg, 0.4 mmol, 10.0 eq) were dissolved in dichloromethane / methanol (1 mL / 1 mL), sodium cyanoborohydride (5 mg, 0.08 mmol, 2.0 eq) and acetic acid (2 mg, 0.04 mmol, 1.0 eq) were added, and the mixture was reacted at 30 °C for 3 hours. The reaction was complete when monitored by LCMS. Saturated sodium bicarbonate solution was added, extracted with dichloromethane, washed with saturated brine, and dried over anhydrous sodium sulfate. After filtration, the filtrate was concentrated and the residue was purified by HPLC preparative chromatography to give: (3S,4S)-4-(5-fluoro-3-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-1-methyl-2-(2,2,2-trifluoroethyl)-1H-indol-6-yl)-1-methylpiperidin-3-ol (3.9 mg, yield: 20%) as a white solid.
[0943] MS m / z:582[M+H]+
[0944] 1 H NMR (400MHz, DMSO-d6) δ7.48(d,J=5.9Hz,1H),7.41(dd,J=8.4,2.0Hz,1H),7.24(d,J=2.0H z,1H),7.08(d,J=10.5Hz,1H),6.94(d,J=8.4Hz,1H),6.45(t,J=6.2Hz,1H),4.67-4.53(m, 1H),4.31(d,J=6.2Hz,2H),3.97-3.84(m,6H),3.74(s,3H),3.09(s,3H),3.00-2.96(m,1H) ,2.79-2.77(m,1H),2.70-2.63(m,1H),2.23(s,3H),1.95-1.89(m,1H),1.84-1.66(m,3H).
[0945] Examples 42 and 43: Cis-5-fluoro-6-[3-fluorohexahydropyridin-4-yl]-3-(3-{[2-methoxy-4-(methyldioxy- 6 -thio)phenyl]amino}prop-1-ynyl)-1-methyl-2-(2,2,2-trifluoroethyl)indole and Trans-5-fluoro-6-[3-fluorohexahydropyridin-4-yl]-3-(3-{[2-methoxy-4-(methyldioxy-λ 6 -thio)phenyl]amino}prop-1-ynyl)-1-methyl-2-(2,2,2-trifluoroethyl)indole (Compounds 42 and 43)
[0946]
[0947] Step 1: Cis-3-fluoro-4-[5-fluoro-1-methyl-2-(2,2,2-trifluoroethyl)indol-6-yl]piperidin-1-carboxylic acid 2-methylpropan-2-yl ester and Trans-3-fluoro-4-[5-fluoro-1-methyl-2-(2,2,2-trifluoroethyl)indol-6-yl]piperidin-1-carboxylic acid 2-methylpropan-2-yl ester
[0948] In a 100mL reaction bottle, tert-butyl (3S, 4S)-4-(5-fluoro-1-methyl-2-(2,2,2-trifluoroethyl)-1H-indol-6-yl)-3-hydroxypiperidine-1-carboxylate (3.0g, 7.0mmol, 1.0eq) was dissolved in dichloromethane (10mL). Diethylaminosulfur trifluoride (3.4g, 21.0mmol, 3.0eq) was added dropwise at -78°C. After the addition was complete, the reaction was allowed to react at room temperature for 1 hour. LCMS monitored the reaction to be complete. The reaction was quenched with aqueous sodium bicarbonate solution, extracted with dichloromethane, and dried over anhydrous sodium sulfate. Filtered, the filtrate was concentrated, and the residue was purified by column (ethyl acetate / petroleum ether: 5-10%) to obtain: a pair of diastereoisomers as a light yellow solid.
[0949] MS m / z:377[M-56] +
[0950] The subsequent synthesis steps refer to Specific Example 40, wherein in step 2, the raw material 4-[5-fluoro-1-methyl-2-(2,2,2-trifluoroethyl)indol-6-yl]-3-hydroxypiperidin-1-carboxylic acid-2-methylpropan-2-yl ester is replaced by Cis-3-fluoro-4-[5-fluoro-1-methyl-2-(2,2,2-trifluoroethyl)indol-6-yl]piperidin-1-carboxylic acid-2-methylpropan-2-yl ester and Trans-3-fluoro-4-[5-fluoro-1-methyl-2-(2,2,2-trifluoroethyl)indol-6-yl]piperidin-1-carboxylic acid-2-methylpropan-2-yl ester, and Cis-5-fluoro-6-[3-fluoropiperidin-4-yl]-3-(3-{[2-methoxy-4-(methyldioxy-λ-yl)-pyridin-5-yl]-1-carboxylic acid-2-methylpropan-2-yl ester is obtained by subsequent reaction. 6 -thio)phenyl]amino}prop-1-ynyl)-1-methyl-2-(2,2,2-trifluoroethyl)indole and Trans-5-fluoro-6-[3-fluorohexahydropyridin-4-yl]-3-(3-{[2-methoxy-4-(methyldioxy-λ 6 -thio)phenyl]amino}prop-1-ynyl)-1-methyl-2-(2,2,2-trifluoroethyl)indole
[0951] Compound 42: LCMS retention time 2.607 minutes; MS m / z: 570 [M+H] +
[0952] 1H NMR(400MHz, DMSO-d6)δ7.59(d,J=5.8Hz,1H),7.41(dd,J=8.4,2.0Hz,1H),7.24(d, J=2.0Hz,1H),7.13(d,J=10.5Hz,1H),6.94(d,J=8.5Hz,1H),6.46(t,J=6.1Hz,1H),4 .88-4.63(m,1H),4.32(d,J=6.2Hz,2H),3.98-3.86(m,5H),3.76(s,3H),3.58-3.45 (m,2H),3.26-3.21(m,1H),3.15-3.06(m,4H),2.61-2.51(m,1H),1.96-1.62(m,2H).
[0953] Compound 43: LCMS retention time 2.579 minutes; MS m / z: 570 [M+H] +
[0954] 1 H NMR(400MHz, DMSO-d6)δ7.61(d,J=5.8Hz,1H),7.41(dd,J=8.4,2.0Hz,1H),7.24(d, J=2.0Hz,1H),7.13(d,J=10.4Hz,1H),6.94(d,J=8.4Hz,1H),6.46(t,J=6.2Hz,1H),5 .03-4.84(m,1H),4.32(d,J=6.2Hz,2H),3.98-3.89(m,5H),3.76(s,3H),3.16-3.04 (m,5H),2.99-2.91(m,1H),2.68-2.56(m,2H),2.17-2.03(m,1H),1.66-1.53(m,1H).
[0955] LCMS method:
[0956] Column: SunFire Prep C18 OBDTM 5μm, 19*250mm Column;
[0957] Flow rate: 25 mL / min;
[0958] Mobile phase: [A (ammonia / water 1 / 999)-B (acetonitrile)]; B%: 25%-38% (v / v), 8 min.
[0959] Examples 44 and 45: Cis-5-fluoro-6-[3-fluoro-1-methylpiperidin-4-yl]-3-(3-{[2-methoxy-4-(methyldioxy- 6-thio)phenyl]amino}prop-1-ynyl)-1-methyl-2-(2,2,2-trifluoroethyl)indole and Trans-Cis-5-fluoro-6-[3-fluoro-1-methylpiperidin-4-yl]-3-(3-{[2-methoxy-4-(methyldioxy-λ 6 -thio)phenyl]amino}prop-1-ynyl)-1-methyl-2-(2,2,2-trifluoroethyl)indole (Compounds 44 and 45)
[0960]
[0961] Synthesis steps Reference Example 41, wherein the raw material 4-(5-fluoro-3-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-1-methyl-2-(2,2,2-trifluoroethyl)-1H-indol-6-yl)piperidin-3-ol is replaced by Cis-5-fluoro-6-[3-fluorohexahydropyridin-4-yl]-3-(3-{[2-methoxy-4-(methyldioxy)phenyl]amino)prop-1-yn-1-yl)-1-methyl-2-(2,2,2-trifluoroethyl)-1H-indol-6-yl)piperidin-3-ol 6 -thio)phenyl]amino}prop-1-ynyl)-1-methyl-2-(2,2,2-trifluoroethyl)indole and Trans-5-fluoro-6-[3-fluorohexahydropyridin-4-yl]-3-(3-{[2-methoxy-4-(methyldioxy-λ 6 -sulfuryl)phenyl]amino}prop-1-ynyl)-1-methyl-2-(2,2,2-trifluoroethyl)indole, the reaction was carried out to obtain Cis-5-fluoro-6-[3-fluoro-1-methylhexahydropyridin-4-yl]-3-(3-{[2-methoxy-4-(methyldioxy-λ 6 -thio)phenyl]amino}prop-1-ynyl)-1-methyl-2-(2,2,2-trifluoroethyl)indole and Trans-5-fluoro-6-[3-fluoro-1-methylhexahydropyridin-4-yl]-3-(3-{[2-methoxy-4-(methyldioxy-λ 6 -thio)phenyl]amino}prop-1-ynyl)-1-methyl-2-(2,2,2-trifluoroethyl)indole.
[0962] Compound 44: LCMS retention time 2.841 minutes; MS m / z: 584 [M+H] +
[0963] 1H NMR(400MHz, CDCl3) δ7.65(d,J=5.9Hz,1H),7.41(dd,J=8.3,2.0Hz,1H),7.24(d,J=2.0Hz ,1H),7.13(d,J=10.5Hz,1H),6.94(d,J=8.5Hz,1H),6.46(t,J=6.2Hz,1H),4.98-4.79(m,1 H),4.31(d,J=6.2Hz,2H),3.98-3.86(m,5H),3.76(s,3H),3.25-3.20(m,1H),3.08(s,3H) ,3.03-2.93(m,1H),2.81-2.78(m,1H),2.28(s,3H),2.07-1.97(m,2H),1.91-1.75(m,2H).
[0964] Compound 45: LCMS retention time 2.780 minutes; MS m / z: 584 [M+H] +
[0965] 1 H NMR (400MHz, DMSO-d6) δ7.66(d,J=5.9Hz,1H),7.41(dd,J=8.4,2.0Hz,1H),7.24(d,J=2 .0Hz,1H),7.14(d,J=10.5Hz,1H),6.94(d,J=8.4Hz,1H),6.46(t,J=6.2Hz,1H),5.01-4 .82(m,1H),4.32(d,J=6.2Hz,2H),3.98-3.89(m,5H),3.76(s,3H),3.31-3.26(m,1H),3 .09(s,3H),2.91-2.86(m,1H),2.79-2.73(m,1H),2.23-2.10(m,6H),1.86-1.74(m,1H).
[0966] LCMS method:
[0967] Column: SunFire Prep C18 OBDTM 5μm, 19*250mm Column;
[0968] Flow rate: 25 mL / min;
[0969] Mobile phase: [A (ammonia / water 1 / 999)-B (acetonitrile)]; B%: 25%-38% (v / v), 8 min.
[0970] Example 46: 3-(3-{[2-methoxy-4-(methyldioxy- 6-thio)phenyl]amino}prop-1-ynyl)-1-methyl-7-(1-methylpiperidin-4-yl)-2-(2,2,2-trifluoroethyl)indole (Compound 46)
[0971]
[0972] The synthesis steps of Example 46 refer to Specific Example 10. Wherein,
[0973] Step 1, 6-bromo-5-fluoro-1H-indole is replaced with 7-bromo-1H-indole, and then 3-(3-{[2-methoxy-4-(methyldioxy-λ 6 -thio)phenyl]amino}prop-1-ynyl)-1-methyl-7-(1-methylpiperidin-4-yl)-2-(2,2,2-trifluoroethyl)indole.
[0974] MS m / z:548.6[M+H] +
[0975] 1 H NMR (400MHz, DMSO-d6) δ7.40(dd,J=8.4,2.0Hz,1H),7.31(dd,J=7.6,1.3Hz,1H),7.25(d,J=2.0Hz,1 H),7.14(dd,J=7.6,1.4Hz,1H),7.07(t,J=7.5Hz,1H),6.94(d,J=8.4Hz,1H),6.47(t,J=6.1Hz,1H), 4.33(d,J=6.2Hz,2H),3.97(d,J=10.7Hz,2H),3.93(s,3H),3.89(s,3H),3.44–3.35(m,1H),3.09(s, 3H),2.94–2.83(m,2H),2.21(s,3H),2.07(td,J=11.0,4.1Hz,2H),1.77(td,J=10.7,9.6,3.4Hz,4H).
[0976] Example 47: N-(3-(7-chloro-1-methyl-6-(1,2,3,4-tetrahydroisoquinolin-6-yl)-2-(2,2,2-trifluoroethyl)-1H-indol-3-yl)prop-2-yn-1-yl)-2-methoxy-4-(methylsulfonyl)aniline (Compound 47)
[0977]
[0978] Example 47 The synthetic route refers to Example 23, wherein in step 1, the raw material 6-bromo-5-chloro-1H-indole is replaced with 6-bromo-7-chloro-1H-indole, and N-(3-(7-chloro-1-methyl-6-(1,2,3,4-tetrahydroisoquinolin-6-yl)-2-(2,2,2-trifluoroethyl)-1H-indol-3-yl)prop-2-yn-1-yl)-2-methoxy-4-(methylsulfonyl)aniline is obtained through subsequent synthetic steps.
[0979] MS m / z:616[M+H] +
[0980] 1 H NMR (400MHz, DMSO-d6) δ7.44-7.40(m,2H),7.25(d,J=2.0Hz,1H),7.12-7.06(m,4H),6.95(d,J=8.4Hz,1H),6.48(t,J=6.2Hz,1H),4.3 4(d,J=6.2Hz,2H),4.08(s,3H),4.01(q,J=10.7Hz,2H),3.89-3.88(m,5H),3.09(s,3H),2.96(t,J=5.8Hz,2H),2.72(t,J=5.9Hz,2H).
[0981] Test Example 1: Proliferation inhibition activity on human pancreatic cancer cells BxPC-3 and human liver cancer cells HuH-7
[0982] The PrestoBlue method was used to determine the in vitro proliferation inhibitory activity of the compounds against human pancreatic cancer cells BxPC-3 and human hepatoma cells HuH-7 with p53 Y220C mutation.
[0983] BxPC-3 (TCHu 12, Cell Bank of the Chinese Academy of Sciences) and HuH-7 cells (TCHu182, Cell Bank of the Chinese Academy of Sciences) were cultured in RPMI1640 complete medium containing 10% fetal bovine serum. BxPC-3 and HuH-7 cells in the logarithmic growth phase were seeded in 96-well plates at a cell density of 500 cells / 135 μL complete medium and cultured in a constant temperature incubator at 37°C containing 5% CO2 for 24 hours. Each compound was dissolved in dimethyl sulfoxide (DMSO) in advance to prepare a 10 mM stock solution, and then the compound was diluted with DMSO and complete medium in turn. Take out the 96-well plate inoculated with cells, and take one of them as a no-growth control group (the medium control group with no cell growth at 0 hours); add 15 μL of different concentrations of compounds to each well of the other 96-well plates, so that the final concentrations are 10000, 5000, 2500, 1250, 625, 312.5, 156.3, 78.1, 39.1, and 19.5 nM, set up three replicate wells for each compound concentration, and set up a negative control group (a medium control group containing cells and no compound), and the concentration of DMSO in each well is 0.5%. The reserved no-growth control group immediately adds PrestoBlue HS cell viability detection reagent and performs subsequent tests, and the other 96-well plates continue to be cultured in a constant temperature incubator at 37°C with 5% CO2 for 144 hours before adding PrestoBlue TM HS cell viability detection reagent (Thermo Fisher catalog number: P50201) and perform subsequent tests.
[0984] Join PrestoBlue TM HS cell viability detection reagent and subsequent detection steps are as follows: Take out the 96-well cell culture plate from the CO2 constant temperature incubator and add PrestoBlue to each well TM 15 μL of HS cell viability detection reagent was added and incubated in a constant temperature incubator at 37°C with 5% CO2 for 3 hours. The 96-well cell culture plate was taken out and the relative fluorescence intensity (RFU) was measured at an excitation wavelength of 560 nm and an emission wavelength of 590 nm using an ELISA reader. The cell inhibition rate of each concentration of the compound was calculated according to the following formula.
[0985]
[0986] The data were analyzed using GraphPad Prism 8.3 software, and nonlinear S-curve regression was used to fit the data to obtain the dose-effect curve, from which the IC 50 The results are shown in Table 1.
[0987] Table 1 IC of Example compounds and controls 50 value
[0988]
[0989]
[0990] Among them, the structure of reference 1 is as follows, and it is prepared according to the method of Example 369 of patent WO2017143291A1,
[0991]
[0992] The test results show that the compound of the present invention exhibits good proliferation inhibition activity on human pancreatic cancer cells BxPC-3 and human liver cancer cells HuH-7 having p53 Y220C mutation.
Claims
1. A compound as represented by formula (I) or a pharmaceutically acceptable salt thereof, in, X1 is CH or N; X2 is CH or N; X3 is CH or N; X4 is CH or N; Each R 1 are independently deuterium, hydroxyl, cyano, halogen, nitro, -N(R 8 )2. -SR 8 、-COR 8 、-COOR 8 、-OCOR 8 、-CON(R 8 )2.-NR 8 COR 8 、-NR 8 COOR 8 、-NR 8 CON(R 8 2. -SOR 8 ,-SON(R 8 )2.-NR 8 SOR 8 、-NR 8 SON(R 8 2. -SO2R 8 、-SO2N(R 8 )2.-NR 8 S02R 8 、-NR 8 SO2N(R 8 )2.-PO(R 8 2. C 1-6 Alkyl, with one or more R 1a Substituted C 1-6 Alkyl, -OC 1-6 Alkyl, with one or more R 1b Replaced-OC 1-6 Alkyl, C 2-6 Alkenyl, one or more R 1c Substituted C 2-6 Alkenyl, C 2-6 Alkynyl, with one or more R 1d Substituted C 2-6 Alkynyl, C 3-7 Cyclic hydrocarbon group, one or more R 1e Substituted C 3-7 Cyclic hydrocarbon group, 3-12 membered heterocyclic hydrocarbon group, one or more R 1f Substituted 3-12 membered heterocyclic hydrocarbon group, C 6-10 Aryl, one or more R 1g Substituted C 6-10 Aryl, 5-10 membered heteroaryl or one or more R 1h substituted 5-10 membered heteroaryl; Each R 1a , R 1b , R 1c , R 1d , R 1e , R 1f , R 1g and R 1h are independently deuterium, hydroxyl, cyano, halogen, -N(R 8 2. C 1-6 Alkyl, one or more -CON(R 13 )2 substituted C 1-6 Alkyl, -OC 1-6 Alkyl or C 3-7 Cycloalkyl; m is 0, 1, 2, 3 or 4; Each R 8 are independently hydrogen, C 1-6 Alkyl, C 3-7 Cyclic hydrocarbon group, 3-12 membered heterocyclic hydrocarbon group or one or more R 8-1 Substituted 3-12 membered heterocyclic hydrocarbon group; Each R 8-1 are independently deuterium, hydroxyl, cyano, halogen, -NH2 or C 1-6 alkyl; Each R 13 are independently hydrogen, C 1-6 Alkyl, C 3-7 Cycloalkyl or 3-12 membered heterocycloalkyl; R 2 Hydrogen, -COR 8 、-COOR 8 、-CON(R 8 2. -SOR 8 ,-SON(R 8 2. -SO2R 8 、-SO2N(R 8 2. C 1-6 Alkyl, with one or more R 2a Substituted C 1-6 Alkyl, C 2-6 Alkenyl, one or more R 2b Substituted C 2-6 Alkenyl, C 2-6 Alkynyl, with one or more R 2c Substituted C 2-6 Alkynyl, C 3-7 Cyclic hydrocarbon group, one or more R 2d Substituted C 3-7 Cyclic hydrocarbon group, 3-12 membered heterocyclic hydrocarbon group, one or more R 2e Substituted 3-12 membered heterocyclic hydrocarbon group, C 6-10 Aryl, one or more R 2f Substituted C 6-10 Aryl, 5-10 membered heteroaryl or one or more R 2g substituted 5-10 membered heteroaryl; Each R 2a , R 2b , R 2c , R 2d , R 2e , R 2f and R 2g are each independently deuterium, hydroxyl, cyano, halogen, -N(R 8 2. C 1-6 Alkyl, -OC 1-6 Alkyl or C 3-7 Cycloalkyl; R 3 is hydrogen, deuterium, hydroxyl, cyano, halogen, nitro, -N(R 8 )2. -SR 8 、-COR 8 、-COOR 8 、-OCOR 8 、-CON(R 8 )2.-NR 8 COR 8 、-NR 8 COOR 8 、-NR 8 CON(R 8 2. -SOR 8 ,-SON(R 8 )2.-NR 8 SOR 8 、-NR 8 SON(R 8 2. -SO2R 8 、-SO2N(R 8 )2.-NR 8 S02R 8 、-NR 8 SO2N(R 8 )2.-PO(R 8 2. C 1-6 Alkyl, with one or more R 3a Substituted C 1-6 Alkyl, -OC 1-6 Alkyl, with one or more R 3b Replaced-OC 1-6 Alkyl, C 2-6 Alkenyl, one or more R 3c Substituted C 2-6 Alkenyl, C 2-6 Alkynyl, with one or more R 3d Substituted C 2-6 Alkynyl, C 3-7 Cyclic hydrocarbon group, one or more R 3e Substituted C 3-7 Cyclic hydrocarbon group, 3-12 membered heterocyclic hydrocarbon group, one or more R 3f Substituted 3-12 membered heterocyclic hydrocarbon group, C 6-10 Aryl, one or more R 3g Substituted C 6-10 Aryl, 5-10 membered heteroaryl or one or more R 3h substituted 5-10 membered heteroaryl; Each R 3a , R 3b , R 3c , R 3d , R 3e , R 3f , R 3g and R 3h are each independently deuterium, hydroxyl, cyano, halogen, -N(R 8 2. C 1-6 Alkyl, -OC 1-6 Alkyl or C 3-7 Cycloalkyl; R 4 and R 5 are independently hydrogen, deuterium, hydroxyl, cyano, halogen, -N(R 8 2. C 1-6 Alkyl, with one or more R 4a Substituted C 1-6 Alkyl, -OC 1-6 Alkyl, with one or more R 4b Replaced-OC 1-6 Alkyl, C 2-6 Alkenyl, one or more R 4c Substituted C 2-6 Alkenyl, C 2-6 Alkynyl, with one or more R 4d Substituted C 2-6 Alkynyl, C 3-7 Cyclic hydrocarbon group, one or more R 4e Substituted C 3-7 Cyclic hydrocarbon group, 3-12 membered heterocyclic hydrocarbon group, one or more R 4f Substituted 3-12 membered heterocyclic hydrocarbon group, C 6-10 Aryl, one or more R 4g Substituted C 6-10 Aryl, 5-10 membered heteroaryl or one or more R 4h substituted 5-10 membered heteroaryl, or R 4 and R 5 Combine to form an oxo group, or R 4 and R 5 Together with the carbon atom to which they are attached, they form C 3-7 Cyclic hydrocarbon group, one or more R 4i Substituted C 3-7 Cyclic hydrocarbon group, 3-12 membered heterocyclic hydrocarbon group or one or more R 4j Substituted 3-12 membered heterocyclic hydrocarbon group; Each R 4a , R 4b , R 4c , R 4d , R 4e , R 4f , R 4g , R 4h , R 4i and R 4j are independently deuterium, hydroxyl, cyano, halogen, -N(R 8 2. C 1-6 Alkyl, -OC 1-6 Alkyl or C 3-7 Cycloalkyl; R 6 Hydrogen, -COR 8 、-COOR 8 、-CON(R 8 2. -SOR 8 ,-SON(R 8 2. -SO2R 8 、-SO2N(R 8 2. C 1-6 Alkyl, with one or more R 6a Substituted C 1-6 Alkyl, C 2-6 Alkenyl, one or more R 6b Substituted C 2-6 Alkenyl, C 2-6 Alkynyl, with one or more R 6c Substituted C 2-6 Alkynyl, C 3-7 Cyclic hydrocarbon group, one or more R 6d Substituted C 3-7 Cyclic hydrocarbon group, 3-12 membered heterocyclic hydrocarbon group, one or more R 6e Substituted 3-12 membered heterocyclic hydrocarbon group, C 6-10 Aryl, one or more R 6f Substituted C 6-10 Aryl, 5-10 membered heteroaryl or one or more R 6g substituted 5-10 membered heteroaryl; Each R 6a , R 6b , R 6c , R 6d , R 6e , R 6f and R 6g are each independently deuterium, hydroxyl, cyano, halogen, -N(R 8 2. C 1-6 Alkyl, -OC 1-6 Alkyl or C 3-7 Cycloalkyl; R 7 For one or more R 7a Substituted C 3-7 Cyclic hydrocarbon group, one or more R 7b substituted 3-12 membered heterocyclic hydrocarbon group, 7c Substituted C 6-10 Aryl or one or more R 7d substituted 5-10 membered heteroaryl; Each R 7a , R 7b , R 7c and R 7d are each independently deuterium, hydroxyl, cyano, halogen, nitro, -N(R 9 )2. -SR 9 、-COR 10 、-COOR 10 、-OCOR 10 、-CON(R 9 )2.-NR 9 COR 10 、-NR 9 COOR 9 、-NR 9 CON(R 9 )2.-SON(R 9 2. -SOR 10 、-NR 9 SOR 10 、-NR 9 SON(R 9 )2、-SO2N(R 9 2. -SO2R 10 、-NR 9 S02R 10 、-NR 9 SO2N(R 9 )2, -S(=O)(=NR 9 )R 10 ,-P(=O)(R 11 2. C 1-6 Alkyl, with one or more R 7-a Substituted C 1-6 Alkyl, -OC 1-6 Alkyl, with one or more R 7-b Replaced-OC 1-6 Alkyl, C 2-6 Alkenyl, one or more R 7-c Substituted C 2-6 Alkenyl, C 2-6 Alkynyl, with one or more R 7-d Substituted C 2-6 Alkynyl, C 3-7 Cyclic hydrocarbon group, one or more R 7-e Substituted C 3-7 Cyclic hydrocarbon group, 3-12 membered heterocyclic hydrocarbon group, one or more R 7-f Substituted 3-12 membered heterocyclic hydrocarbon group, C 6-10 Aryl, one or more R 7-g Substituted C 6-10 Aryl, 5-10 membered heteroaryl, substituted by one or more R 7-h Substituted 5-10 membered heteroaryl, -OC 3-7 Cyclic hydrocarbon group, one or more R 7-i Replaced-OC 3-7 Cycloalkyl, -O-(3-12 membered heterocycloalkyl), 7-j substituted-O-(3-12 membered heterocyclic hydrocarbon group); and R 7a , R 7b , R 7c and R 7d Each has at least one -SON(R 9 2. -SOR 10 、-SO2N(R 9 2. -SO2R 10 、-S(=O)(=NR 9 )R 10 or -P(=O)(R 11 )2; Each R 7-a , R 7-b , R 7-c , R 7-d , R 7-e , R 7-f , R 7-g , R 7-h and R 7-i and R 7-j are independently deuterium, hydroxyl, cyano, halogen, -N(R 12 2. C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, -OC 1-6 Alkyl, -SC 1-6 Alkyl, C 3-7 Cycloalkyl, 3-12 membered heterocyclic alkyl, C 6-10 Aryl, 5-10 membered heteroaryl, -COR 10 、-COOR 10 、-OCOR 10 、-CON(R 9 )2.-NR 9 COR 10 、-NR 9 COOR 9 、-NR 9 CON(R 9 )2.-SON(R 9 2. -SOR 10 、-NR 9 SOR 10 、-NR 9 SON(R 9 )2、-SO2N(R 9 2. -SO2R 10 、-NR 9 S02R 10 、-NR 9 SO2N(R 9 )2, -S(=O)(=NR 9 )R 10 or -P(=O)(R 11 ) 2, said C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, -OC 1-6 Alkyl, -SC 1-6 Alkyl, C 3-7 Cycloalkyl, 3-12 membered heterocyclic alkyl, C 6-10 The aryl and 5-10 membered heteroaryl groups are each independently optionally substituted with one or more R 7-a-1 replace; Each R 7-a-1 are each independently deuterium, hydroxyl, cyano, halogen, -NH2 or C 1-6 alkyl; Each R 9 are independently hydrogen, cyano, -CO(C 1-6 Alkyl), C 1-6 Alkyl, with one or more R 9a Substituted C 1-6 Alkyl, C 3-7 Cyclic hydrocarbon group, one or more R 9b Substituted C 3-7 Cyclic hydrocarbon group, 3-12 membered heterocyclic hydrocarbon group or one or more R 9c Substituted 3-12 membered heterocyclic hydrocarbon group; Each R 9a , R 9b and R 9c are independently deuterium, hydroxyl, cyano, halogen, -N(R 12 2. C 1-6 Alkyl, -OC 1-6 Alkyl or C3-7 cycloalkyl; Each R 10 are independently hydrogen, hydroxyl, C 1-6 Alkyl, with one or more R 10a Substituted C 1-6 Alkyl, C 3-7 Cyclic hydrocarbon group, one or more R 10b Substituted C 3-7 Cyclic hydrocarbon group, 3-12 membered heterocyclic hydrocarbon group or one or more R 10c Substituted 3-12 membered heterocyclic hydrocarbon group; Each R 10a , R 10b and R 10c are independently deuterium, hydroxyl, cyano, halogen, -N(R 12 2. C 1-6 Alkyl, -OC 1-6 Alkyl or C 3-7 Cycloalkyl; Each R 11 are independently hydrogen, hydroxyl, C 1-6 Alkyl, with one or more R 11a Substituted C 1-6 Alkyl, C 3-7 Cyclic hydrocarbon group, one or more R 11b Substituted C 3-7 Cyclic hydrocarbon group, 3-12 membered heterocyclic hydrocarbon group or one or more R 11c substituted 3-12 membered heterocyclic hydrocarbon group, or two R 11 Connected to them Together form a 4-8 membered heterocyclic hydrocarbon group or one or more R l1d Substituted 4-8 membered heterocyclic hydrocarbon group; Each R 11a , R 11b , R 11c and R 11d are independently deuterium, hydroxyl, cyano, halogen, -N(R 12 2. C 1-6 Alkyl, -OC 1-6 Alkyl or C 3-7 Cycloalkyl; Each R 12 are independently hydrogen or C 1-6 alkyl; In each "3-12 membered heterocyclic hydrocarbon group", the heteroatom species are independently selected from one, two or more of N, O and S, and the number of heteroatoms is independently 1, 2 or 3; "Two R's 11 Connected to them Together form a 4-8 membered heterocyclic hydrocarbon group or one or more R l1d In each "4-8 membered heterocyclic hydrocarbon group" in the "substituted 4-8 membered heterocyclic hydrocarbon group", the number of heteroatoms or heteroatom groups is independently 1, 2 or 3. When the number of "hetero" is 1, it is a heteroatom group P(O). When the number of "hetero" is 2 or 3, one of them is a heteroatom group P(O), and the rest are heteroatoms, and the heteroatoms are independently selected from one or two of N, O and S. In each "5-10 membered heteroaryl", the heteroatom species are independently selected from one, two or more of N, O and S, and the number of heteroatoms is independently 1, 2 or 3; When m is 1, R 1 Not halogen.
2. The compound of formula (I) or a pharmaceutically acceptable salt thereof according to claim 1, characterized in that: The scheme is as follows: in, X1 is CH or N; X2 is CH or N; X3 is CH or N; X4 is CH or N; Each R 1 are independently deuterium, hydroxyl, cyano, halogen, nitro, -N(R 8 )2. -SR 8 、-COR 8 、-COOR 8 、-OCOR 8 、-CON(R 8 )2.-NR 8 COR 8 、-NR 8 COOR 8 、-NR 8 CON(R 8 2. -SOR 8 ,-SON(R 8 )2.-NR 8 SOR 8 、-NR 8 SON(R 8 2. -SO2R 8 、-SO2N(R 8 )2.-NR 8 S02R 8 、-NR 8 SO2N(R 8 )2.-PO(R 8 2. C 1-6 Alkyl, with one or more R 1a Substituted C 1-6 Alkyl, -OC 1-6 Alkyl, with one or more R 1b Replaced-OC 1-6 Alkyl, C 2-6 Alkenyl, one or more R 1c Substituted C 2-6 Alkenyl, C 2-6 Alkynyl, with one or more R 1d Substituted C 2-6 Alkynyl, C 3-7 Cyclic hydrocarbon group, one or more R 1e Substituted C 3-7 Cyclic hydrocarbon group, 3-12 membered heterocyclic hydrocarbon group, one or more R 1f Substituted 3-12 membered heterocyclic hydrocarbon group, C 6-10 Aryl, one or more R 1g Substituted C 6-10 Aryl, 5-10 membered heteroaryl or one or more R 1h substituted 5-10 membered heteroaryl; Each R 1a , R 1b , R 1c , R 1d , R 1e , R 1f , R 1g and R 1h are independently deuterium, hydroxyl, cyano, halogen, -N(R 8 2. C 1-6 Alkyl, -OC 1-6 Alkyl or C 3-7 Cycloalkyl; m is 0, 1, 2, 3 or 4; Each R 8 are independently hydrogen, C 1-6 Alkyl, C 3-7 Cycloalkyl or 3-12 membered heterocycloalkyl; R 2 For hydrogen, -COR 8 、-COOR 8 、-CON(R 8 2. -SOR 8 ,-SON(R 8 2. -SO2R 8 、-SO2N(R 8 2. C 1-6 Alkyl, with one or more R 2a Substituted C 1-6 Alkyl, C 2-6 Alkenyl, one or more R 2b Substituted C 2-6 Alkenyl, C 2-6 Alkynyl, with one or more R 2c Substituted C 2-6 Alkynyl, C 3-7 Cyclic hydrocarbon group, one or more R 2d Substituted C 3-7 Cyclic hydrocarbon group, 3-12 membered heterocyclic hydrocarbon group, one or more R 2e Substituted 3-12 membered heterocyclic hydrocarbon group, C 6-10 Aryl, one or more R 2f Substituted C 6-10 Aryl, 5-10 membered heteroaryl or one or more R 2g substituted 5-10 membered heteroaryl; Each R 2a , R 2b , R 2c , R 2d , R 2e , R 2f and R 2g are independently deuterium, hydroxyl, cyano, halogen, -N(R 8 2. C 1-6 Alkyl, -OC 1-6 Alkyl or C 3-7 Cycloalkyl; R 3 is hydrogen, deuterium, hydroxyl, cyano, halogen, nitro, -N(R 8 )2. -SR 8 、-COR 8 、-COOR 8 、-OCOR 8 、-CON(R 8 )2.-NR 8 COR 8 、-NR 8 COOR 8 、-NR 8 CON(R 8 2. -SOR 8 ,-SON(R 8 )2.-NR 8 SOR 8 、-NR 8 SON(R 8 2. -SO2R 8 、-SO2N(R 8 )2.-NR 8 S02R 8 、-NR 8 SO2N(R 8 )2.-PO(R 8 2. C 1-6 Alkyl, with one or more R 3a Substituted C 1-6 Alkyl, -OC 1-6 Alkyl, with one or more R 3b Replaced-OC 1-6 Alkyl, C 2-6 Alkenyl, one or more R 3c Substituted C 2-6 Alkenyl, C 2-6 Alkynyl, with one or more R 3d Substituted C 2-6 Alkynyl, C 3-7 Cyclic hydrocarbon group, one or more R 3e Substituted C 3-7 Cyclic hydrocarbon group, 3-12 membered heterocyclic hydrocarbon group, one or more R 3f Substituted 3-12 membered heterocyclic hydrocarbon group, C 6-10 Aryl, one or more R 3g Substituted C 6-10 Aryl, 5-10 membered heteroaryl or one or more R 3h substituted 5-10 membered heteroaryl; Each R 3a , R 3b , R 3c , R 3d , R 3e , R 3f , R 3g and R 3h are independently deuterium, hydroxyl, cyano, halogen, -N(R 8 2. C 1-6 Alkyl, -OC 1-6 Alkyl or C 3-7 Cycloalkyl; R 4 and R 5 are independently hydrogen, deuterium, hydroxyl, cyano, halogen, -N(R 8 2. C 1-6 Alkyl, with one or more R 4a Substituted C 1-6 Alkyl, -OC 1-6 Alkyl, with one or more R 4b Replaced-OC 1-6 Alkyl, C 2-6 Alkenyl, one or more R 4c Substituted C 2-6 Alkenyl, C 2-6 Alkynyl, with one or more R 4d Substituted C 2-6 Alkynyl, C 3-7 Cyclic hydrocarbon group, one or more R 4e Substituted C 3-7 Cyclic hydrocarbon group, 3-12 membered heterocyclic hydrocarbon group, one or more R 4f Substituted 3-12 membered heterocyclic hydrocarbon group, C 6-10 Aryl, one or more R 4g Substituted C 6-10 Aryl, 5-10 membered heteroaryl or one or more R 4h substituted 5-10 membered heteroaryl, or R 4 and R 5 Combine to form an oxo group, or R 4 and R 5 Together with the carbon atom to which they are attached, they form C 3-7 Cyclic hydrocarbon group, one or more R 4i Substituted C 3-7 Cyclic hydrocarbon group, 3-12 membered heterocyclic hydrocarbon group or one or more R 4j Substituted 3-12 membered heterocyclic hydrocarbon group; Each R 4a , R 4b , R 4c , R 4d , R 4e , R 4f , R 4g , R 4h , R 4i and R 4j are independently deuterium, hydroxyl, cyano, halogen, -N(R 8 2. C 1-6 Alkyl, -OC 1-6 Alkyl or C 3-7 Cycloalkyl; R 6 For hydrogen, -COR 8 、-COOR 8 、-CON(R 8 2. -SOR 8 ,-SON(R 8 2. -SO2R 8 、-SO2N(R 8 2. C 1-6 Alkyl, with one or more R 6a Substituted C 1-6 Alkyl, C 2-6 Alkenyl, one or more R 6b Substituted C 2-6 Alkenyl, C 2-6 Alkynyl, with one or more R 6c Substituted C 2-6 Alkynyl, C 3-7 Cyclic hydrocarbon group, one or more R 6d Substituted C 3-7 Cyclic hydrocarbon group, 3-12 membered heterocyclic hydrocarbon group, one or more R 6e Substituted 3-12 membered heterocyclic hydrocarbon group, C 6-10 Aryl, one or more R 6f Substituted C 6-10 Aryl, 5-10 membered heteroaryl or one or more R 6g substituted 5-10 membered heteroaryl; Each R 6a , R 6b , R 6c , R 6d , R 6e , R 6f and R 6g are independently deuterium, hydroxyl, cyano, halogen, -N(R 8 2. C 1-6 Alkyl, -OC 1-6 Alkyl or C 3-7 Cycloalkyl; R 7 For one or more R 7a Substituted C 3-7 Cyclic hydrocarbon group, one or more R 7b substituted 3-12 membered heterocyclic hydrocarbon group, 7c Substituted C 6-10 Aryl or one or more R 7d substituted 5-10 membered heteroaryl; Each R 7a , R 7b , R 7c and R 7d are each independently deuterium, hydroxyl, cyano, halogen, nitro, -N(R 9 )2. -SR 9 、-COR 10 、-COOR 10 、-OCOR 10 、-CON(R 9 )2.-NR 9 COR 10 、-NR 9 COOR 9 、-NR 9 CON(R 9 )2.-SON(R 9 2. -SOR 10 、-NR 9 SOR 10 、-NR 9 SON(R 9 )2、-SO2N(R 9 2. -SO2R 10 、-NR 9 S02R 10 、-NR 9 SO2N(R 9 )2, -S(=O)(=NR 9 )R 10 ,-P(=O)(R 11 2. C 1-6 Alkyl, with one or more R 7-a Substituted C 1-6 Alkyl, -OC 1-6 Alkyl, with one or more R 7-b Replaced-OC 1-6 Alkyl, C 2-6 Alkenyl, one or more R 7-c Substituted C 2-6 Alkenyl, C 2-6 Alkynyl, with one or more R 7-d Substituted C 2-6 Alkynyl, C 3-7 Cyclic hydrocarbon group, one or more R 7-e Substituted C 3-7 Cyclic hydrocarbon group, 3-12 membered heterocyclic hydrocarbon group, one or more R 7-f Substituted 3-12 membered heterocyclic hydrocarbon group, C 6-10 Aryl, one or more R 7-g Substituted C 6-10 Aryl, 5-10 membered heteroaryl, substituted by one or more R 7-h Substituted 5-10 membered heteroaryl, -OC 3-7 Cyclic hydrocarbon or one or more R 7-i Replaced-OC 3-7 Cycloalkyl; and R 7a , R 7b , R 7c and R 7d Each has at least one -SON(R 9 2. -SOR 10 、-SO2N(R 9 2. -SO2R 10 、-S(=O)(=NR 9 )R 10 or -P(=O)(R 11 )2; Each R 7-a , R 7-b , R 7-c , R 7-d , R 7-e , R 7-f , R 7-g , R 7-h and R 7-i are independently deuterium, hydroxyl, cyano, halogen, -N(R 12 2. C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, -OC 1-6 Alkyl, -SC 1-6 Alkyl, C 3-7 Cycloalkyl, 3-12 membered heterocyclic alkyl, C 6-10 Aryl, 5-10 membered heteroaryl, -COR 10 、-COOR 10 、-OCOR 10 、-CON(R 9 )2.-NR 9 COR 10 、-NR 9 COOR 9 、-NR 9 CON(R 9 )2.-SON(R 9 2. -SOR 10 、-NR 9 SOR 10 、-NR 9 SON(R 9 )2、-SO2N(R 9 2. -SO2R 10 、-NR 9 S02R 10 、-NR 9 SO2N(R 9 )2, -S(=O)(=NR 9 )R 10 or -P(=O)(R 11 )2; Each R 9 are independently hydrogen, cyano, -CO(C 1-6 Alkyl), C 1-6 Alkyl, with one or more R 9a Substituted C 1-6 Alkyl, C 3-7 Cyclic hydrocarbon group, one or more R 9b Substituted C 3-7 Cyclic hydrocarbon group, 3-12 membered heterocyclic hydrocarbon group or one or more R 9c Substituted 3-12 membered heterocyclic hydrocarbon group; Each R 9a , R 9b and R 9c are independently deuterium, hydroxyl, cyano, halogen, -N(R 12 2. C 1-6 Alkyl, -OC 1-6 Alkyl or C3-7 cycloalkyl; Each R 10 are independently hydrogen, hydroxyl, C 1-6 Alkyl, with one or more R 10a Substituted C 1-6 Alkyl, C 3-7 Cyclic hydrocarbon group, one or more R 10b Substituted C 3-7 Cyclic hydrocarbon group, 3-12 membered heterocyclic hydrocarbon group or one or more R 10c Substituted 3-12 membered heterocyclic hydrocarbon group; Each R 10a , R 10b and R 10c are independently deuterium, hydroxyl, cyano, halogen, -N(R 12 2. C 1-6 Alkyl, -OC 1-6 Alkyl or C 3-7 Cycloalkyl; Each R 11 are independently hydrogen, hydroxyl, C 1-6 Alkyl, with one or more R 11a Substituted C 1-6 Alkyl, C 3-7 Cyclic hydrocarbon group, one or more R 11b Substituted C 3-7 Cyclic hydrocarbon group, 3-12 membered heterocyclic hydrocarbon group or one or more R 11c substituted 3-12 membered heterocyclic hydrocarbon group, or two R 11 Connected to them Together form a 4-8 membered heterocyclic hydrocarbon group or one or more R l1d Substituted 4-8 membered heterocyclic hydrocarbon group; Each R 11a , R 11b , R 11c and R 11d are independently deuterium, hydroxyl, cyano, halogen, -N(R 12 2. C 1-6 Alkyl, -OC 1-6 Alkyl or C 3-7 Cycloalkyl; Each R 12 are independently hydrogen or C 1-6 alkyl; In each "3-12 membered heterocyclic hydrocarbon group", the heteroatom species are independently selected from one, two or more of N, O and S, and the number of heteroatoms is independently 1, 2 or 3; "Two R's 11 Connected to them Together form a 4-8 membered heterocyclic hydrocarbon group or one or more R l1d In each "4-8 membered heterocyclic hydrocarbon group" in the "substituted 4-8 membered heterocyclic hydrocarbon group", when the number of heteroatom groups is 1, the heteroatom group is P(O); when the number of heteroatoms or heteroatom groups is 2 or 3, one of the heteroatom groups is P(O), and the remaining heteroatoms are independently selected from one or two of N, O and S; In each "5-10 membered heteroaryl", the heteroatom species are independently selected from one, two or more of N, O and S, and the number of heteroatoms is independently 1, 2 or 3; When m is 1, R 1 Not halogen.
3. The compound of formula (I) or a pharmaceutically acceptable salt thereof according to claim 1 or 2, characterized in that: It meets one or more of the following conditions: (1) Each halogen may independently be fluorine, chlorine, bromine or iodine, for example fluorine or chlorine, for example fluorine; (2) Each C 1-6 Alkyl is independently methyl, ethyl, n-propyl, isopropyl, n-butyl, tert-butyl, isobutyl or sec-butyl, for example methyl, ethyl or isopropyl, for example methyl or ethyl; (3) each 3-12 membered heterocyclic hydrocarbon group is independently a 3-12 membered heterocyclic alkyl group or a 3-12 membered heterocyclic alkenyl group; The 3-12 membered heterocycloalkyl group may be a 3-6 membered monocyclic heterocycloalkyl group or a 6-12 membered polycyclic heterocycloalkyl group, wherein the heteroatom is selected from one or both of N and O, and the number of heteroatoms is 1, 2 or 3, for example, a 3-6 membered monocyclic heterocycloalkyl group wherein the heteroatom is N or O, and the number of heteroatoms is 1, 2 or 3, for example piperazinyl, morpholinyl, tetrahydropyrrolyl, oxetanyl or azetidinyl, further for example Further, for example The 6-12 membered polycyclic heterocycloalkyl may be a 6-12 membered polycyclic heterocycloalkyl, a 6-12 membered spirocyclic heterocycloalkyl or a 6-12 membered bridged heterocycloalkyl; preferably a 6-12 membered spirocyclic heterocycloalkyl, preferably More preferred The 3-12 membered heterocycloalkenyl group may be a 3-6 membered monocyclic heterocycloalkenyl group or a 6-12 membered polycyclic heterocycloalkenyl group, wherein the heteroatom is selected from one or both of N and O, and the number of heteroatoms is 1, 2 or 3. For example, the heteroatom is selected from N, and the number of heteroatoms is 1, 2 or 3. Further example The 6-12 membered polycyclic heterocycloalkenyl group may be a 6-12 membered cyclic heterocycloalkenyl group, a 6-12 membered spirocyclic heterocycloalkenyl group or a 6-12 membered bridged heterocycloalkenyl group; Preferably, each 3-12 membered heterocycloalkyl group is independently a 3-12 membered heterocycloalkyl group or a 3-12 membered heterocycloalkenyl group; The 3-12 membered heterocycloalkyl is preferably a 3-6 membered monocyclic heterocycloalkyl or a 6-12 membered polycyclic heterocycloalkyl wherein the heteroatom is selected from N and the number of heteroatoms is 1, 2 or 3, for example, a 3-6 membered monocyclic heterocycloalkyl wherein the heteroatom is selected from N and the number of heteroatoms is 1, 2 or 3, for example piperazinyl, morpholinyl, tetrahydropyrrolyl, oxetanyl or azetidinyl, further for example The 3-12 membered heterocycloalkenyl group is preferably a 3-6 membered monocyclic heterocycloalkenyl group or a 6-12 membered polycyclic heterocycloalkenyl group wherein the heteroatom is selected from N and the number of heteroatoms is 1, 2 or 3, for example, a 3-6 membered monocyclic heterocycloalkenyl group wherein the heteroatom is selected from N and the number of heteroatoms is 1, 2 or 3, for example Further example (4) Each 5-10 membered heteroaryl group is independently a 5-6 membered monocyclic heteroaryl group or an 8-10 membered bicyclic heteroaryl group, wherein the heteroatom species is one or two selected from the group consisting of N, O and S, and the number of heteroatoms is 1, 2 or 3. The 5-6 membered monocyclic heteroaryl group is, for example Another example The 8-10 membered bicyclic heteroaryl group may be an 8-10 membered cyclic heteroaryl group, an 8-10 membered spirocyclic heteroaryl group or an 8-10 membered bridged heteroaryl group, for example Another example Preferably, each 5-10 membered heteroaryl group is independently a 5-6 membered monocyclic heteroaryl group or an 8-10 membered bicyclic heteroaryl group, wherein the heteroatom species is N and the number of heteroatoms is 1, 2 or 3, for example Another example (5) Each 5-10 membered heteroaryl group is independently a 5-10 membered cycloheteroaryl group, preferably an 8-10 membered cycloheteroaryl group, wherein the cycloheteroaryl group is preferably a 6-membered cycloheteroaryl group, such as a 6-membered heterocycloalkylcyclophenyl group; (6) Each C 3-7 The cycloalkyl groups are independently C 3-7 Cycloalkyl or C 3-7 Cycloalkenyl, such as C 3-7 Cycloalkyl, the C 3-7 The cycloalkyl group is preferably C 3-7 Monocyclic cycloalkyl or C 6-7 Polycyclic cycloalkyl, more preferably cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl, such as cyclopropyl; the C 3-7 The cycloalkenyl group is preferably C 3-7 Monocyclic cycloalkenyl or C 6-7 polycyclic cycloalkenyl; (7) Each C 6-10 Aryl is independently phenyl or naphthyl, for example phenyl; (8) Each-OC 1-6 Alkyl is independently methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, sec-butoxy or tert-butoxy, for example methoxy; (9) Each C 2-6 Alkenyl is independently ethenyl, propenyl, butenyl or pentenyl; (10) Each C 2-6 Alkynyl is independently ethynyl, propynyl, butynyl or pentynyl; (11) Each-SC 1-6 Alkyl is independently methylmercapto, ethylmercapto, n-propylmercapto, isopropylmercapto, n-butylmercapto, isobutylmercapto, sec-butylmercapto or tert-butylmercapto; (12) Each -CO(C 1-6 alkyl) is independently -CO(C 1-4 Alkyl), preferably -C(O)CH3, -C(O)CH2CH3, -C(O)(CH2)2CH3, -C(O)CH(CH3)2 or -C(O)(CH2)3CH3; (13) Each-OC 3-7 The cycloalkyl groups are independently -OC 3-7 Cycloalkyl or -OC 3-7 Cycloalkenyl, the -OC 3-7 The cycloalkyl group is preferably -OC 3-7 Monocyclic cycloalkyl or -OC 6-7 Polycyclic cycloalkyl, the -OC 3-7 The cycloalkenyl group is preferably -OC 3-7 Monocyclic cycloalkenyl or -OC 6-7 polycyclic cycloalkenyl; (14) each 4-8 membered heterocycloalkyl group is independently a 4-8 membered heterocycloalkyl group or a 4-8 membered heterocycloalkenyl group; The 4-8 membered heterocycloalkyl is preferably a 4-6 membered monocyclic heterocycloalkyl or a 6-8 membered bicyclic heterocycloalkyl, when the number of heteroatom groups is 1, the heteroatom group is P(O), when the number of heteroatoms or heteroatom groups is 2 or 3, one of which is P(O), and the remaining heteroatoms are independently selected from one or two of N, O and S; the 4-6 membered monocyclic heterocycloalkyl is preferably a 4-6 membered monocyclic heterocycloalkyl, when the number of heteroatom groups is 1, the heteroatom group is P(O), when the number of heteroatoms or heteroatom groups is 2 or 3, one of which is P(O), and the remaining heteroatoms are independently selected from N and / or O, more preferably The 4-8 membered heterocycloalkenyl group is preferably a 4-6 membered monocyclic heterocycloalkenyl group or a 6-8 membered bicyclic heterocycloalkenyl group, wherein when the number of the heteroatom group is 1, the heteroatom group is P(O); when the number of the heteroatom or heteroatom group is 2 or 3, wherein one heteroatom group is P(O), and the remaining heteroatoms are independently selected from one or two of N, O and S; and (15) each "one or more" is independently 1, 2 or 3.
4. The compound of formula (I) or a pharmaceutically acceptable salt thereof according to claim 1 or 2, characterized in that: It meets one or more of the following conditions: (1) X1 is CH; (2) X2 is CH; (3) X3 is CH; (4) X4 is CH; (5) Each R 1 are independently cyano, halogen, hydroxyl, C 1-6 Alkyl, with one or more R 1a Substituted C 1-6 Alkyl, 3-12 membered heterocyclic hydrocarbon, 1f substituted 3-12 membered heterocyclic hydrocarbon group, 5-10 membered heteroaryl group, substituted by one or more R 1h Substituted 5-10 membered heteroaryl, C 2-6 Alkynyl, -N(R 8 2. -COR 8 、-COOR 8 or-CON(R 8 )2; cyano, one or more R 1a Substituted C 1-6 Alkyl, C 2-6 Alkynyl, -N(R 8 2. -COR 8 、-COOR 8 or-CON(R 8 )2; preferably cyano, halogen, C 1-6 Alkyl, with one or more R 1a Substituted C 1-6 Alkyl, 3-12 membered heterocyclic hydrocarbon, 1f substituted 3-12 membered heterocyclic hydrocarbon group, 5-10 membered heteroaryl group, substituted by one or more R 1h Substituted 5-10 membered heteroaryl, C 2-6 Alkynyl, -N(R 8 2. -COR 8 、-COOR 8 or-CON(R 8 )2; preferably cyano, halogen, C 1-6 Alkyl, with one or more R 1f substituted 3-12 membered heterocyclic hydrocarbon group, 5-10 membered heteroaryl group, substituted by one or more R 1h Substituted 5-10 membered heteroaryl, C 2-6 Alkynyl or -COOR 8 ; further preferably halogen, C 1-6 Alkyl, 5-10 membered heteroaryl or -COOR 8 ; Preferably, each R 1 are independently halogen, hydroxyl, C 1-6 Alkyl, 3-12 membered heterocyclic hydrocarbon, 1f substituted 3-12 membered heterocyclic hydrocarbon group, 5-10 membered heteroaryl group or one or more R 1h Substituted 5-10 membered heteroaryl, preferably halogen, C 1-6 Alkyl, with one or more R 1f substituted 3-12 membered heterocyclic hydrocarbon group, 5-10 membered heteroaryl group or one or more R 1h Substituted 5-10 membered heteroaryl, preferably halogen, C 1-6 Alkyl or 5-10 membered heteroaryl; (6) Each R 1f are independently hydroxy, halogen or C 1-6 Alkyl, also C 1-6 alkyl (7) Each R 1h Independently for C 1-6 Alkyl or one or more -CON(R 13 )2 substituted C 1-6 Alkyl; preferably, each R 1h Independently for C 1-6 alkyl; (8) m is 1, 2 or 3; (9)R 2 C 1-6 Alkyl, with one or more R 2a Substituted C 1-6 Alkyl, C 3-7 Cyclic hydrocarbon or one or more R 2d Substituted C 3-7 Cycloalkyl, preferably C 1-6 Alkyl or C 3-7 Cycloalkyl, more preferably C 1-6 alkyl; (10) Each R 2a are independently halogen; (11) Each R 2d Independently for C 1-6 alkyl; (12)R 3 For hydroxyl, cyano, halogen, C 1-6 Alkyl or one or more R 3a Substituted C 1-6 Alkyl, preferably with one or more R 3a Substituted C 1-6 alkyl; (13) Each R 3a are independently halogen; (14)R 4 and R 5 are independently hydrogen, hydroxy, cyano, halogen or C 1-6 Alkyl, preferably hydrogen; (15)R 6 is hydrogen; (16)R 7 For one or more R 7c Substituted C 6-10 Aryl; (17) Each R 7c Independently -SO2R 10 ,-P(=O)(R 11 )2. -OC 1-6 Alkyl, with one or more R 7-b Replaced-OC 1-6 Alkyl or one or more R 7-j Substituted -O-(3-12 membered heterocyclic hydrocarbon group), with at least one R 7c SO2R 10 or -P(=O)(R 11 )2; Preferably, each R 7c Independently -SO2R 10 ,-P(=O)(R 11 )2 or -OC 1-6 Alkyl, and at least one R 7c SO2R 10 or -P(=O)(R 11 )2; preferably -SO2R 10 or -OC 1-6 Alkyl, and at least one R 7c SO2R 10 ; (18) Each R 10 Independently for C 1-6 alkyl; (19) Each R 11 Each independently is C 1-6 Alkyl, or two R 11 Connected to them Together form a 4-8 membered heterocyclic hydrocarbon group or one or more R l1d Substituted 4-8 membered heterocyclic hydrocarbon group; preferably C 1-6 alkyl; (20) Each R 11d are independently -N(R 12 )2 or C 1-6 alkyl; (21) Each R 12 Independently for C 1-6 alkyl; (22) Each R 1a are independently hydroxy or halogen; (23) Each R 8 are independently hydrogen, C 1-6 Alkyl or one or more R 8-1 Substituted 3-12 membered heterocyclic hydrocarbon group, also C 1-6 alkyl; (24) Each R 8-1 are independently halogen or C 1-6 alkyl; (25) Each R 13 are independently hydrogen or C 1-6 Alkyl, again hydrogen; (26) Each R 7-b is independently a 3-12 membered heterocyclic hydrocarbon group or is replaced by one or more R 7-a-1 Substituted 3-12 membered heterocyclic hydrocarbon group; (27) Each R 7-a-1 Independently for C 1-6 alkyl; and (28) each R 7-j Independently for C 1-6 alkyl.
5. The compound of formula (I) or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 4, characterized in that: It meets one or more of the following conditions: (1) Each R 1 Independently Fluorine, chlorine, cyano, Methyl, -NH2, Best Fluorine, chlorine, cyano, Methyl, -NH2, (2)R 2 for Methyl or ethyl, preferably Methyl or ethyl; (3)R 3 for (4) Each R 7c are independently -OCH3, -SO2CH3, Preferred -OCH3, Or -SO2CH3; More preferably -OCH3 or -SO2CH3; (5)R 7 for Best More preferred (6) Each R 8 are independently hydrogen, methyl or Preferably hydrogen, methyl, (7) Each R 7-b Independently For example (8) Each R 7-a-1 are independently methyl; and (9) each R 7-j are independently methyl.
6. The compound of formula (I) or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 4, characterized in that: The definitions of the groups in the compound represented by formula (I) or a pharmaceutically acceptable salt thereof are as described in Scheme 1, Scheme 2, Scheme 3, Scheme 4, Scheme 5, Scheme 6, Scheme 7, Scheme 8, Scheme 9, or Scheme 10. Solution 1: X1 is CH; X2 is CH; X3 is CH; X4 is CH; Each R 1 are independently halogen, hydroxyl, C 1-6 Alkyl, 3-12 membered heterocyclic hydrocarbon, 1f substituted 3-12 membered heterocyclic hydrocarbon group, 5-10 membered heteroaryl group or one or more R 1h substituted 5-10 membered heteroaryl; Each R 1f Independently for C 1-6 alkyl; Each R 1h Independently for C 1-6 alkyl; m is 1, 2 or 3; R 2 C 1-6 Alkyl, with one or more R 2a Substituted C 1-6 Alkyl, C 3-7 Cyclic hydrocarbon or one or more R 2d Substituted C 3-7 Cycloalkyl; Each R 2a are independently halogen; Each R 2d Independently for C 1-6 alkyl; R 3 For hydroxyl, cyano, halogen, C 1-6 Alkyl or one or more R 3a Substituted C 1-6 alkyl; Each R 3a are independently halogen; R 4 and R 5 are independently hydrogen, hydroxy, cyano, halogen or C 1-6 alkyl; R 6 is hydrogen; R 7 For one or more R 7c Substituted C 6-10 Aryl; Each R 7c Independently -SO2R 10 ,-P(=O)(R 11 )2 or -OC 1-6 Alkyl, and at least one R 7c SO2R 10 or -P(=O)(R 11 )2; Each R 10 Independently for C 1-6 alkyl; Each R 11 Independently for C 1-6 Alkyl, or two R 11 Connected to them Together form a 4-8 membered heterocyclic hydrocarbon group or one or more R l1d Substituted 4-8 membered heterocyclic hydrocarbon group; Each R 11d are independently -N(R 12 )2 or C 1-6 alkyl; Each R 12 Independently for C 1-6 alkyl; And when m is 1, R 1 Not halogen; Solution 2 X1 is CH; X2 is CH; X3 is CH; X4 is CH; Each R 1 are independently halogen, C 1-6 Alkyl, with one or more R 1f substituted 3-12 membered heterocyclic hydrocarbon group, 5-10 membered heteroaryl group or one or more R 1h substituted 5-10 membered heteroaryl; Each R 1f Independently for C 1-6 alkyl; Each R 1h Independently for C 1-6 alkyl; m is 1, 2 or 3; R 2 C 1-6 Alkyl, with one or more R 2a Substituted C 1-6 Alkyl, C 3-7 Cyclic hydrocarbon or one or more R 2d Substituted C 3-7 Cycloalkyl; Each R 2a are independently halogen; Each R 2d Independently for C 1-6 alkyl; R 3 For one or more R 3a Substituted C 1-6 alkyl; Each R 3a are independently halogen; R 4 and R 5 each independently is hydrogen; R 6 is hydrogen; R 7 For one or more R 7c Substituted C 6-10 Aryl; Each R 7c Independently -SO2R 10 ,-P(=O)(R 11 )2 or -OC 1-6 Alkyl, and at least one R 7c SO2R 10 or -P(=O)(R 11 )2; Each R 10 Independently for C 1-6 alkyl; Each R 11 Independently for C 1-6 alkyl; And when m is 1, R 1 Not halogen; Solution 3 X1 is CH; X2 is CH; X3 is CH; X4 is CH; Each R 1 are independently halogen, C 1-6 Alkyl, with one or more R 1f substituted 3-12 membered heterocyclic hydrocarbon group, 5-10 membered heteroaryl group or one or more R 1h substituted 5-10 membered heteroaryl; Each R 1f Independently for C 1-6 alkyl; Each R 1h Independently for C 1-6 alkyl; m is 1 or 2; R 2 C 1-6 Alkyl or C 3-7 Cycloalkyl; R 3 For one or more R 3a Substituted C 1-6 alkyl; Each R 3a are independently halogen; R 4 and R 5 each independently is hydrogen; R 6 is hydrogen; R 7 For one or more R 7c Substituted C 6-10 Aryl; Each R 7c Independently -SO2R 10 or -OC 1-6 Alkyl, and at least one R 7c SO2R 10 ; Each R 10 Independently for C 1-6 alkyl; And when m is 1, R 1 Not halogen; Solution 4: X1 is CH; X2 is CH; X3 is CH; X4 is CH; Each R 1 are independently halogen, C 1-6 Alkyl, with one or more R 1f substituted 3-12 membered heterocyclic hydrocarbon group, 5-10 membered heteroaryl group or one or more R 1h substituted 5-10 membered heteroaryl; Each R 1f Independently for C 1-6 alkyl; Each R 1h Independently for C 1-6 alkyl; m is 1 or 2; R 2 C 1-6 alkyl; R 3 For one or more R 3a Substituted C 1-6 alkyl; Each R 3a are independently halogen; R 4 and R 5 each independently is hydrogen; R 6 is hydrogen; R 7 For one or more R 7c Substituted C 6-10 Aryl; Each R 7c Independently -SO2R 10 or -OC 1-6 Alkyl, and at least one R 7c SO2R 10 ; Each R 10 Independently for C 1-6 alkyl; And when m is 1, R 1 Not halogen; Solution 5: X1 is CH; X2 is CH; X3 is CH; X4 is CH; Each R 1 are independently halogen, C 1-6 Alkyl or 5-10 membered heteroaryl, R 1 The 5-10 membered heteroaryl group is connected to the 6-position of the indole; m is 1 or 2; R 2 C 1-6 alkyl; R 3 For one or more R 3a Substituted C 1-6 alkyl; Each R 3a are independently halogen; R 4 and R 5 each independently is hydrogen; R 6 is hydrogen; R 7 For one or more R 7c Substituted C 6-10 Aryl; Each R 7c Independently -SO2R 10 or -OC 1-6 Alkyl, such as -SO2CH3 or methoxy, and at least one R 7c SO2R 10 ; Each R 10 Independently for C 1-6 alkyl; And when m is 1, R 1 Not halogen; Solution 6: X1 is CH; X2 is CH; X3 is CH; X4 is CH; Each R 1 are independently cyano, halogen, hydroxyl, C 1-6 Alkyl, with one or more R 1a Substituted C 1-6 Alkyl, 3-12 membered heterocyclic hydrocarbon, 1f substituted 3-12 membered heterocyclic hydrocarbon group, 5-10 membered heteroaryl group, substituted by one or more R 1h Substituted 5-10 membered heteroaryl, C 2-6 Alkynyl, -N(R 8 2. -COR 8 、-COOR 8 or-CON(R 8 )2; Each R 1a are independently hydroxy or halogen; Each R 1f are independently hydroxy, halogen or C 1-6 alkyl; Each R 1h Independently for C 1-6 Alkyl or one or more -CON(R 13 )2 substituted C 1-6 alkyl; Each R 8 are independently hydrogen, C 1-6 Alkyl or one or more R 8-1 Substituted 3-12 membered heterocyclic hydrocarbon group; Each R 8-1 are independently halogen or C 1-6 alkyl; Each R 13 are independently hydrogen or C 1-6 alkyl; m is 1, 2 or 3; R 2 C 1-6 Alkyl, with one or more R 2a Substituted C 1-6 Alkyl, C 3-7 Cyclic hydrocarbon or one or more R 2d Substituted C 3-7 Cycloalkyl; Each R 2a are independently halogen; Each R 2d Independently for C 1-6 alkyl; R 3 For hydroxyl, cyano, halogen, C 1-6 Alkyl or one or more R 3a Substituted C 1-6 alkyl; Each R 3a are independently halogen; R 4 and R 5 are independently hydrogen, hydroxy, cyano, halogen or C 1-6 alkyl; R 6 is hydrogen; R 7 For one or more R 7c Substituted C 6-10 Aryl; Each R 7c Independently -SO2R 10 、-P(=O)(R 11 )2. -OC 1-6 Alkyl, with one or more R 7-b Replaced-OC 1-6 Alkyl or one or more R 7-j Substituted -O-(3-12 membered heterocyclic hydrocarbon group), with at least one R 7c SO2R 10 or -P(=O)(R 11 )2; Each R 7-b is independently a 3-12 membered heterocyclic hydrocarbon group or is replaced by one or more R 7-a-1 Substituted 3-12 membered heterocyclic hydrocarbon group; Each R 7-a-1 Independently for C 1-6 alkyl; Each R 7-j Independently for C 1-6 alkyl; Each R 10 Independently for C 1-6 alkyl; Each R 11 Independently for C 1-6 Alkyl, or two R 11 Connected to them Together form a 4-8 membered heterocyclic hydrocarbon group or one or more R l1d Substituted 4-8 membered heterocyclic hydrocarbon group; Each R 11d are independently -N(R 12 )2 or C 1-6 alkyl; Each R 12 Independently for C 1-6 alkyl; And when m is 1, R 1 Not halogen; Solution 7: X1 is CH; X2 is CH; X3 is CH; X4 is CH; Each R 1 are independently cyano, halogen, C 1-6 Alkyl, with one or more R 1a Substituted C 1-6 Alkyl, 3-12 membered heterocyclic hydrocarbon, 1f substituted 3-12 membered heterocyclic hydrocarbon group, 5-10 membered heteroaryl group, substituted by one or more R 1h Substituted 5-10 membered heteroaryl, C 2-6 Alkynyl, -N(R 8 2. -COR 8 、-COOR 8 or-CON(R 8 )2; Each R 1a are independently hydroxy or halogen; Each R 1f are independently hydroxy, halogen or C 1-6 alkyl; Each R 1h Independently for C 1-6 Alkyl or one or more -CON(R 13 )2 substituted C 1-6 alkyl; Each R 8 are independently hydrogen, C 1-6 Alkyl or one or more R 8-1 Substituted 3-12 membered heterocyclic hydrocarbon group; Each R 8-1 are independently halogen or C 1-6 alkyl; Each R 13 are independently hydrogen; m is 1, 2 or 3; R 2 C 1-6 Alkyl, with one or more R 2a Substituted C 1-6 Alkyl, C 3-7 Cyclic hydrocarbon or one or more R 2d Substituted C 3-7 Cycloalkyl; Each R 2a are independently halogen; Each R 2d Independently for C 1-6 alkyl; R 3 For one or more R 3a Substituted C 1-6 alkyl; Each R 3a are independently halogen; R 4 and R 5 each independently is hydrogen; R 6 is hydrogen; R 7 For one or more R 7c Substituted C 6-10 Aryl; Each R 7c Independently -SO2R 10 、-P(=O)(R 11 )2. -OC 1-6 Alkyl, with one or more R 7-b Replaced-OC 1-6 Alkyl or one or more R 7-j Substituted -O-(3-12 membered heterocyclic hydrocarbon group), with at least one R 7c SO2R 10 or -P(=O)(R 11 )2; Each R 7-b is independently a 3-12 membered heterocyclic hydrocarbon group or is replaced by one or more R 7-a-1 Substituted 3-12 membered heterocyclic hydrocarbon group; Each R 7-a-1 Independently for C 1-6 alkyl; Each R 7-j Independently for C 1-6 alkyl; Each R 10 Independently for C 1-6 alkyl; Each R 11 Independently for C 1-6 alkyl; And when m is 1, R 1 Not halogen; Solution 8: X1 is CH; X2 is CH; X3 is CH; X4 is CH; Each R 1 are independently cyano, halogen, C 1-6 Alkyl, with one or more R 1a Substituted C 1-6 Alkyl, 3-12 membered heterocyclic hydrocarbon, 1f substituted 3-12 membered heterocyclic hydrocarbon group, 5-10 membered heteroaryl group, substituted by one or more R 1h Substituted 5-10 membered heteroaryl, C 2-6 Alkynyl, -N(R 8 2. -COR 8 、-COOR 8 or-CON(R 8 )2; Each R 1a are independently hydroxy or halogen; Each R 1f are independently hydroxy, halogen or C 1-6 alkyl; Each R 1h Independently for C 1-6 Alkyl or one or more -CON(R 13 )2 substituted C 1-6 alkyl; Each R 8 are independently hydrogen, C 1-6 Alkyl or one or more R 8-1 Substituted 3-12 membered heterocyclic hydrocarbon group; Each R 8-1 are independently halogen or C 1-6 alkyl; Each R 13 are independently hydrogen; m is 1 or 2; R 2 C 1-6 Alkyl or C 3-7 Cycloalkyl; R 3 For one or more R 3a Substituted C 1-6 Alkyl; for example ethyl substituted by 1, 2 or 3 fluorine groups; Each R 3a are independently halogen; for example fluorine; R 4 and R 5 each independently is hydrogen; R 6 is hydrogen; R 7 For one or more R 7c Substituted C 6-10 Aryl; Each R 7c Independently -SO2R 10 、-P(=O)(R 11 )2 or -OC 1-6 Alkyl, with at least one R 7c SO2R 10 or -P(=O)(R 11 )2; For example, each R 7c are independently preferably -SO2CH3, -P(=O)(CH3)2 or methoxy, and at least one R 7c is -SO2CH3 or -P(=O)(CH3)2; Each R 10 Independently for C 1-6 Alkyl; for example, methyl; Each R 11 Independently for C 1-6 Alkyl; for example, methyl; And when m is 1, R 1 Halogen-free Solution 9: X1 is CH; X2 is CH; X3 is CH; X4 is CH; Each R 1 are independently cyano, halogen, C 1-6 Alkyl, with one or more R 1f substituted 3-12 membered heterocyclic hydrocarbon group, 5-10 membered heteroaryl group, substituted by one or more R 1h Substituted 5-10 membered heteroaryl, C 2-6 Alkynyl or -COOR 8 ; Each R 1f Independently for C 1-6 alkyl; Each R 1h Independently for C 1-6 alkyl; Each R 8 Independently for C 1-6 alkyl; m is 1 or 2; R 2 C 1-6 Alkyl; for example, methyl; R 3 For one or more R 3a Substituted C 1-6 Alkyl; for example ethyl substituted by 1, 2 or 3 fluorine groups; Each R 3a are independently halogen; for example fluorine; R 4 and R 5 each independently is hydrogen; R 6 is hydrogen; R 7 For one or more R 7c Substituted C 6-10 Aryl; Each R 7c Independently -SO2R 10 、-P(=O)(R 11 )2 or -OC 1-6 Alkyl, with at least one R 7c SO2R 10 or -P(=O)(R 11 )2; For example, each R 7c are independently preferably -SO2CH3, -P(=O)(CH3)2 or methoxy, and at least one R 7c is -SO2CH3 or -P(=O)(CH3)2; Each R 10 Independently for C 1-6 Alkyl; for example, methyl; Each R 11 Independently for C 1-6 Alkyl; for example, methyl; And when m is 1, R 1 Not halogen; Solution 10: X1 is CH; X2 is CH; X3 is CH; X4 is CH; Each R 1 are independently halogen, C 1-6 Alkyl, 5-10 membered heteroaryl or -COOR 8 , when the 5-10 membered heteroaryl is an 8-10 membered bicyclic heteroaryl, R 1 The 8-10 membered bicyclic heteroaryl group is connected to the 6-position of the indole; Each R 8 Independently for C 1-6 Alkyl; for example, methyl; m is 1 or 2; R 2 C 1-6 Alkyl; for example, methyl or ethyl; R 3 For one or more R 3a Substituted C 1-6 Alkyl; for example ethyl substituted by 1, 2 or 3 fluorine groups; Each R 3a are independently halogen; for example fluorine; R 4 and R 5 each independently is hydrogen; R 6 is hydrogen; R 7 For one or more R 7c Substituted C 6-10 Aryl; Each R 7c Independently -SO2R 10 or -OC 1-6 Alkyl, and at least one R 7c SO2R 10 ; For example, each R 7c are independently preferably -SO2CH3 or methoxy, and at least one R 7c is -SO2CH3; Each R 10 Independently for C 1-6 Alkyl; for example, methyl; And when m is 1, R 1 Not halogen.
7. The compound of formula (I) or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 6, characterized in that: The compound represented by formula (I) is a compound represented by formula (I-1), (I-2), (I-3), (I-4), (I-5) or (I-6): Among them, in formula (I-1), (I-2) and (I-3), R 1-a For one or more R 1f substituted 3-12 membered heterocyclic hydrocarbon group, 5-10 membered heteroaryl group or one or more R 1h substituted 5-10 membered heteroaryl; R 1-b Halogen or C 1-6 alkyl; m' is 0, 1, 2 or 3; m、R 1 , R 1f , R 1h , R 2 , R 3 and R 7 The definition as in any one of claims 1 to 6; Among them, among (I-4), (I-5) or (I-6), R 1-c For one or more R 1f substituted 3-12 membered heterocyclic hydrocarbon group, 5-10 membered heteroaryl group, substituted by one or more R 1h Substituted 5-10 membered heteroaryl or -N(R 8 )2; R 1-d For cyano, halogen, C 1-6 Alkyl, with one or more R 1a Substituted C 1-6 Alkyl, 5-10 membered heteroaryl, 1h Substituted 5-10 membered heteroaryl, -COR 8 、-COOR 8 , C 2-6 Alkynyl, -N(R 8 )2 or -CON(R 8 )2; R 1-e is a 5-10 membered heteroaryl group, 1h substituted 5-10 membered heteroaryl or one or more R 1f Substituted 3-12 membered heterocyclic hydrocarbon group; R 1-f Halogen or C 1-6 alkyl; m' is 0, 1, 2 or 3; m、R 1 , R 1a , R 1f , R 1h , R 2 , R 3 , R 7 , R 7c and R 8 The definition as described in any one of claims 1 to 6.
8. The compound of formula (I) or a pharmaceutically acceptable salt thereof according to claim 1, characterized in that: The compound represented by formula (I) is any of the following compounds:
9. A pharmaceutical composition comprising substance A and a pharmaceutically acceptable excipient, wherein substance A is a compound represented by formula (I) as described in any one of claims 1 to 8 or a pharmaceutically acceptable salt thereof.
10. Use of the compound of formula (I) or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 8 or the pharmaceutical composition according to claim 9 in the preparation of a p53 Y220C activator.
11. A use of a compound as shown in formula (I) or a pharmaceutically acceptable salt thereof as described in any one of claims 1 to 8 or a pharmaceutical composition as described in claim 9 in the preparation of a medicament for treating and / or preventing a disease associated with the p53 Y220C mutation; preferably, the compound as shown in formula (I) or a pharmaceutically acceptable salt thereof or the pharmaceutical composition is in a therapeutically effective amount, and / or the disease is cancer, preferably ovarian cancer, breast cancer, lung cancer, colorectal cancer, gastric cancer, head and neck cancer, prostate cancer, endometrial cancer, pancreatic cancer or liver cancer, more preferably ovarian cancer, breast cancer, lung cancer, pancreatic cancer or liver cancer, such as pancreatic cancer or liver cancer.
12. A use of a compound as shown in formula (I) as described in any one of claims 1 to 8 or a pharmaceutically acceptable salt thereof or a pharmaceutical composition as described in claim 9 in the preparation of a medicament for treating and / or preventing cancer; preferably, the compound as shown in formula (I) or a pharmaceutically acceptable salt thereof or the pharmaceutical composition is a therapeutically effective amount, and / or the cancer is preferably ovarian cancer, breast cancer, lung cancer, colorectal cancer, gastric cancer, head and neck cancer, prostate cancer, endometrial cancer, pancreatic cancer or liver cancer, more preferably ovarian cancer, breast cancer, lung cancer, pancreatic cancer or liver cancer, such as pancreatic cancer or liver cancer.
13. A method for preparing a compound of formula (I) or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 8, which is Scheme 1 or Scheme 2: Scheme 1: When the compound represented by formula (I) is a compound represented by formula (I'), it comprises the following steps: In a solvent, the compound represented by formula (Ia) is subjected to a deprotection reaction to prepare a compound represented by formula (I'); in, R a’ for R a for Ring A is a 3-12 membered heterocyclic hydrocarbon group containing at least one N, surrounded by one or more R 1f substituted 3-12-membered heterocyclic hydrocarbon group containing at least one N or 5-10-membered heteroaryl group containing at least one N; Ring A' is replaced by one or more R 8-1 A substituted 3-12-membered heterocyclic hydrocarbon group containing at least one N; Y is an amino protecting group, and Y is connected to the N of ring A or ring A' through a single bond; Each R b are independently halogen, cyano, -N(R 8 2. -COR 8 、-COOR 8 、-CON(R 8 2. One or more R 1a Substituted C 1-6 Alkyl, C 2-6 Alkynyl, 5-10 membered heteroaryl, substituted by one or more R 1h Substituted 5-10 membered heteroaryl or C 1-6 alkyl; m' is 0, 1, 2 or 3; X1, X2, X3, X4, R 1a , R 1f , R 1h , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 and R 8-1 The definition as in any one of claims 1 to 8; Preferably, the solvent is selected from aromatic hydrocarbon solvents, such as toluene; And / or, said Y is tert-butyloxycarbonyl; Scheme 2: When the compound represented by formula (I) is a compound represented by formula (I”), it comprises the following steps: in a solvent, a compound represented by formula (Ib) is reacted with paraformaldehyde under the action of a reducing agent to prepare a compound represented by formula (I”); Among them, R c’ for R c for Ring A is a 3-12 membered heterocyclic hydrocarbon group containing at least one N or a 5-10 membered heteroaryl group containing at least one N; Ring A' is a 8-1 A substituted 3-12 membered heterocyclic hydrocarbon group containing at least one N; Each R d are independently halogen or C 1-6 alkyl; m' is 0, 1, 2 or 3; X1, X2, X3, X4, R 2 , R 3 , R 4 , R 5 , R 6 , R 7 and R 8-1 The definition as in any one of claims 1 to 8; Preferably, the solvent is selected from halogenated hydrocarbon solvents and / or alcohol solvents, preferably dichloromethane and / or methanol, such as dichloromethane and methanol; And / or, the reaction is carried out under acidic conditions, and the acid is preferably a Lewis acid, such as acetic acid or TiCl4; And / or, the reducing agent is sodium cyanoborohydride, sodium acetate borohydride or sodium borohydride, preferably sodium cyanoborohydride.
14. A compound of formula (Ia) or formula (Ib) as shown below, in, R a’ , R b , R c’ , R d 、m'、X1、X2、X3、X4、R 2 , R 3 , R 4 , R 5 , R 6 and R 7 The definition of as in claim 13; Preferably, the compound of formula (Ia) is the following compound:
